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Abstract 
Abstract 
Breast cancer is one of the most common cancers in females in the western world, 
and despite the advances in diagnosis and treatment it is still associated with 
significant morbidity. Thus, improvements to existing treatment modalities 
remain a priority. Understanding the molecular mechanisms controlling tumour 
growth and its modulation will be key to developing new therapies. In recent 
years it has been shown that posttranslational modifications (PTMs) of histones 
and p53 are functionally important in the regulation of cellular processes such as 
proliferation, differentiation and DNA damage repair. Thus, this study assessed 
the incidence of histone and p53 PTMs in breast tumours, and investigated how 
small molecule inhibitors of acetyltransferases can manipulate the levels of these 
PTMs in tumour cells.  
Our initial study demonstrated that hypoacetylation of H4K16 is 
associated with higher grade breast tumours (Elsheikh et al., 2009). Therefore, the 
expression levels of enzymes that are known to modulate H4K16 acetylation in 
vivo was assessed using immunohistochemical staining of 880 human breast 
tumour tissue microarrays. This led to the identification of a cluster of biomarkers 
(hMOF, H4K16ac, H3K9me3 and SUV39H1) which are significantly associated 
with patient outcome. We also assessed in tumours the incidence of other 
potential biomarkers including selected p53 PTMs such as p53K373ac and p53 
K386ac. These were also found to be associated with favourable patient outcome 
in Kaplan-Meier survival analysis. Other potential biomarkers were also assessed 
such as the histone variant H2A.Z and its hyperacetylated form. H2A.Z correlated 
with Estrogen Receptor status of the tumours, consistent with a report that the 
Abstract 
gene encoding this histone variant is estrogen-regulated. In summary, this study 
has revealed that histone and p53 PTMs in breast tumours are potentially useful 
biomarkers for the classification of tumour type and as prognostic indicators, for 
use in conjunction with other clinicopathological indicators, and other well 
established biomarkers such as estrogen receptor and HER2.  
In a second aspect of the study, we investigated the effects of the 
acetyltransferase inhibitors curcumin and garcinol on a breast cancer cell model 
(MCF-7 cells). Garcinol blocked transcription-related PTMs such as H3K18ac, 
but surprisingly induced hyperacetylation of H4K16. This was found to be 
correlated with increased TIP60 expression, and correlated with increased 
incidence of DNA damage and cell cycle arrest. Other changes in cancer -
associated PTMs were also observed, including increased H4K20 trimethylation. 
Garcinol compounds also reduced colony formation by MCF-7 cells and 
augmented sensitivity to etoposide.  In summary, the data shows that histone and 
p53 PTMs constitute novel biological prognostic markers in breast cancer, and 
that targeting the enzymes that regulate these events may provide new avenues to 
drug therapies. 
  
 Acknowledgments 
I dedicate this work to my parents who devoted their lives to raising their sons. I 
am also indebted to my wife and daughters, as without their support this work 
would not have been accomplished. Finally, to the souls of the  Egyptian 
revolutionaries who gave their lives for the sake of Egypt, my beloved country. 
 I am very grateful to Professor David M Heery for his role as my project 
supervisor and a research group leader; his principles will be guidance in my 
future in academia. Under his supervision, laboratory experiments became a 
source of joy and writing up became a challenge to achieve excellence. 
                $ ODUJH SDUW RI P\ ZRUN ZRXOGQ¶W EH GRQH ZLWKRXW WKH FROODERUDWLRQ
with Prof Ian Ellis and Dr Andy Green, who provided access to tumour samples 
and laboratory resources to accomplish important parts of my work. 
                I am really grateful for the great help from Dr Hilary Collins, Dr Karin 
Kindle and Dr Akhmed Aslam who introduced me to Molecular Biology 
techniques. They were a constant source of assistance and advice throughout my 
study. 
This study was performed under the financial support of the Ministry of Higher 
Education, Egypt to whom I am indebted. 
 
 
 LIST OF CONTENTS 
 
1 INTRODUCTION .............................................................................................  
1.1 What is Cancer? ........................................................................................ 1 
1.1.1 Breast Cancer Incidence and Mortality ............................................. 2 
1.1.2 Physiology and Symptoms of Breast Tumours ................................. 3 
1.1.3 Detection and Diagnosis .................................................................... 5 
1.1.4 Classification of Breast Tumours ...................................................... 7 
1.1.5 Staging of Breast Cancer ................................................................. 20 
1.1.6 Histological Grading of Breast Cancer ........................................... 23 
1.1.7 Tumour Prognosis ........................................................................... 25 
1.1.8 Models to Study Breast Cancer-Cell Lines ..................................... 28 
1.2 Molecular Pathology of Breast Cancer ................................................... 28 
1.2.1 From DNA to Protein ...................................................................... 28 
1.2.2 Overview of Chromatin Structure ................................................... 30 
1.2.3 Epigenetic Modifications in Chromatin .......................................... 32 
1.2.4 Common Epigenetic Changes in Cancer ......................................... 33 
1.2.5 DNA Methylation in Cancer ........................................................... 34 
1.2.6 DNA Methylation in Breast Cancer ................................................ 35 
1.2.7 Histone Methyltransferases ............................................................. 36 
1.2.8 Histone Post Translational Modifications (PTMs) in Cancer ......... 38 
1.2.9 Histone Variants in Cancer .............................................................. 48 
1.2.10 Tumour Suppressor p53: Post Translational Modifications (PTMs) 
and its Role in Cancer ................................................................................... 55 
1.2.11 Histone Acetyltransferases (HATs) ................................................. 62 
1.2.12 HATs Inhibitors ............................................................................... 67 
 1.2.13 Histone Deacetylases (HDACs) ...................................................... 71 
1.2.14 HDAC inhibitors and Cancer .......................................................... 76 
1.3 Aims of This Thesis ................................................................................ 80 
2 MATERIALS AND METHODS .................................................................. 82 
2.1 General .................................................................................................... 83 
2.2 Breast Tumour Tissue ............................................................................. 83 
2.2.1 The Tissue Microarrays (TMAs) ..................................................... 83 
2.2.2 Construction of the Tissue Microarray Blocks ................................ 84 
2.2.3 Immunohistochemistry (IHC) Staining and Data Analysis ............. 84 
2.2.4 Statistical analysis ........................................................................... 88 
2.3 Cell Culture ............................................................................................. 90 
2.3.1 Reagents .......................................................................................... 90 
2.3.2 Cell Line Maintenance .................................................................... 90 
2.3.3 Freezing Down Cells for Liquid Nitrogen Stocks ........................... 93 
2.3.4 Thawing Cells from Liquid Nitrogen Stocks .................................. 93 
2.3.5 Harvesting adherent cells ................................................................ 93 
2.4 Biochemical Techniques ......................................................................... 94 
2.4.1 Solutions and Buffers ...................................................................... 94 
2.4.2 Antibodies ....................................................................................... 97 
2.4.3 Total Protein Assay ......................................................................... 97 
2.4.4 Protein Separation and Transfer to Nitrocellulose .......................... 98 
2.4.5 Western Blotting and Immunodetection .......................................... 98 
2.4.6 Immunocytochemistry and Fluorescence Microscopy .................... 99 
2.4.7 Bivariate Flow Cytometric Analysis of the Cell Cycle ................. 100 
2.4.8 Colony formation study ................................................................. 102 
 2.5 Bacterial Manipulations ........................................................................ 102 
2.5.1 Reagents, cells, media, supplements ............................................. 102 
2.5.2 &XOWXUHRI(FROL'+Į ................................................................ 103 
2.5.3 Preparation of Escherichia coli (E. coli) competent cells. ............ 103 
2.5.4 Plasmid DNA Transformation into E. coli  cells ........................... 104 
2.6 Molecular biology techniques ............................................................... 106 
2.6.1 Plasmid Purification from E.coli ................................................... 106 
2.6.2 Determination of Nucleic Acid Concentration .............................. 106 
2.6.3 Sequencing of Plasmid DNA ........................................................ 106 
2.6.4 Calcium Phosphate-Mediated Transfection of Adherent Cells ..... 107 
2.6.5 Data bank analysis ......................................................................... 107 
2.6.6 RNA interference .......................................................................... 108 
3 EVALUATION OF HISTONE PTMs IN BREAST TUMOURS .............. 110 
3.1 Evaluation of the H4K16ac Regulatory Axis as a Novel Biomarker Set 
in Breast Tumours ........................................................................................... 111 
3.1.1 Enzymes that Regulate H4K16 Acetylation: The H4K16ac Axis 112 
3.1.2 TMA profiling of the H4K16ac Regulatory Axis in Breast Tumours
 117 
3.2 : Histone Variants in Breast Cancer ...................................................... 158 
3.2.1 Detection of Histone Variants in Breast Tumour TMAs .............. 161 
4 EVALUATION OF p53 PTMs AND THEIR MODULATORS IN BREAST 
CANCER ............................................................................................................. 185 
4.1 p53 Post Translational Modifications (PTMs) ..................................... 186 
4.1.1 Acetylation of p53 in breast cancer ............................................... 186 
4.1.2 Detection of p53 Acetylation in Breast Tumour Tissue ................ 187 
 4.2 p53 Acetylation Modulators ................................................................. 212 
4.2.1 Detection of p53 Acetylation Modulators in Breast Tumour TMA
 214 
4.2.2 Tumour Outcome in relation to p53 Acetylation Marks and their 
Modulators ................................................................................................... 233 
4.2.3 Cluster analysis of p53 PTMs and their regulators ....................... 239 
5 THE EFFECT OF THE HAT INHIBITORs ON HISTONE AND p53 PTMs 
AND MCF-7 CELL CYCLE PROLIFERATION .............................................. 253 
5.1.1 HAT inhibitors Alter Histone H3 and H4 Acetylation .................. 254 
5.1.2 HATi treatment Alters Histone H3 and H4 Methylation .............. 260 
5.1.3 Effects of HATi on HATs and HDACs Expression ...................... 265 
5.1.4 Garcinol induces DNA Damage in vivo ........................................ 269 
5.1.5 HATi Alters p53 Function ............................................................. 271 
5.1.6 HATi Treatment Alters p53 Function ........................................... 280 
5.1.7 HATi Treatment Sensitizes MCF-7 Cells to Etoposide and Reduces 
Colony Formation ........................................................................................ 288 
5.1.8 Summary of Results: HATi Treatment can Reverse the Loss of 
Histone and p53 PTMs in Breast Cancer Cells. .......................................... 291 
6 CONCLUDING REMARKS ...................................................................... 295 
7 REFERENCES ............................................................................................ 305 
8 APPENDIX ................................................................................................. 344 
 
 
  
 LIST OF TABLES 
 
TABLE 1:1: FREQUENCY AND 5-YEAR SURVIVAL FOR BREAST CANCER 
HISTOPATHOLOGICAL TYPES. ........................................................................................ 8 
TABLE 1:2: BREAST CANCER TUMOUR SUBTYPES BY CDNA HIERARCHICAL 
CLUSTERING. ..................................................................................................................... 15 
TABLE   1:3: BREAST CANCER TNM STAGING. ................................................................... 22 
TABLE 1:4: CLASSES OF HUMAN HDACS ............................................................................. 73 
TABLE  2:1: MAMMALIAN CELL LINES USED IN THE STUDY. ......................................... 92 
TABLE 2:2: SOLUTION COMPOSITIONS FOR PREPARING RESOLVING GELS FOR TRIS-
GLYCINE SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS. ............................... 96 
TABLE 2:3: PLASMIDS USED IN THE STUDY. ..................................................................... 105 
TABLE 3:1: H4K16AC REGULATORY AXIS DETECTION LEVELS IN RELATIONSHIP TO 
TUMOUR HISTO-PATHOLOGICAL TYPES. ................................................................ 123 
TABLE 3:2: H4K16AC REGULATORY AXIS DETECTION LEVELS IN RELATIONSHIP TO 
TUMOUR PHENOTYPE GROUPS OF BREAST CANCER AS DEFINED BY NIELSEN 
ET AL (NIELSEN ET AL., 2004). ...................................................................................... 124 
TABLE 3:3: H4K16AC REGULATORY AXIS DETECTION LEVELS AND PHENOTYPE 
GROUPS OF BREAST CANCER AS DEFINED BY ABE EL-REHIM ET AL (ABD EL-
REHIM ET AL., 2005). ...................................................................................................... 125 
TABLE 3:4: H4K16AC, HMOF AND SIRT1 DETECTION LEVELS IN RELATIONSHIP TO 
TUMOUR CLINICOPATHOLOGICAL PARAMETERS; BIOLOGICAL FACTORS. .. 129 
3:5: H3K9ME3, DBC1 AND SUV39H1 DETECTION LEVELS IN RELATIONSHIP TO 
TUMOUR CLINICOPATHOLOGICAL PARAMETERS; BIOLOGICAL FACTORS. .. 132 
TABLE 3:6: H4K16AC, HMOF AND SIRT1 DETECTION LEVEL AND HISTONE PTMS 
AND THEIR MODULATORS. .......................................................................................... 136 
TABLE 3:7: H3K9ME3, DBC1 AND SUV39H1 DETECTION LEVEL AND HISTONE PTMS 
AND THEIR MODULATORS. .......................................................................................... 140 
TABLE 3:8: COX PROPORTIONAL HAZARD MODEL SHOWING HAZARD RATIOS FOR 
BCSS AND DFS CONFERRED BY H4K16AC, HMOF, SUV39H1 AND 
CLINICOPATHOLOGICAL VARIABLES ...................................................................... 146 
 TABLE 3:9: HISTONE VARIANTS DETECTION LEVELS IN DIFFERENT TUMOUR 
HISTO-PATHOLOGICAL TYPES. ................................................................................... 167 
TABLE 3:10: HISTONE VARIANTS DETECTION LEVELS AND PHENOTYPE GROUPS OF 
BREAST CANCER AS DEFINED BY NIELSEN AND COLLEAGUES (NIELSEN ET 
AL., 2004). .......................................................................................................................... 168 
TABLE 3:11: HISTONE VARIANTS DETECTION LEVELS AND PHENOTYPE GROUPS OF 
BREAST CANCER AS DEFINED BY ABE EL-REHIM AND COLLEAGUES (ABD EL-
REHIM ET AL., 2005). ...................................................................................................... 169 
TABLE 3:12: RELATION BETWEEN HISTONE VARIANTS DETECTION LEVELS AND 
CLINICO-PATHOLOGICAL PARAMETERS AND BIOLOGICAL FACTORS. .......... 172 
TABLE 3:13: CORRELATION BETWEEN HISTONE VARIANTS LEVELS AND HISTONE 
PTMS AND THEIR MODULATORS. .............................................................................. 175 
TABLE 3:14: COX PROPORTIONAL HAZARD MODEL SHOWING HAZARD RATIOS FOR 
BCSS AND DFS CONFERRED BY H2A.Z AND CLINICOPATHOLOGICAL 
VARIABLES ...................................................................................................................... 179 
TABLE 4:1:P53 PTMS DETECTION LEVELS IN RELATIONSHIP TO TUMOUR 
HISTOPATHOLOGICAL TYPES. .................................................................................... 195 
TABLE 4:2: P53 PTMS DETECTION LEVELS IN RELATIONSHIP TO TUMOUR 
PHENOTYPE GROUPS OF BREAST CANCER AS DEFINED BY NIELSEN AND 
COLLEAGUES (NIELSEN ET AL., 2004). ...................................................................... 196 
TABLE 4:3: P53 PTMS DETECTION LEVELS AND PHENOTYPE GROUPS OF BREAST 
CANCER AS DEFINED BY ABE EL-REHIM AND COLLEAGUES (ABD EL-REHIM 
ET AL., 2005). .................................................................................................................... 197 
TABLE  4:4: RELATION BETWEEN P53 PTMS DETECTION LEVELS AND CLINICO-
PATHOLOGICAL PARAMETERS AND BIOLOGICAL FACTORS. ............................ 201 
TABLE 4:5: P53 PTMS IN RELATION TO HISTONE PTMS AND THEIR MODULATORS.
 ............................................................................................................................................ 208 
TABLE 4:6: THE DETECTION LEVEL OF P53 ACETYLATION MODULATORS IN 
DIFFERENT TUMOUR HISTOPATHOLOGICAL TYPES. ........................................... 220 
 TABLE 4:7: THE DETECTION LEVEL OF P53 ACETYLATION MODULATORS AND 
PHENOTYPE GROUPS OF BREAST CANCER AS DEFINED BY NIELSEN AND 
COLLEAGUES (NIELSEN ET AL., 2004). ...................................................................... 221 
TABLE 4:8: THE RELATIONSHIP OF P53 ACETYLATION MODULATORS TO 
PHENOTYPE GROUPS OF BREAST CANCER AS DEFINED BY ABD EL-REHIM 
AND COLLEAGUES (ABD EL-REHIM ET AL., 2005). ................................................. 222 
TABLE 4:9: THE RELATIONSHIP BETWEEN DETECTION LEVELS OF THE P53 
ACETYLATION MODULATORS AND CLINICO-PATHOLOGICAL PARAMETERS 
AND BIOLOGICAL FACTORS. ....................................................................................... 225 
TABLE 4:10: P53 PTM ACETYLATION MODULATORS DETECTION LEVELS IN 
RELATIONSHIP TO HISTONE PTMS AND THEIR MODULATORS. ......................... 230 
TABLE 4:11: COX PROPORTIONAL HAZARD MODEL SHOWING HAZARD RATIOS FOR 
BCSS AND DFS CONFERRED BY P53K373AC AND P53K386AC AND 
CLINICOPATHOLOGICAL VARIABLES ...................................................................... 238 
 
 
  
 LIST OF FIGURES 
FIGURE 1.1: TERMINAL DUCT LOBULAR UNIT (TDLU). ...................................................... 4 
FIGURE 1.2: BREAST CANCER TUMOURS CLUSTERING BASED ON IHC STAINING 
DATA. .................................................................................................................................. 19 
FIGURE 1.3: NOTTINGHAM GRADING SYSTEM. .................................................................. 24 
FIGURE 1.4: NOTTINGHAM PROGNOSTIC INDEX. .............................................................. 27 
FIGURE 1.5: THE NUCLEOSOME IS THE BASIC UNIT OF CHROMATIN .......................... 31 
FIGURE 1.6: COVALENT MODIFICATIONS OF THE N-TERMINAL TAIL OF THE CORE 
HISTONES. .......................................................................................................................... 40 
FIGURE 1.7: P53 PTMS. ............................................................................................................... 58 
FIGURE 1.8: MDM2, MDM4 AND P53 REGULATORY LOOP. ............................................... 61 
FIGURE 1.9: HISTONE ACETYLATION STATUS OF CHROMATIN .................................... 63 
FIGURE 3.1: THE H4K16AC AXIS. .......................................................................................... 116 
FIGURE 3.2: DETECTION OF THE H4K16AC REGULATORY AXIS IN BREAST CANCER 
TMAS AS DETERMINED BY IHC. ................................................................................. 119 
FIGURE 3.3: H4K16AC REGULATORY AXIS AND PATIENT OUTCOME. ....................... 145 
FIGURE 3.4: K-MEANS CLUSTERING ALGORITHM FOR BREAST CANCER TUMOUR 
TMA IN REGARDS TO H4K16AC REGULATORY AXIS DETECTION LEVELS AND 
VALIDITY INDICES TESTS. ........................................................................................... 149 
FIGURE 3.5: PAM CLUSTERING ALGORITHM FOR BREAST CANCER TUMOUR TMA IN 
REGARDS TO H4K16AC REGULATORY AXIS DETECTION LEVELS AND 
VALIDITY INDICES TESTS. ........................................................................................... 150 
FIGURE 3.6: COMMON CLUSTERING OF H4K16AC REGULATORY AXIS, CLUSTER 2 
CORRELATES WITH FAVOURABLE TUMOUR GRADE AND BETTER SURVIVAL.
 ............................................................................................................................................ 151 
FIGURE 3.7: HISTONE PTMS, HATS AND HDACS RELATIONSHIP ................................. 160 
FIGURE 3.8: DETECTION OF MH2A IN BREAST CANCER TMAS AS DETERMINED BY 
IHC...................................................................................................................................... 162 
FIGURE 3.9: DETECTION OF H2A.Z IN BREAST CANCER TMAS AS DETERMINED BY 
IHC...................................................................................................................................... 163 
 FIGURE 3.10: DETECTION OF H2A.ZAC IN BREAST CANCER TMAS AS DETERMINED 
BY IHC ............................................................................................................................... 164 
FIGURE 3.11: HIGH H2A.ZAC LEVEL CORRELATES WITH BETTER PATIENT 
SURVIVAL. ....................................................................................................................... 178 
FIGURE 4.1: DETECTION OF P53K120 ACETYLATION MARK IN BREAST CANCER AS 
DETERMINED BY IHC. ................................................................................................... 189 
FIGURE 4.2: DETECTION OF P53K373 ACETYLATION MARK IN BREAST CANCER AS 
DETERMINED BY IHC. ................................................................................................... 190 
FIGURE 4.3: DETECTION OF P53K386 ACETYLATION MARK IN BREAST CANCER AS 
DETERMINED BY IHC. ................................................................................................... 191 
FIGURE 4.4: P53 PTMS, HATS AND HDACS AND THEIR EFFECTS ON CELL CYCLE 
PROGRESSION. ................................................................................................................ 213 
FIGURE 4.5: DETECTION OF TIP60 IN BREAST CANCER TMAS AS DETERMINED BY 
IHC STAINING. ................................................................................................................. 215 
FIGURE 4.6: DETECTION OF CBP IN BREAST CANCER TMAS AS DETERMINED BY IHC 
STAINING. ......................................................................................................................... 216 
FIGURE 4.7: DETECTION OF HDAC1 IN BREAST CANCER TMAS AS DETERMINED BY 
IHC STAINING. ................................................................................................................. 217 
FIGURE 4.8: TUMOUR OUTCOME IN BREAST CANCER TMA STAINED FOR P53 
ACETYLATION MARKS AND THEIR ACETYLATION MODULATORS ................. 235 
FIGURE 4.9: TUMOUR OUTCOME IN BREAST CANCER TMA STAINED FOR P53 
ACETYLATION MODULATORS .................................................................................... 236 
FIGURE 4.10: K-MEANS CLUSTERING ALGORITHM AND VALIDITY INDICES TESTS 
FOR BREAST CANCER TUMOUR TMA WITH REGARD TO P53K373AC, CBP, SIRT1 
AND SUV39H1 DETECTION LEVELS. .......................................................................... 241 
FIGURE 4.11: PAM CLUSTERING ALGORITHM FOR BREAST CANCER TUMOUR TMA 
WITH REGARDS TO P53K373AC, CBP, SIRT1 AND SUV39H1 DETECTION LEVELS.
 ............................................................................................................................................ 242 
FIGURE 4.12: CLUSTERING OF (P53K373, CBP, SIRT1 AND SUV39H1), CORRELATION 
WITH TUMOUR GRADE AND TUMOUR OUTCOME. ................................................ 243 
 FIGURE 4.13: K-MEANS CLUSTERING ALGORITHM AND VALIDITY INDICES TESTS 
FOR BREAST CANCER TUMOUR TMA IN REGARDS TO P53K386AC, HMOF AND 
SIRT1 DETECTION LEVELS. .......................................................................................... 246 
FIGURE 4.14: PAM CLUSTERING ALGORITHM AND VALIDITY INDICES TESTS FOR 
BREAST CANCER TUMOUR TMA IN REGARDS TO P53K386AC, HMOF AND SIRT1 
DETECTION LEVELS. ..................................................................................................... 247 
FIGURE 4.15: CLUSTERING OF (P53K386AC, HMOF AND SIRT1) AND TUMOUR 
OUTCOME ......................................................................................................................... 248 
FIGURE 5.1: DIFFERENTIAL EFFECTS OF HATI TREATMENT ON HISTONE H3 AND H4 
ACETYLATION. ............................................................................................................... 257 
FIGURE 5.2: HISTONE PTMS IN MRC-5 CELLS AFTER HATI TREATMENT ................... 259 
FIGURE 5.3: HAT INHIBITORS TREATMENT ALTERS HISTONE METHYLATION. ...... 263 
FIGURE 5.4: HAT INHIBITORS INDUCE ALTERATIONS IN THE LEVELS OF HISTONE 
ACETYLATION REGULATORS. .................................................................................... 268 
FIGURE 5.5: HATI INDUCES HIGH LEVELS OF DNA DAMAGE RESPONSE MARKERS.
 ............................................................................................................................................ 270 
FIGURE 5.6: CURCUMIN ALTERS P53 ACETYLATION. ..................................................... 272 
FIGURE 5.7: GARCINOL ALTERS P53 ACETYLATION. ...................................................... 276 
FIGURE 5.8: CONT. GARCINOL ALTERS P53 ACETYLATION, VALIDATION OF P53 
PTMS ANTIBODIES. ........................................................................................................ 277 
FIGURE 5.9: HATI TREATMENT ALTERS P53 ACETYLATION AT K386, K373 AND K120 
IN MRC-5 CELLS. ............................................................................................................. 279 
FIGURE 5.10: HATI TREATMENT ALTERS P53 TRANSCRIPTIONAL ACTIVITY. .......... 282 
FIGURE 5.11: GARCINOL, ISOGARCINOL AND LTK14 TREATMENT IMPEDES 
PROLIFERATION OF MCF-7 CELLS BY BLOCKING S PHASE. ................................ 285 
FIGURE 5.12: CURCUMIN TREATMENT IMPEDES PROLIFERATION OF MCF-7 CELLS 
BY BLOCKING S PHASE. ................................................................................................ 286 
FIGURE 5.13: CELL CYCLE CHANGES IN MRC-5 CELLS UPON HATI TREATMENT. .. 287 
FIGURE 5.14: EFFECTS OF HATI ON MCF-7 CELLS PROLIFERATION. ........................... 289 
 6.1: THE POSSIBLE PATHWAYS THROUGH WHICH GARCINOL TREATMENT ALTERS 
CELL PROLIFERATION. ................................................................................................. 303 
 
  
 LIST OF ABBREVIATIONS 
BCSS: Breast cancer specific survival 
BSE: Breast self examination 
CBP: CREB binding protein 
CK: cytokeratin 
DAB: Diaminobenzidine 
DBC1: Deleted in Breast Cancer 1 
DCIS: Ductal carcinoma in situ 
DDP:  cisplatin 
DFS: disease free survival 
DNMT: DNA methyltransferase 
DOX: doxorubicin 
EGFR: epidermal growth factor receptor 
ER: oestrogen receptor  
FNA: Fine Needle Aspiration 
FFPE: formalin fixed paraffin embedded 
FGFR1: fibroblast growth factor receptor 1 
H&E: haematoxylin and Eosin 
H3K9ac: acetylated H3K9 
H3K12ac: acetylated H3K12 
H3K18ac: acetylated H3K18 
H3K4me2: dimethylated H3K4 
H4K16ac: acetylated H3K16 
H4K20me3: trimethylated H4K20 
H4R3me2: dimethylated H4R3 
HATs: histone acetyltransferases 
HATi: histone acetyltransferase inhibitors 
HDACs: histone deacetylases 
HD: high detection 
HMT: histone methyltransferase 
LD: low detection 
MI: mitotic index 
NC: not classified 
 NHS: National Health Service 
NICE: National Institute of Clinical Excellence 
NOS: not otherwise specific 
NPI:  Nottingham Prognostic Index 
PTMs: Post Translational Modifications 
PR: progesterone receptor 
TNM: Tumour, Node, Metastases 
UK: United Kingdom 
USA: United States of America 
WHO: World Health Organisation 
 
Abbreviations used in Materials and Methods 
APS: Ammonium persulphate 
BSA: Bovine Serum Albumin 
dH2O: distilled water 
DNA: Deoxyribonucleic acid 
DTT: Dithiothreitol 
ECL: Enhanced Chemi-Luminescence 
EDTA: ethylenediamine tetra-acetic acid 
FACS: Fluorescencea ctivated cell sorting (Flow cytometry) 
FCS: Foetal calf serum 
H-score: Histo-score 
HRP: Horseradish peroxidise 
IHC: immunohistochemistry 
IF: immunofluorescence 
kD: kiloDalton 
LB: broth Luria-Bertrani broth 
NSS: Normal Swine Serum 
PAM: Partitioning Around Medoids 
SPSS: Statistical Package for Social Scientists 
PAGE: Polyacryalmide gel electrophoresis 
PBS: Phosphate buffered saline 
PCR: Polymerase chain reaction 
PSA: Ammonium Persulfate 
 rpm: revolutions per minute 
RT: room temperature 
SDS: Sodium dodecyl sulphate 
TBS:Tris buffered saline 
TBS-T: Tris buffered saline-Tween 
TEMED: N, N, N, 'N-tetramethylethylenediamine 
TMA: tissue microarray 
Tween: 20 polyoxyethylene-sorbitanm onolaurate  
WB: western blotting 
 
   
 
 
 
 
 
 
 
 
1 INTRODUCTION
Chapter One: Introduction 
 
1 
1.1 What is Cancer? 
Body tissues are made up of highly specialised cells that have become 
differentiated to perform specific functions. The growth, homeostasis and death of 
normal cells in these tissues are highly regulated. Cancer describes a wide range 
of diseases in which unregulated cell growth leads to a cell mass or tumour, which 
may be benign or malignant. Tumours can stimulate the growth of blood vessels 
to supply their nutrients, and malignant tumours can infiltrate mesenchymal 
tissues and enter the blood and lymphatic systems to metastasise to other sites in 
the body.  
 Some of the earliest evidence for tumours in man has come from 
paleopathological studies, in particular the mummified remains of ancient 
Egyptian and Incan cultures. For example, in 2001 researchers at the Czech 
Institute of Egyptology identified a benign nerve sheath tumour (schwannoma) 
inside the sacrum of the mummy of Imakhetkherresnet, sister of priest Iufaa 
(Strouhal and Nemeckova, 2009). Another study identified four malignant 
tumours among 325 samples, providing clear evidence that malignant tumours 
were not rare in the ancient Egyptian population (Zink et al., 1999). Moreover, 
papyrus documents from Egypt dating from 1500 B.C. describe cases of breast 
WXPRXUVDQGWKHLUWUHDWPHQWE\³ILUHGULOO´DIRUPRIFDXWHUization. Interestingly, 
natural remedies used by the ancient Egyptians to treat cancers included 
beverages made from fermented medicinal plants. In a recent review of drug 
discovery among ancient populations, two case studies from ancient Egypt and 
China were used to illustrate how ancient medicines can be reconstructed from 
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chemical and archaeological data and their active compounds delimited for testing 
their anticancer or other medicinal uses (McGovern et al., 2010). As will be 
demonstrated in this thesis, medicinal plants continue to be an important potential 
source of bioactive compounds in the search for new antitumour agents. My study 
is just one more step in the journey of understanding cancer and discovering a 
cure. 
 
1.1.1 Breast Cancer Incidence and Mortality 
Recent statistics reveal that breast cancer is currently the most commonly 
diagnosed cancer in females in the UK 
(http://info.cancerresearchuk.org/cancerstats/.), and similar trends are seen 
worldwide (Parkin et al., 2001, Ott et al., 2010, Barrett, 2010, Westlake S, 2008). 
In 2006, precisely 45,822 new cases of breast cancer were diagnosed in the UK: 
over 99% (45,508) in women and less than 1% (314) in men. The UK has the 
highest age standardised incidence in the world. Among women aged 50, the 
incidence approaches 2 per 1000 women per year and increases particularly 
among the older age group aged 50-64. Over the last 30 years, the epidemiology 
of breast cancer has been dynamic, although the incidence of breast cancer in the 
UK is on the increase, survival rates are improving due to earlier diagnosis and 
advances in treatments (Miller et al., 2005, Coleman, 2000). 
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1.1.2 Physiology and Symptoms of Breast Tumours  
Cancer of the breast originates from the epithelial cells that line the terminal duct 
lobular unit (TDLU) (Sainsbury et al., 2000 ), which is also identified as a breast 
lobule (Fig 1.1). The TDLU consists of 10-100 acini that drain into terminal ducts. 
A single breast cancer cell has to undergo at least 30 doublings to reach 1cm, to 
be clinically palpable (Mittra et al., 2000). The terminal duct drains into larger 
ducts and finally into the main duct of the lobe that eventually drains into the 
nipple. The breast contains 15-20 lobes; each one contains 20-40 lobules. Most 
invasive cancers arise from the TDLU (Tot, 2010, Petersen et al., 2003). 
 
 Signs of early disease include a palpable mass, nipple discharge, nipple 
scaling or ulceration or with Paget's disease, axillary mass, skin dimpling, oedema 
and erythema. Symptoms of early disease may include breast pain and axillary 
discomfort. Advanced disease will typically present as a fixed mass to the chest, 
which sometimes can be associated with oedema of the arm. Patients in advanced 
stage of breast cancer usually complain from breast enlargement, breast 
ulceration, back pain, bone pain, jaundice and weight loss. 
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Figure 1.1: Terminal Duct Lobular Unit (TDLU). 
 
Breast carcinoma originates from the epithelial cells that line the terminal duct 
lobular unit (TDLU) which is also identified as a breast lobule (Highlight in right 
panel). The TDLU consists of 10-100 acini that drain into terminal ducts (Arrow 
head). The terminal duct drains into larger ducts and finally into the main duct of 
the lobe that eventually drains into the nipple (Left panel). Reproduced from 
(Pijnappel, 2008). 
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1.1.3 Detection and Diagnosis 
Mammography 
 The NHS National Breast Screening Programme began inviting women for 
screening in 1990 and national coverage was achieved by 1993. It invites women 
in their late 40s and up to the age of 73. Women are invited for the screening 
every 3 years; women over the age of 70 who are not automatically invited for 
breast screening are still encouraged to go for screening every three years. The 
programme is carried through a regular breast screening and self examination. 
The first step involves an x-ray of each breast; in which a mammogram is taken 
while carefully compressing the breast. Mammograms can detect small changes in 
breast tissue which may indicate cancers that are too small to be felt either by the 
woman herself or by a doctor. Noticeably, early diagnosis has contributed to the 
reduction in breast cancer related mortality in the past 20 years (Quinn and Allen, 
1995, McPherson et al., 2000). 
Breast Awareness 
Women are also encouraged to perform regular Breast Self Examination (BSE). 
The aim of BSE is to help women to familiarize themselves with their own breasts 
in order to discover what is normal for them and to recognise any irregularities. 
The breast is subjected to regular changes as a reflection of menstrual cycle 
changes; hence, it has been suggested that BSE one week after the onset of 
menstruation is beneficial for breast mass detection (Austoker, 2003). Although 
BSE is widely encouraged, some researchers do not think early detection through 
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screening or BSE has much impact on the patient survival within groups with the 
same individual stages (Richards et al., 1999).  
 
Diagnosis 
Upon presentation of a breast lump, triple assessments are performed, including; 
clinical examination, imaging the breast by mammography (see before) and/or 
ultrasound and needle biopsy (Blamey et al., 2000). Fine needle aspiration 
cytology (FNAC) of breast lumps-which is performed by a histopathlogist- is both 
cost effective and reduces the need for an open biopsy that has a risk of 
complications. FNAC is currently considered the first choice for obtaining tissue 
for diagnosis of a palpable lump (National Institute for Clinical Excellence, 2002).  
 
Recent technology in breast cancer early diagnosis 
Human plasma assays for selected biomarkers have been marketed for breast 
cancer detection; this assay is measured by Mass spectrometry based MRM 
(Multiple Reaction Monitoring) technology; which is used to measure the level of 
25 proteins in patient plasma sample 
(http://www.nextgensciences.com/assays/breast.php). This technology is also 
available for other human cancers like lung, liver, prostate and others 
(http://www.nextgensciences.com/indices/Plasma%20Assay%20Product%20Over
view%20brochure_03-2011final.pdf). The manufacturer claims that this assay 
overcomes issues related to antibody availability, specificity and reproducibility.   
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1.1.4 Classification of Breast Tumours 
Breast tumours can be classified according to histopathological type, 
biomolecular markers, and immunohistological staining phenotype. In addition, 
more recently, molecular profiling by transcript microarray analysis has 
characterized several prognostic gene expression signatures.  Gene expression 
profiling potentially outperforms histopathological factors in identifying low-risk 
patients in specific breast cancer subgroups, with high predictive values (90%). 
This promises a potential role for a clinical application. Caldas et al. proposed 
that further improvements and insights may come from integrative expression 
pathway analyses that dissect prognostic signatures into modules related to cancer 
hallmarks (Teschendorff et al., 2010). In the following section, an overview of 
breast cancer classifications is presented.  
Histopathological typing of breast tumours is a vital element in pathological 
diagnosis as it provides an insight for the tumour prognosis (Li et al., 2005a) as 
shown in Table 1.1. 
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Table 1:1: Frequency and 5-year Survival for Breast Cancer 
Histopathological Types. 
Histological type Frequency 
(%) 
5-year Survival 
(%) 
Ductal Carcinoma in situ (DCIS) 3.6 >99 
   
Lobular Carcinoma in situ (LCIS) 1.6 >99 
   
Mixed Ductal and Lobular Carcinoma in 
situ 
0.2 >99 
   
3DJHW¶VGLVHDVH 1 79 
   
Infiltrating Duct Carcinoma 71.4 79 
   
Infiltrating Lobular Carcinoma 9 84 
   
Mixed Ductal and Lobular Carcinoma 7 85 
   
Medullary Carcinoma 1.1 82 
   
Mucinous Carcinoma 2.3 95 
   
Papillary Carcinoma 0.5 96 
   
Tubular Carcinoma 1.4 96 
   
 
Data adapted from (Li et al., 2005a, Li et al., 2003), based on the International 
Classification of Diseases for Oncology (ICD-O) histological category approach. 
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In situ carcinoma is characterised by the proliferation of malignant epithelial cells 
within the lobules or ducts, where tumour cells have not penetrated the basement 
membrane (Goussia et al., 2006). These carcinomas are subdivided into ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), according to 
whether the lesion involves only the ducts in TDLU (DCIS), or both small ducts 
and lobules (LCIS) (Buerger et al., 2000). 
 
 Ductal carcinoma in situ (DCIS) is a heterogeneous group of lesions, with 
several microscopic variants. It has been subdivided according to a nuclear grade, 
which include differences in nuclear morphology (Nuclear atypia), cellular 
architectural patterns and a presence of necrosis. Three subtypes are known: 
firstly, low grade such as a cribriform and a clinging patterns, which are 
characterized by a mild nuclear atypia, a low number of mitotic cells and are 
devoid of necrosis; secondly, intermediate grade such as a solid pattern, which is 
characterized by moderate nuclear atypia, some necrosis and the presence of 
occasional mitosis; finally, high grade such as a µµcomedo¶¶ pattern which is 
characterized by marked nuclear pleomorphism, necrosis and a high number of 
mitotic figures (Rosai, 2004). 
 
  Lobular carcinoma in situ (LCIS) lesion is characterized by clusters of 
distended acini or solid expansion of ductules. The LCIS cells lack 
glandular/acinar formations; are characterized by loss of cell-cell cohesion and 
nuclear atypia. Notably, women with LCIS have an increased risk of getting 
breast cancer in the future (Afonso and Bouwman, 2008). 
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 Infiltrating Ductal Carcinoma (IDC) is the most common type of breast 
cancer, accounting for two thirds of infiltrating breast tumours. It comprises 
multiple histological variants, among them the classical IDC not otherwise 
specified (NOS) which is considered the classical picture of IDC (Rosai, 2004). 
Other histological variants of IDC that are characterized by some biological 
differences include the following: 
 
 Tubular Carcinoma which is a well differentiated form of IDC. It is 
composed of regular rounded or angulated tubules scattered in a fibrous stroma 
without any lobular arrangement. The tubules are linked by a single layer of cells 
with bland-looking nuclei, and rare mitotic figures. In general, tubular tumours 
and tubular mixed tumours (>75% of the component is tubular) have an excellent 
prognosis (Sheppard et al., 2000). 
 
 Mucinous (Colloid) Carcinoma comprises approximately 2% of breast 
carcinomas. Cells of IDC NOS type usually contain discrete mucinous material, 
which is PAS+ve , present in both tumour cells, as well as in the stroma (Komaki et 
al., 1988). 
 
 Medullary Carcinoma is another variant, in which the hallmark is the 
presence of solid sheets or nests of relatively poorly differentiated cells; 
surrounded by a mantle of plasma cells and lymphocytes, sometimes with 
germinal centres (Malyuchik and Kiyamova, 2008). Despite the nuclear features, 
medullary carcinomas have a more favourable prognosis than IDC NOS. Hence, 
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nuclear grading is not done for this special type of infiltrating cancer (Pedersen et 
al., 1995). 
 
 Papillary Carcinoma is formed of a spectrum of papillary patterns, 
micropapillae, solid areas, a cribriform growth and occasional cysts. Again, the 
prognosis is usually more favourable than IDC NOS (Chen et al., 2008a). 
 
 A number of breast tumour types are associated with poor prognosis. For 
example, metaplastic carcinoma which comprises 3.7% of breast cancers; the 
epithelial elements of the tumour undergo metaplastic changes to a non-glandular 
pattern, most frequently squamous (Breuer et al., 2007), or osseous (Lee et al., 
2008) differentiation. Inflammatory carcinoma is another variant which is a 
clinical rather than histopathological designation; is characterized by a large, 
erythematous and painful mass showing purple discoloration of the skin. A patient 
with such a tumour is usually associated with unfavourable prognosis (Renz et al., 
2008). Interestingly, invasive lobular carcinoma (ILC) which is usually composed 
of small uniform cells have a low mitotic rate; its cells have a characteristic 
pattern of stromal infiltration. The cells are arranged in a single-file, linear 
arrangement "Indian files". Cells can also seen or individually embedded in a 
fibroblastic stroma; or concentrically positioned around ducts and lobules 
described as a "targetoid pattern".  The tumour can also show solid, alveolar or 
tubular patterns. Sometimes, frequent remnants of in situ lobular components are 
seen in the territory. Generally, the tumour cells are large characterized by 
hyperchromatic, pleomorphic nuclei (Rosai, 2004). Finally, Paget's disease of the 
nipple; the lesion is usually interpreted as an adenocarcinoma arising either 
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independently or from the underlying tumour. The lesion is characterized by the 
presence of large cells, abundant pale cytoplasm and large atypical nuclei on the 
surface epithelium (Caliskan et al., 2008). 
 
Biomarker Sub-typing of Breast Tumours  
Biomarker expression is also used to classify breast tumours. A major subtype 
comprises the Luminal/ER-positive breast tumours; which, are characterized by 
high expression of the estrogen receptors and tend to be more differentiated. In 
general they have a better clinical outcome to hormonal therapy; especially, if 
quantitative analysis of ER expression was assessed (Mazouni et al., 2010 
). HER2 is another subtype that is characterized by amplification of the ERBB2 
oncogene; these tumours respond to Herceptin® (Trastuzumab) by targeting this 
receptor kinase (Kakar et al., 2000). Finally, basal-like tumours, which are 
distinguished by poor cellular differentiation, show high expression of cytokeratin 
5/6 and a lack of hormone receptors and HER2. Generally, those tumours have a 
tendency towards the worst clinical outcome because of their propensity to 
develop distant metastases and a lack of targeted therapy (Nielsen et al., 2004).  
 
Breast Cancer Molecular Profiling 
Breast cancer is a heterogeneous disease with varying clinical outcome. Thus, as 
previously discussed, many efforts have been made to establish a hierarchical 
classification for breast cancer tumours based on histopathological features or 
biomarkers, which can inform clinical treatment. More recently, efforts have been 
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made to apply gene expression profiling to tumours using microarray analysis 
techniques. High throughput gene expression data has iGHQWL¿HG four distinct 
molecular groups: luminal epithelial/estrogen (ER) positive, HER2 positive, 
basal-like and normal breast-like (Perou et al., 2000). A follow up study by Sorlie 
et al (2001) extended the clustering by subdivision of the luminal tumours into 
three subtypes: luminal A, B and C (Sorlie et al., 2001). Each subtype is generally 
characterized by a distinct gene expression. Hierarchical clustering by cDNA 
microarray analysis revealed two main categories:  
 The first category showed low or absent expression of the ER and 
contained three groups (Table1.2):  
1. Normal breast-like showed the highest expression of many 
genes (CD36 antigen collagen type, vascular adhesion protein 
and integrin alpha7) known to be expressed by adipose tissue 
and other nonepithelial cell types.       
2.  ERBB2 which are characterized by high expression of several 
genes in the ERBB2 amplicon at 17q22.24 including ERBB2, 
and GRB7. 
3.  Basal-like which are characterized by high expression of 
keratins 5 and 17, laminin, and fatty acid binding protein 7. 
 The second category is luminal subtype, which is characterized by 
positive expression of ER genes, it also contained three groups  
1. Luminal subtype A group that showed highest expression of the 
ER gene, GATA binding protein 3, X-box binding protein 1, 
trefoil factor 3, hepatocyte nuclear factor 3a, and estrogen-
regulated LIV-1. 
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2. Luminal subtype B which is characterized by low to moderate 
expression of the luminal specific genes and the ER cluster.  
3. Luminal subtype C is also characterized by low to moderate 
expression of the luminal specific genes and ER cluster and 
further distinguished from luminal subtypes A and B by the 
high expression of a novel set of genes whose coordinated 
function is unknown, which is a feature they share with the 
basal-like and ERBB2 subtypes. 
 
 Interestingly, gene expression profiling was found to predict clinical 
outcome of breast cancer (van 't Veer et al., 2002).  Later, in 2003, Sorlie et al. 
eliminated subtype C; and classified breast tumours into 5 subgroups comprising 
normal breast tissue-like subgroup, in addition to the previous 4 subgroups: basal, 
ERBB2-overexpressing, luminal A, B (Sorlie et al., 2003). In the same year, 
Sotiriou et al (2003) demonstrated six similar groups: Luminal type 1, 2, 3, 
ERBB2, Basal 1 and 2. Later on, more studies proposed other classes and tried to 
assign a distinct prognostic pattern to each tumour class. Afterwards, a ³FRPELQHG
WHVWVHW´was shaped. It was created by combining the data sets of a number of the 
aforementioned studies; which, characterized tumour subtype classifications as 
objective methods for tumour classification and revealed some variations in 
between (Hu et al., 2006). In order to deal with the variation between different 
clusters, a µFRQVHQVXV FOXVWHULQJ¶ method was developed which focused on the 
comparison and concordance among different clustering methods and clustering 
validation (Monti et al., 2003). 
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Table 1:2: Breast Cancer Tumour Subtypes by cDNA Hierarchical 
Clustering. 
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 Women presenting with breast cancer receive classic intervention (surgery 
followed by chemotherapy). However, only those who are likely to have breast 
cancer recurrence later in their life (15%) benefit from chemotherapy. Many 
efforts have been made to identify the high risk group that require chemotherapy 
and save the rest of patients from undergoing this treatment. Since 2004, a 
commercially available kit (Oncotype DX®) has been marketed in the United 
States. The kit has been used by half of the breast cancer patients in the USA and 
is used to detect the expression level of 21 genes to predict the likelihood of 
breast cancer recurrence. Oncotype DX was also shown to predict the benefit of 
chemotherapy in response to a variety of different chemotherapeutic regimes. 
These results suggested that the 21-gene test can generally predict the benefit 
from chemotherapy (http://www.genomichealth.com/en-
US/Pipeline/NextGeneration.aspx). However, it is still too early to confirm if this 
test is better than conventionally established risk factors such as age, grade or 
standard biomolecular marks (Buchen, 2011).   
 
 Unfortunately, not all tumours can be assigned into the above categories, 
and moreover these categories are insufficient to predict outcome with high 
accuracy. Tumours within each molecular subtype described above are still fairly 
heterogeneous with respect to clinical outcome. In addition, many of them are 
placed in the grey zone between major molecular subtypes. Thus, molecular-
based classifications may be oversimplified. Few molecular studies have 
attempted to analyze tumour progression from a population biology point of view. 
Allred et al. (2008) have taken on the challenging task of evaluating intertumoural 
and intratumoural diversity in DCIS of the breast. Their study found that DCIS 
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showed a broad distribution of conventional histological grades and standard 
biomarkers ranging from well differentiated to poorly differentiated, in which 
some tumours were nearly identical to Invasive Breast Cancer (IBCs). Moreover, 
microarray expression profiling studies showed the same intrinsic subtypes in 
DCIS as in IBCs. However, higher resolution analysis showed coexistence of 
multiple histological grades, biomarker phenotypes, and intrinsic subtypes within 
the same DCIS. In addition, diversity within cases of DCIS was highly correlated 
with p53 mutations (Allred et al., 2008). This supports the idea of Polyak (2008) 
that breast cancer tumours incorporate clonally diverse cells; which is considered 
a driving force of progression.(Polyak, 2008). 
 
On this basis, we should keep in mind that on one level, breast tumours 
share some characteristics, which enable the pathologist to segregate them into 
distinctive histological types or biological categories. However, on a cellular 
basis, tumours are heterogeneous and a marked molecular difference is the 
hallmark of tumour cells. So, studying a tumour on multiple levels is important 
for proper tumour management.  
 
Breast Cancer Tumour Clustering Based on IHC Staining 
A clustering profile study was performed by the Breast Cancer Pathology 
Research Group in Nottingham, on a well characterized series of 1076 breast 
cancer patient. In that study, 25 commercially available antibodies were used 
against a known relevance for: tumour phonotypical type, hormonal receptors and 
a number of biological markers. Assessment of staining reactivity for each mark 
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was done by H-score (described later in Material and Methods); followed by 
hierarchical clustering analysis with Euclidean distance measure which revealed 
six cluster classes for breast cancer tumours (Abd El-Rehim et al., 2005). In 2010, 
Soria et al. used K-means and PAM clustering algorithms and further validated 
the clusters obtained with validity indexes (described later in Material and 
Methods). Six classes were described (Fig. 1.2) as follows: HER2 which were 
characterized by positive HER2 and negative ER expression; a broad basal class 
characterized by positive basal cytokeratin (CK5/6, CK14) and negative ER 
expression; and a broad luminal class (comprising A, B and N classes) which 
characterized by positive expression for luminal cytokeratin CK7/8, CK18 and 
CK19. Noteworthy, 38% of tumours did not fit into any of these six classes, 
referred to as mixed class. The basal class was subdivided into two subclasses 
according to mutant forms of p53 expression: p53 altered and p53 normal. The 
luminal tumours were subdivided according to progesterone receptor negative 
(Class B) or progesterone receptor positive status. The progesterone positive class 
can be further divided into FODVV ³$´, which is characterised by expression of 
HER3 and HER4, and class ³1 +(5+(5 QHJDWLYH (Abd El-Rehim et al., 
2005, Soria et al., 2010). Some data mentioned in this cluster class were used in 
the statistical analyses carried out in this thesis. 
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 Figure 1.2: Breast Cancer Tumours Clustering based on IHC Staining data. 
 
Adapted from (Soria et al., 2010). 
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1.1.5 Staging of Breast Cancer 
Assessment of tumour stage and grade is complementary to tumour type in 
histopathological diagnosis. The most common world-wide used system is the 
TNM staging system of the American Joint Committee on Cancer (AJCC). It 
VWDQGV IRU µWXPRXU QRGH DQG PHWDVWDVHV¶ ,W WDNHV LQWR DFFRXQW WKH VL]H RI WKH
primary tumour, the draining lymph node, and whether the cancer has spread 
outside the primary site or not (Singletary et al., 2002). A summary of the TNM 
staging system for Breast cancer is emphasised in Table 1.3  
Stage 0: DCIS, Cancer cells are present in the breast but no sign of spread.  
Stage I: Breast tumours are very small and measure less than 2 centimetres in 
size. Which is considered "early breast cancer", no axillary lymph node (N) 
involved. 
Stage IIA: The tumour (T) is between size 2-5 centimetres (cm), N negative; or 
T<2cm, N positive (<4 axillary nodes). 
Stage IIB: T >5 cm, N negative; or T 2-5 cm and N positive (<4 axillary nodes) 
No sign of spread of breast cancer to any other part of the body. This is still 
termed ''early breast cancer''. 
Stage IIIA: T >5 cm, N positive; or T 2-5 cm and N positive in 4 or more axillary 
nodes.  
Stage IIIB: The tumour extended to the chest wall or skin, N less than 10 positive 
lymph nodes  
Stage IIIC: N is more than 10 Lymph nodes; one or more lymph nodes in 
subraclavicular, infraclavicular or internal mammary lymph nodes. But there is 
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still no sign of disease spread any further throughout the body. This is known as 
''locally-advanced breast cancer'' 
Stage IV: Breast tumours are of any size. The lymph nodes are affected and the 
cancer has spread to other parts of' the body, which known as ''advanced or 
metastatic breast cancer''. Tumour staging has a marked impact on tumour 
prognosis (Woodward et al., 2003).  
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Table   1:3: Breast Cancer TNM Staging. 
Stage Description 
Stage 0 DCIS 
 
 
Stage I T <2cm, no nodal metastasis (N0) 
 
 
Stage IIA 2< Size <5cm, N negative; or  T<2cm, N positive (<4 axillary 
nodes) 
  
Stage IIB T >5 cm, N negative; or T 2-5 cm and N positive (<4 axillary nodes) 
 
 
Stage IIIA T >5 cm, N positive; or T 2-5 cm and N positive in > 4 axillary 
nodes.  
 
 
Stage IIIB T extends  to the chest wall or skin, N < 10 positive lymph nodes  
 
 
Stage IIIC N > 10 Lymph nodes; involvement of subraclavicular, 
infraclavicular or internal mammary N. No distant metastasis of the 
tumour (M0) 
 
 
Stage IV T has spread to other parts of' the body (M1) 
 
 
Where T, Tumour; N, Lymph node; and M, Metastasis. Data adapted from 
(Singletary et al., 2002). 
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1.1.6 Histological Grading of Breast Cancer  
Histological grading is used widely to assess prognosis in breast cancer. The 
standard tumour grading system in use for breast cancer in the UK was developed 
by the Nottingham Breast Unit, with whom this collaborative project was 
performed. The current Nottingham grading system is a modification of the 
original Scarff-Bloom-Richardson (SBR). The system analyses three features, 
variation in the size and shape of nuclei, the degree of tubule formation and 
mitotic rate. In general, each element is given a score of 1 to 3 (1 being the best 
and 3 the worst) and the score of all three components are added together to give 
the "grade" as follow: Grade I, well differentiated, 3-5 points; Grade II, 
moderately differentiated, 6-7 points; Grade III, poorly differentiated, 8-9 points 
(Elston, 1984, Elston and Ellis, 1991) (Fig. 1.3). Histological grade in breast 
cancer was found to be strongly correlated with prognosis. For example, a study 
in Nottingham by Elston and Ellis (1991) on 1831 primary breast cancers revealed 
that survival for patients with grade I tumours is significantly better than those 
with grade II and III tumours, furthermore, a relatively large study (2219 cases) in 
Nottingham identified tumour grade in primary breast cancer tumours as an 
independent predictor for patient survival (Rakha et al., 2008). 
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Figure 1.3: Nottingham Grading System.  
 
 
Mitotic count is carried out using the high power field (hpf) lens, data adapted 
from (Elston and Ellis, 1991). 
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1.1.7 Tumour Prognosis 
By definition tumour prognosis refers to the probable course and outcome of a 
tumour and the likelihood of patient recovery. A prognostic factor is a measurable 
factor in the primary tumour that can predict the tumour outcome and possibility 
of metastasis. Regarding breast cancer, the tumour prognosis strikingly varies 
from one patient to another. A predictive factor is a measurable factor that can 
predict the response to the treatment. Significant efforts over recent years have 
been made to identify tumour and host factors that would clearly predict tumour 
prognosis. Combinations of prognostic and predictive factors are used by 
clinicians, pathologists and oncologists during the process of tumour management 
to reach an accurate diagnosis measuring tumour differentiation, aggressiveness, 
rate of growth and metastatic potential and accordingly to decide the proper 
treatment modality based on sensitivity/ resistance to treatment (Pantel and 
Brakenhoff, 2004).  
 
 Prognostic factors in use: Considerable efforts have been done to further 
portray the prognosis of 70% of breast tumour patients, who 30% of them are 
going to develop metastasis in the future. A number of new prognostic markers 
have been established in specific patient groups. For example, lympho-vascular 
invasion in the nodal negative group is a poor prognostic marker; conversely, 
steroid receptor and HER2 protein positivity and their gene amplification is an 
established indicator for adjuvant therapy. In addition, uPA/PAI1 protein level is 
an independent prognostic factor associated with high metastatic risk. Overall, 
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gene expression profiling is still a focus for further investigation that proposes a 
bright future in breast cancer management (Weigelt et al., 2005).   
   
  Nottingham Prognostic Index (NPI) is used to work out the likely 
prognosis of the patient, according to information about the stage and grade of the 
breast cancer tumour. The calculation takes account of three factors: the size of 
the cancer; whether or not the cancer has spread to the axillary lymph nodes (and 
if so how many nodes are affected) and the grade of the cancer. The formula (as 
shown in Fig. 1.4) is as follow: NPI = (0.2 * tumour diameter in centimetres) + 
lymph node stage + tumour grade. Applying the formula gives scores which are 
grouped into 3 bands: a score of less than 3.4 suggests a good outcome with 80% 
overall survival (OS) and a high chance of cure. A score between 3 .4 and 5.4 is 
considered intermediate which is characterized by 42% OS and suggests a 
moderate chance of a cure. Finally, any score of more than 5.4 suggests the worst 
outlook (13% OS) with a low chance of a cure. Generally, the NPI index is used 
as a guide to tumour outcome and considered as an important predictor of both 
disease free survival and overall survival. Furthermore, it can be influential in 
determining the treatment recommended (Galea et al., 1992). 
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Figure 1.4: Nottingham Prognostic Index. 
 
Data adapted from (Galea et al., 1992) 
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1.1.8 Models to Study Breast Cancer-Cell Lines  
In the last decade, exploring tumour biology in cell lines and xenografts has 
provided invaluable insights into tumour physiology. Gene expression profiles of 
145 primary breast tumours and 51 breast cancer cell lines revealed similar 
genomic and transcriptional characteristics, although, some significant differences 
between cell line models and solid tumours were also documented (Neve et al., 
2006). This study indicated that most of the genomic abnormalities in original 
tumours were retained in the cell lines derived from them. In addition, as shown 
for Trastuzumab (Herceptin®) monotherapy, cell lines can be useful models to 
measure tumour response to treatment, and can be used to identify molecular 
features that predict or indicate response to targeted therapies (Neve et al., 2006). 
Similarly, applying HDACi treatment (see section 1.2.14) in the H157 human 
lung cancer cell line sensitised the cells for etoposide, which suggests a possible 
use of histone acetylation modulators in combination with conventional 
chemotherapy (Hajji et al., 2009).  
 
1.2 Molecular Pathology of Breast Cancer 
1.2.1 From DNA to Protein 
The genetic material of all cells is deoxyribonucleic acid (DNA) a long 
polymer made up of a sugar phosphate backbone and the 4 bases adenine (A), 
thymidine (T), guanine (G) and cytosine (C). DNA is double stranded, i.e. it 
consists of two complementary nucleic acid chains that form a double helix. Base 
pairing between A: T and G: C is facilitated by hydrogen bonds ensuring the anti-
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parallel DNA strands have complementary sequences. The DNA strands coil to 
form a right-handed double helix (B-DNA), with 10 nucleotide pairs per helical 
turn (Watson and Crick, 1953a, Watson and Crick, 1953b).  The sequence of 
bases on the nucleic acid carries the genetic information, and an RNA copy is 
made by one of three RNA polymerases by the process known as transcription. In 
vivo, DNA strands are further assembled by structural proteins called histones to 
enable the compaction of ~ 1 meter DNA into ~ 10 µm cell nucleus in a well 
ordered structure that permit access to all the genomic material. The DNA 
sequence codes for the whole genomic information. The genome is formed of 
interrupted genes that consists of exons (representing the final RNA products) and 
introns (removed from the initial transcript) (Breathnach and Chambon, 1981). 
The process of splicing involves the deletion of introns from a primary transcript  
to give messenger RNA (mRNA) (Faustino and Cooper, 2003). Generation of 
mRNA is the 1st major step of gene expression; mRNA is generated from DNA 
double helix by RNA polymerases through a complementary base pairing process. 
The mRNA strand is complementary with the sequence of only one strand of 
DNA (the template strand) and is identical (apart from the replacement of T with 
U) with the other strand of DNA. Each mRNA consists of a non-WUDQVODWHG ¶
leader, a coding region, and a non-WUDQVODWHG¶ region. Translation which is the 
2nd stage of gene expression, involves the conversion of the nucleotide sequence 
of mRNA into the sequence of amino acid comprising a protein. mRNA is 
translated by ribosomes. A ribosome is an organelle composed of specialised 
ribonuclear proteins, arranged into small and large subunit, which provide the 
environment that control the recognition of a codon of mRNA and the anticodon 
of tRNA. The genetic code is a series of adjacent triplets. The ribosome translates 
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P51$IURPWKH¶HQGZKHUHLWWUDQVODWHVHDFKWULSOHWFRGRQLQWRDQDPLQRDFLG
DVLWSURFHHGVWRZDUGWKH¶HQG(Dintzis, 1961). The process of protein synthesis 
involves three main stages. The process is initiated by the binding of ribosome to 
the mRNA, forming initiation complex that contain the first aminoacyl-tRNA. 
Followed by the elongation step where amino acids are added to the first one; with 
synthesis of a series of peptide bonds between them to form amino acid chain. 
And finally, the termination step in which the completed peptide chain is released 
(Safer, 1989).  
1.2.2 Overview of Chromatin Structure  
Eukaryotic genomes are assembled as chromatin (DNA and histones), the basic 
unit of which is the nucleosome. The nucleosome consists of 147 base pairs of 
DNA wrapped 1.7 times around a histone octamer; built from two subunits of 
each of histones H2A, H2B, H3, and H4 (Fig. 1.5). The octamer is composed of a 
tetramer core of two H3 and two H4 histones, with H2A and H2B dimers on each 
side. Nucleosomes form a µµEHDGVRQDVWULQJ¶¶ structure, also known as the 10nm 
ILEUH ZKLFK FDQ EH IXUWKHU SDFNDJHG LQWR VROHQRLGV NQRZQ DV µQP ILEUHV¶ RU
higher order structures. Linker histones such as H1 are located between core 
nucleosomes, to facilitate further compaction of chromatin (Khorasanizadeh, 
2004, Luger, 2003). In addition to the core histones, a variety of histone variant 
proteins such as H2A.Z, macroH2A and H2A.X can replace H2A in the 
nucleosome, serving as landmarks for specific cellular functions (Gervais and 
Gaudreau, 2009). Specifically, epigenetic changes in canonical histone and 
histone variants have been found to play a critical role in regulating gene 
transcription (Sutcliffe et al., 2009).  
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Figure 1.5: The Nucleosome is the Basic Unit of Chromatin 
 
 
A schematic representation of the chromatin where the nucleosomes (Arrows) are 
formed from DNA (black threads) wrapped 1.7 turns around two histone 
octamers. The front of the octamer is formed of two subunits of histones H2A, 
H2B; the back of the octamer is formed of two subunits of histones H3, and H4. 
Linker histone H1 (black sphere) is located between the core nucleosomes.  
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1.2.3 Epigenetic Modifications in Chromatin 
Epigenetics is the study of meiotically and mitotically heritable changes in gene 
expression, which are not coded for in the DNA sequence (Egger et al., 2004); 
(Feinberg, 2004). Epigenetic signals include direct modification of the DNA (e.g. 
DNA methylation) and posttranslational modifications of histones. These 
inheritable and stable changes are responsible for maintaining tissue and cellular 
function (Lund and van Lohuizen, 2004b). Epigenetic changes differ from genetic 
changes in that they are (1) reversible, (2) they can affect more than one gene or 
locus, (3) can have positional effects, depending on their sequential or 3-
dimensional proximity to other genes, (4) they are subjected to a high frequency 
of alteration, orders of magnitude greater than that of mutation and (5) can be 
altered by environmental factors i.e. regulation of histone modifications by  
natural products (Feinberg, 2004, Lund and van Lohuizen, 2004b). 
 
Epigenetic changes modulate the accessibility of chromatin to 
transcription regulators and RNA polymerases, and also regulate other nuclear 
processes such as DNA replication, DNA repair and recombination. Epigenetic 
signals induce localised or global changes in the arrangement and composition of 
nucleosomes (Lund and van Lohuizen, 2004b). Structural studies have revealed 
that the N-terminal tails of core histones protrude from the nucleosomal core 
particles (Luger, 2003), and these are subjected to Post Translational 
Modifications (PTMs) (See section 1.2.8). These tails serve as regulatory 
subdomains onto which epigenetic signals can be written. The pattern of histone 
modifications determines the status of the chromatin at that site and is referred to 
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as the ¶¶histone code¶¶ (Jenuwein and Allis, 2001, Fingerman et al., 2008, Yue et 
al., 2007). Many of the enzymes that generate the histone code are recruited to 
chromatin as cofactors of transcription regulators. Other chromatin regulatory 
proteins contain histone PTM recognition modules such as the bromodomain, 
chromodomain or PHD domains. These domains use the epigenetic marks on the 
histone tails as recognition landmarks for chromatin binding to initiate 
downstream biological processes such as chromatin compaction, transcription 
regulation, or DNA repair (Lund and van Lohuizen, 2004b).  
 
1.2.4 Common Epigenetic Changes in Cancer 
In the past, the genetic model was used to explain the origin of cancer as a change 
in DNA sequence. One therefore may investigate the cancer mechanism by a 
search for mutations, deletions, rearrangements and gene amplification. The 
genetic model is able to explain most rare familial cancer syndromes, the cancer 
initiation of most common tumours and a number of mutations in a few genes 
have been shown to be responsible for cancer progression (Feinberg, 2004). In 
addition, an epigenetic model was proposed to further explain features of cancer. 
One therefore investigates the cancer mechanism by a search for changes in DNA 
methylation, chromatin modifications and gene imprinting errors (Feinberg, 
2004). In addition, there is no doubt that histone modifications are contributing to 
carcinogenesis (Li et al., 2005b). Recently, it is well established that both models 
play together i.e. they are either combined or consecutive events (Feinberg, 2004). 
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1.2.5 DNA Methylation in Cancer 
DNA methylation of the genome is a defence mechanism by which the repeated 
DNA (accounts for 50%) is transcriptionally silent. Demethylation of normally 
methylated DNA can result in activation of the corresponding genes (Li et al., 
2005b). It has been found that a change in the methylation status of a gene 
promoter or first exon could cause the same effect of mutations of various tumour 
suppressor genes (TSGs) or protooncogenes (Jagodzinski, 2006). 
 
Dysfunction of DNA methylation is tightly connected to cancer 
development. Global genomic hypomethylation abolishes oncogene activity; 
oncogenesis is promoted by local hypermethylation of tumour-suppressor genes 
(Lund and van Lohuizen, 2004a). DNA hypomethylation is linked to a number of 
cancers: MAGE in melanoma (De Smet et al., 1996), CA9 in renal cell cancer 
(Cho et al., 2001), cyclin D2 and maspin in gastric cancer (Oshimo et al., 2003), 
and hypomethylation of Cyclin D1 promoter as an underlying mechanism of its 
increased expression in gastric carcinoma development and progression (Oshimo 
et al., 2003).  
 
A study of CpG methylation of human papilloma virus type 16 (HPV-16) 
DNA in cervical cancer cell lines revealed an efficiently targeted CpG 
methylation particularly in genomic segments overlying the late genes, while the 
the LCR gene are unmethylated. Moreover, in 81 patient smears, the LCR gene of 
HPV-16 DNA were found to be hypermethylated in 52% of asymptomatic smears, 
21.7% of precursor lesions, and 6.1% of invasive carcinomas; which suggested 
Chapter One: Introduction 
 
35 
that neoplastic transformation may be suppressed by CpG methylation, while 
demethylation occurs as the cause of or concomitant with neoplastic progression 
(Badal et al., 2003). In contrast, hypermethylation is associated with tumour 
suppressor gene silencing (Bestor, 2003), like E-cadherin in human breast and 
prostate carcinomas (Graff et al., 1995). Furthermore, CpG-island-promoter 
hypermethylation is associated with transcriptional silencing of  tumour 
suppressor genes (Esteller, 2007b); hypermethylation of the pro-apoptotic gene 
caspase-8 is a common hallmark of relapsed glioblastoma multiforme (Martinez et 
al., 2007). 
 
1.2.6 DNA Methylation in Breast Cancer 
Regarding breast cancer tumours, an analysis of DNA sequence methylation in 
MCF-7 cells showing drug-resistance (to DOX and cisDDP) revealed dysfunction 
of the genes involved in estrogen metabolism, apoptosis and cell-cell contact. Cell 
line dysfunction was explained by the two opposing hypo- and hyper-methylation 
processes (Chekhun et al., 2007). In addition, Yang et al. (2001) pointed to the 
incidence of methylation of critical tumour suppressors and growth regulatory 
genes in breast cancer. Actually, they lie in several categories including: cell cycle 
regulating genes like p16/p16INK4A/CDKN2A/MTS; steroid receptor genes like 
ER , PR, RAR 2; tumour susceptibility like BRCA1; carcinogen detoxification 
like GSTP1; the cell adhesion gene E-cadherin and the matrix metalloproteinase 
(MMP) inhibitory gene TIMP-3 (Yang et al., 2001). 
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 As these epigenetic changes are reversible events, they are a potential 
therapy targets in cancer (Das and Singal, 2004). There are two categories of 
drugs that epigenetically influence chromatin structure: DNA methyltransferase 
(DNMT) and histone deacetylase (HDAC) inhibitors (Jagodzinski, 2006). HDAC 
and DNMT inhibition are currently being evaluated in clinical trials with cancer 
patients (Issa et al., 2004, Garcia-Manero et al., 2008, Rudek et al., 2005). 
Moreover, Lan Yan (2001) suggested that inhibition of DNA methylation and 
histone deacetylation might be a therapeutic strategy in breast cancer especially 
for the ER and PR negative breast cancer phenotype. Recently, in a cell line 
model HDACi treatment sensitised the cancer cells to topoisomerase II (Hajji et 
al., 2009).  
 
1.2.7 Histone Methyltransferases 
Histone methyltransferases catalyze the addition of one or more methyl groups to 
a specific lysine or arginine residue within histones (Fingerman et al., 2008). 
Methylation of histones or combinations of post translational modifications can 
result in a variety of diverse biological processes. For example, trimethylation of 
lysine 9 in histone 3 (H3K9me3) is related to gene silencing/heterochromatin 
formation and trimethylation of lysine 4 in histone 3 (H3K4me3) is tightly linked 
to transcriptional regulation (Schotta et al., 2002, Tachibana et al., 2005, Lund and 
van Lohuizen, 2004b). Moreover, distinct effector molecules can read different 
methyl-lysine modification codes through specific interactions with the 
methylated histone. For example, heterochromatin protein 1 (HP1) mediates 
transcriptional repression via its high-affinity interactions with histone H3 
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methylated at K9 and K27 (Bannister et al., 2001). Several SET (SuVar39, 
Enhancer of Zeste and Trithorax) domain proteins have been established as 
histone methyltransferases capable of covalently altering the lysine residues of 
histone proteins. Many of those SET domain proteins have been tightly linked to 
cancer development (Lund and van Lohuizen, 2004b).  
 
Several methyltransferases were found to be relevant to the histone 
modifications described in this study. The SUV39H1 protein is the first SET 
domain recognized as a histone methyltransferase (HMT) (Lund and van 
Lohuizen, 2004b). It methylates histone H3K9 and localizes to transcriptionally 
silent heterochromatin, where it recruits the transcriptional repressor HP1. 
SUV39H1 and HP1 have also been implicated in transcriptional repression at 
euchromatic loci (Bhaumik et al., 2007). 
 
 SUV420H1/2 were first identified in 2004 as two novel SET domain 
HMTases, that localize to pericentric heterochromatin in conjunction with HP1. 
SUV420H1/2 have been found to specifically trimethylate H4 at K20 (Schotta et 
al., 2004, Benetti et al., 2007). Reduced expression of SUV420H2 and loss of 
H4K20me3 were illustrated in human lung cancer (Van Den Broeck et al., 2008) 
and  preneoplastic liver nodules in mice (Pogribny et al., 2006). In regards to 
breast cancer, loss of H4K20me3 was correlated with poor prognostic breast 
cancer subtypes (Elsheikh et al., 2009). In breast cancer cell lines, 
characterization of SUV420 enzymes in non- tumourigenic MCF-10-2A epithelial 
breast cells versus malignant cell lines (MCF-7, MDA-MB-231 and MDA-MB-
231/S30) revealed a dysregulation of SUV420 and reduced H4K20me3 in 
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malignant cell lines especially MDA-MB-231 (Tryndyak et al., 2006). Moreover, 
diminished level of SUV420 expression was described in MCF-7 cells (Chekhun 
et al., 2007), suggesting an epigenetic role for SUV420 in breast cancer drug 
resistance.   
   
The methyltransferase Set7/9 is capable of the lysine methylation of 
histone tails which has important functions in many biological processes that 
include heterochromatin formation, X-chromosome inactivation and 
transcriptional regulation (Martin and Zhang, 2005). Also non-histone proteins 
can be methylated by Set7/9, in particular, it was shown to catalyze methylation 
of p53 at lysine 372 (p53K372me) and to modulate p53 activity in a human cancer 
cell line. Moreover, it is involved in the binding of the acetyltransferase TIP60 to 
p53 and for the subsequent acetylation of p53. So, lysine methylation of p53 by 
Set7/9 is important for p53 activation in vivo suggesting a mechanistic link 
between methylation and acetylation of p53 through TIP60 (Kurash et al., 2008). 
 
1.2.8 Histone Post Translational Modifications (PTMs) in Cancer 
As described above, histones have a key role in the regulation of gene 
transcription. The N-terminal tail of the histone is subjected to several post-
translational modifications such as acetylation, deacetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, and ADP-ribosylation 
(Khorasanizadeh, 2004). Together these modifications are referred to as the 
histone code (Jenuwein and Allis, 2001). Generally, histone hyperacetylation at 
gene promoters is correlated with transcription activity, whereas deacetylation is 
Chapter One: Introduction 
 
39 
correlated with inactive genes. Histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) are the modulators for histone acetylation. Moreover, 
HMTs also play a similar role on histone modification and eventually gene 
regulation (Berger, 2002). For example, in prostate cancer, the expression of 
several tumour-associated genes were found to be associated with high levels of 
histone acetylation compared to normal cells (Li et al., 2005b). Another study in 
the same field  by Tsubaki, Hwa et al. (2002), documented that treatment of 
prostate cancer cells with HDAC inhibitors increased the expression of genes such 
as insulin-like growth factor±binding protein 3 and carboxypeptidase A3 (CPA3); 
confirming the role for histone acetylation in gene regulation. Figure 1.6 is an 
overview of the modifications occurring in the histone tails which lead to changes 
in gene expression. 
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Figure 1.6: Covalent Modifications of the N-terminal tail of the Core 
Histones.  
 
Acetylation and methylation marks are in  green and blue circle, reproduced from 
(Esteller, 2007a) and modified. 
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Global Histone Modifications are Altered in Cancer 
 Seligson et al., (2005) found that changes in bulk histone modifications are 
associated with cancer and that these changes are predictive of clinical outcome, 
independently of tumour stage, biomarkers, or capsular invasion. In addition, they 
proposed that the varied levels of specific histone modifications in prostate cancer 
may indicate an undiscovered molecular heterogeneity that might explain the 
broad range of clinical behaviour in cancer patients.  
 
 Our recent work on 880 breast cancer cases has showed that global histone 
PTMs are associated with tumour morphologic types, biomarker phenotype, 
tumour grade and  clinical outcome (Elsheikh et al., 2009). Altered global histone 
PTMs has also been found as a prognostic marker in other tumours such as renal 
cell carcinoma, glioma (Mosashvilli et al., 2010, Liu et al., 2010) and in 
inflammatory bowel disease (Tsaprouni et al., 2011). In addition, targeting global 
histone modification levels was speculated as a future therapy in cancer especially 
pancreatic and prostatic cancer (Manuyakorn et al., 2010, Reynoird et al., 2010, 
Ellinger et al., 2010). In the following section, I will discuss some of the most 
important histone PTMs that have a critical role in cellular function and 
tumourgenesis. 
 
 H3 lysine 9 methylation has been implicated in a variety of cell functions; 
such as, transcriptional silencing (Tachibana et al., 2005). It was considered the 
primary signal sufficient for initiating a gene repression pathway in vivo 
(Snowden et al., 2002). Generally, silenced or inactive promoters exhibit a loss of 
histone H3-acetylation and an increase in H3 lysine 9 trimethylation (H3K9me3) 
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(Groner et al., 2010). Regarding cancer, H3K9 methylation was illustrated in the 
silenced loci of three genes in colorectal cancer. Interestingly, treatment with the 
DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5Aza-dC) rapidly 
reduced H3K9 methylation at silenced loci and resulted in reactivation of all three 
genes (Kondo et al., 2003). Furthermore, in DKO cells, the DNMT3B-deficient 
HCT116 colon cell line, elimination of H3K9 methylation from p16 (INK4a) gene 
resulted in profound changes in the surrounding histone PTMs; conversely, H3K9 
methylation resulted in re-silencing of genes (Bachman et al., 2003).  
  
 H3K9me3 is a hallmark of heterochromatin formation; in conjunction with 
heterochromatic protein1 (HP1) family proteins they play a key role in 
constitutive heterochromatin formation (Bernstein et al., 2006, Wako and Fukui, 
2007).  H3K9me3 is recognized and recruited by HP1 to discrete regions of the 
genome, thereby regulating gene expression, chromatin packaging and 
heterochromatin formation (Dormann et al., 2006). In addition, H3K9me3 has a 
role in DNA double-strand break repair. The histone acetyltransferase TIP60 
binds to H3K9me3 at heterochromatic sites, triggering acetylation and activation 
of DNA double-strand break repair factors (Fischle, 2009). 
 
 The role of H3k9me3 in cancer has been described; for example, 
dysregulation of H3K9me3 has been identified in acute myeloid leukaemia 
(AML). A decrease in H3K9me3 levels at promoter regions resulted in enhanced 
transcription factor activity at those sites. In addition, using the H3K9me3 
signature in combination with established clinical prognostic markers 
outperformed prognosis prediction based on clinical parameters alone; and 
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enhanced AML outcome prediction (Muller-Tidow et al., 2010). In a mouse 
model, a study of hepatogenesis revealed that a methyl deficient diet resulted in 
altered global histone methylation/acetylation during tumourgenesis. They found 
altered levels of H4K20me3, H3K9me3, H4K16ac and H3K9ac and their 
modulators, the HATs and methyltransferases; this signifies the importance of 
histone PTMs in tumourgenesis (Pogribny et al., 2007). In prostate cancer, a 
recent study on 113 prostate cancer and 23 non-malignant samples revealed that 
levels of H3K9me3 were significantly reduced in cancer samples compared to 
non-malignant prostate tissue (Ellinger et al., 2010).  
 
Multiple efforts have been made to modulate global H3K9me3 levels. 
Identification of GASC1, the putative oncogene which demethylates H3K9me3, 
delocalizes HP1 and reduces heterochromatin formation makes it a good target for 
anticancer therapy (Cloos et al., 2006). In addition, cobalt compounds have been 
implicated in reducing global H3K9me3 levels in A549 (a human lung carcinoma 
cell line) and Beas-2B, (a human bronchial epithelial cell line) by directly 
inhibiting JMJD2A demethylase activity (Li et al., 2009a). Finally, a mouse 
model study revealed that a methyl-deficient diet was found to induce malignant 
transformation in rat liver cells; mainly through an increase in global H3K9me3 in 
the formed tumours (Pogribny et al., 2007). 
 
H3 Lysine 18 acetylation (H3K18ac), lower global/cellular levels of this acetyl 
mark were found to predict a higher risk of prostate cancer recurrence and poorer 
survival probabilities in both lung and kidney cancer groups (Seligson et al., 
2009, Lall, 2008). In contrast, in oesophageal cancer, low expression of H3K18ac 
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correlated with a better prognosis, especially for those with early stage cance, 
strengthened by a correlation between tumour differentiation and high H3K18ac 
levels (Tzao et al., 2008). CBP and p300, the histone acetyltransferases (HATs) 
are required for H3K18 acetylation (Horwitz et al., 2008, Lall, 2008).  
 
H4 Lysine 16 acetylation (H4K16ac) specifically disrupts the formation of 
higher-order chromatin structures (Shogren-Knaak et al., 2006). An open 
chromatin configuration provides accessibility for specific transcription factors 
and the general transcription machinery (Glozak and Seto, 2007).  H4K16ac was 
found to be lost at the promoters of certain tumour suppressor genes (Kapoor-
Vazirani et al., 2008) and has been described as a common feature in human 
cancer (Pfister et al., 2008). This single histone PTM was found to have a key role 
in modulating both higher order chromatin structure and functional interactions 
between non-histone proteins and chromatin fibres (Shogren-Knaak et al., 2006).  
 
 H4K16ac is regulated by the histone acetyltransferase human MOF 
(hMOF) which is required for bulk H4K16 acetylation (Taipale et al., 2005). 
Knockdown of hMOF in HeLa and HepG2 cells caused a dramatic reduction of 
histone H4K16ac. In addition, hMOF has a role in DNA damage response during 
cell cycle progression. In HeLa cells, this reduction in hMOF levels by RNA 
interference resulted in an accumulation of cells in the G2 and M phases (Taipale 
et al., 2005). Moreover, down-regulation of hMOF results in decreased H4K16ac 
at the TMS1 gene loci (a tumour suppressor), a loss of nucleosomes positioning, 
and gene silencing. Interestingly, the induced gene silencing was independent of 
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histone methylation or DNA methylation and was reversed on hMOF re-
expression (Kapoor-Vazirani et al., 2008).  
 
 Pfister et al., (2008) examined the involvement of both H4K16ac and 
hMOF expression in breast cancer (n=100) and medulloblastomas (n=102) 
samples. mRNA expression profiling revealed down regulation of hMOF by 40% 
(breast cancer) and 11% (medulloblastoma). In addition, in a larger series of 
primary breast carcinomas (n=298) and primary medulloblastomas (n=180), 
immunohisto-chemistry (IHC) staining revealed low detection levels of both 
marks in both types of cancer compared to control non-malignant tissues (Pfister 
et al., 2008). In addition, hMOF protein expression was tightly correlated with 
acetylation of H4K16 in all tested samples (Pfister et al., 2008). 
 
H4 Lysine 20 trimethylation (H4K20me3) dysregulation has been described in 
brain, breast and lung cancer (Liu et al., 2010, Elsheikh et al., 2009, Van Den 
Broeck et al., 2008). Loss of H4K20me3 has been found to play a crucial role in 
tumourgenesis of non-small cell lung carcinoma (Van Den Broeck et al., 2008). 
Cancer cells were found to display an aberrant pattern of histone H4 
modifications, i.e. H4K16 hypo-acetylation and loss of H4K20me3 in comparison 
to normal lung tissue (Van Den Broeck et al., 2008). Methylation of H4 lysine 20 
has been described in the DNA damage response in both yeast (Sanders et al., 
2004) and Drosophila (Sakaguchi and Steward, 2007), especially in functional 
interaction with H4K16ac (Hsiao and Mizzen, 2010). The HMT SUV420H1 was 
found responsible for trimethylation of histone 4 at lysine 20 (Pannetier et al., 
2008); Loss of H4K20 trimethylation in lung and breast cancer has been found 
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associated with a decrease in SUV420H2 expression (Van Den Broeck et al., 
2008, Tryndyak et al., 2006). Using a mouse model of multistage skin 
carcinogenesis, Fraga et al., (2005) reported loss of both H4K16ac and 
H4K20me3 during early stages of the tumourigenic process, in association with 
hypomethylation of DNA repetitive sequences, a well-known characteristic of 
cancer cells. This suggested that global loss of both monoacetylation and 
trimethylation of histone H4 is a common hallmark of human tumour cells.  
 
H3K9me3, H4K20me3 and their Modulators, trimethylation of H3K9 is catalysed 
by the enzyme SUV39H1, (Bhaumik et al., 2007) the human homologue of the 
dominant Drosophila modifier of position-effect-variegation (PEV) Su (var) 3-9; 
(Aagaard et al., 1999). SUV39H1 co-localizes with methyl-lysine binding protein 
HP1, suggesting  a regulatory role for SUV39H1 in higher order chromatin 
organisation (Aagaard et al., 2000). The SUV39H1-induced H3K9 trimethylation 
is associated with the repressed state of chromatin (O'Carroll et al., 2000, Rea et 
al., 2000, Bhaumik et al., 2007, Bannister et al., 2001). In addition to the 
involvement of SUV39H1-HP1 complex in heterochromatic gene silencing, it 
was also described in relation to Retinoblastoma protein (RB) repressive function 
at euchromatic genes in vivo (Nielsen et al., 2001). Modulation of 
heterochromatin formation has been proved to alter gene activity through 
stabilizing transcriptional "on" or "off" states. For example, in a mouse model 
study, over expression of SUV39H1 has been found to be associated with 
embryonic mice growth retardation (Czvitkovich et al., 2001).  
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The levels of H3K9me3 in vivo are indirectly regulated by the NAD-
dependent acetyltransferase SIRT1. It has been reported that acetylation of 
SUV39H1 at K266 results in lower MTase activity of the enzyme. Reversal of this 
modification by SIRT1 stimulates SUV39H1 methyltransferase activity. 
Consistent with this, loss of SIRT1 greatly affects SUV39H1-dependent 
trimethylation of H3K9 and impairs localization with heterochromatin protein 1 
(Vaquero et al., 2007). Moreover, Deleted in Breast Cancer 1 (DBC1), a negative 
regulator for SIRT1 (Kim et al., 2008) was found to inhibit SUV39H1 activity as 
well by disrupting the SUV39H1-SIRT1 protein complex (Li et al., 2009d). 
 
 Schotta et al (2004) reported that H3K9 trimethylation by SUV39H1 plays 
a critical role in the subsequent induction of H4-K20 trimethylation, although the 
H4 Lys 20 position is not an intrinsic substrate for SUV39H1. Like SUV39H1, 
both SUV420H1 and SUV420H2 can interact with HP1, suggesting the existence 
of a sequential mechanism to establish H3-K9 and H4-K20 trimethylation at 
pericentric heterochromatin (Schotta et al., 2004). 
 
 
Crosstalk and Synergy between Histone PTMs, a profile for Active and 
Repressed Genes 
While efforts are still underway to understand the functions of single histone 
PTMs, the histone code hypothesis predicts that histone PTMs act combinatorially 
to signal to chromatin regulators. Recent examples from the literature and 
unpublished data from our laboratory indicate that some chromatin binding 
proteins contain multiple modules such as chromo, bromo and PHD domains that 
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recognise multiple histone PTMs simultaneously (Ruthenburg et al., 2011, Deeves 
et al., unpublished). These combinatorial signals control nuclear processes such as 
transcription (Daujat et al., 2002), DNA damage response (van Attikum and 
Gasser, 2009) and transcriptional elongation (Zippo et al., 2009). Specifically, a 
study of TMS1/ASC, the pro-apoptotic gene that undergoes epigenetic silencing 
in human cancers revealed that, in active state of the TMS1 gene, the CpG island 
is marked by histone H4K16ac and H3K4 methylation. Conversely, silencing of 
this gene was accompanied by CpG loss of H4K16ac, H3K4 hypomethylation, 
and hypermethylation of H3K9. In addition, a single peak of histone H4K20me3 
was observed near the transcription start site (Kapoor-Vazirani et al., 2008). 
Clearly, crosstalk and synergy between PTMs is therefore an important aspect of 
functional signalling in chromatin. Thus, it will be necessary to investigate the 
occurrence of multiple histone PTMs to discover new and informative cancer 
biomarkers.  
1.2.9 Histone Variants in Cancer 
Histone variants have evolved to perform different functions in the genome, such 
as chromosome segregation, DNA repair and gene regulation. Thus it is of 
interest to know whether global levels of histone variants were altered in breast 
tumours. In this study we investigated the expression of two variants of histone 
H2A, whose functions are outlined here.  
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Macro H2A (mH2A)  
mH2A a member of the histone variant family (Abbott et al., 2004), which was 
first described in rat liver nucleosomes is nearly three times the size of 
conventional H2A histone. Although mH2A closely resembles the full length 
histone H2A, it contains a large C-terminal addition that is not conserved in other 
histone variants. The N-terminal region is 64 percent identical to full-length H2A 
(Pehrson and Fried, 1992). Two subtypes of macroH2A (macroH2A1.1 and 
macroH2A1.2) were described, which are likely to have distinct roles in 
chromatin structure and function (Pehrson et al., 1997).  
 mH2A has been described to be involved in a number of cellular 
functions. For example, nucleosome remodelling in repressed heterochromatin 
(Angelov et al., 2003) and in the inactive X chromosome study, where it was 
found preferentially (Costanzi and Pehrson, 1998). In addition, mH2A is also 
involved in transcriptional repression by interfering with the binding of the 
transcription factor NF-kappaB (Angelov et al., 2003), repression of p300- and 
Gal4-VP16-dependent polymerase II transcription (Doyen et al., 2006). 
Consistent with this, it was shown to be enriched at inactive genes as revealed in 
an immunopurification study; where mH2A.1 was found to be confined to the 
promoters of inactive genes in a complex containing PARP-1. mH2A.1 binding to 
PARP-1 inactivates its enzymatic activity and  interferes with transcription 
(Ouararhni et al., 2006). mH2A.1 also has a role in heterochromatin formation; it 
consistently colocalizes with the heterochromatin markers (H3K27me2 and  
H3K27me3); while, mH2A2 colocalizes with the euchromatin marker, H3K4me3 
Chapter One: Introduction 
 
50 
(Araya et al., 2010). Thus the mH2A variant appears to function principally to 
suppress gene expression.  
 
 
 With regard to a potential role for mH2A in tumours, a study of mH2A 
function in a melanoma cell line revealed a favourable role for mH2A in 
controlling malignant melanoma tumour progression. Knockdown of mH2A in 
melanoma cells of low malignancy results in significantly increased proliferation 
and migration in vitro and enhanced growth and metastasis in vivo (Kapoor et al., 
2010). Interestingly, mH2A binding to chromatin is not affected by the 
acetylation of the other core histones  (Abbott et al., 2004). 
 
Histone Variant H2A.Z 
H2A.Z is another variant of the core histone H2A and represents 10% of the total 
H2A in the cells (Redon et al., 2002). In humans H2A.Z is incorporated into 
nucleosomes by Snf-2-related CREB-binding protein activator protein (SRCAP) 
and p400/TIP60 complexes (Gevry et al., 2007, Svotelis et al., 2009a); which 
catalyse nucleosome sliding and help ATP-dependent exchange of histone 
H2A/H2B dimers containing H2A.Z into nucleosomes (Cai et al., 2006). H2A.Z 
was found to contribute to biophysical property changes in the nucleosomes; for 
example, H2A.Z containing nucleosomes exhibited higher mobility and weaker 
correlations between internal motions compared to the respective canonical H2B 
and H2A containing nucleosome (Placek et al., 2005). 
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 H2A.Z has a pleiotropic action and, most interestingly, has been proposed 
as an epigenetic marker for memory for repressed previously-active genes 
(Brickner et al., 2007). Other functions have also been suggested, such as a 
requirement for H2A.Z in heterochromatin integrity (Rangasamy et al., 2003), a 
guard against heterochromatin propagation (Shia et al., 2006), and roles in DNA 
damage repair (Ahmed et al., 2007, Gevry et al., 2007), chromosome segregation 
(Dhillon et al., 2006, Altaf et al., 2009), nucleosome stability (Jin and Felsenfeld, 
2007) and for transcription factor recruitment (Fu et al., 2008, Draker and 
Cheung, 2009, Lemieux et al., 2008).  
 
 Importantly, H2A.Z is subjected to post translational modifications 
(PTMs) which appear to correlate with gene activity (Thambirajah et al., 2009). 
Acetylation of H2A.Z is linked to genome-wide gene activity in yeast (Millar et 
al., 2006), chicken (Bruce et al., 2005) and mammalian cells (Chen et al., 2006). 
In yeast, H2A.Zac is deacetylated by Sir2 prior to degradation via a 
ubiquitin/proteasome-dependent pathway (Chen et al., 2006, Seligson et al., 
2009). In human cells, H2A.Z is incorporated into nucleosomes as an H2A.Z/H2B 
dimer by the SRCAP and p400/TIP60 complexes (Svotelis et al., 2009a). A study 
on SRCAP remodelling complexes revealed its role as a co-activator for a number 
of transcription factors (Svotelis et al., 2009a) as a result of its ability to promote 
incorporation of H2A.Z into chromatin (Ruhl et al., 2006).  
 
In yeast, H2A.Z was correlated with global gene activation as it was found 
in nucleosomes located within two thirds of active gene promoters (Guillemette 
and Gaudreau, 2006). In addition, it configures chromatin structure to poise genes 
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for transcriptional activation (Guillemette et al., 2005). Interestingly, a synergistic 
combination between H2A.Z and H4K16ac has been described at active gene loci 
(Shia et al., 2006). Particularly, H4K16ac was found to be necessary for H2A.Z 
incorporation near telomeres; synergistic attendance of both H2A.Z and H4K16ac 
was found to be essential for preventing the ectopic propagation of 
heterochromatin (Shia et al., 2006). H2A.Z and H4 mutants which cannot be 
acetylated were incompatible with life (Babiarz et al., 2006), which demonstrates 
how essential H2A.Z and H4K16 acetylation are for living organisms.  
 
H2A.Z has also been shown to prevent the spreading of silent chromatin 
into proximal euchromatin telomeres (Rong, 2008). In addition, a close 
relationship between H2A.Z and H3K9me3 has been described during 
heterochromatin formation in vertebrate (Bulynko et al., 2006) and mammalian 
cells (Greaves et al., 2007). Consistently, in the metazoan genome, the affinity of 
HP1 binding to nucleosomal arrays was increased by 2-fold when H2A was 
replaced with H2A.Z (Fan et al., 2007). Together, H2A.Z maintains 
heterochromatin formation and gene silencing through promoting H3K9me3 and 
its modulators. 
 
  H2A.Z also has a role in transcriptional regulation, as it was found in 
association with functional gene regulatory elements (Barski et al., 2007, Gevry et 
al., 2007). H2A.Z was also found in association with active p53 during apoptosis 
in mammalian balstocysts (Rodriguez et al., 2007), which emphasises it s role in 
gene transcription. In addition, studying H2A.Z in nucleosome core particles 
(NCPs) revealed a role in contributing to different biophysical properties of 
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nucleosomes (Placek et al., 2005) that regulate promoters and enhance 
transcription of genes (Jin and Felsenfeld, 2007). 
 
H2A.Z has also been proposed to have a function in the DNA damage 
response. In yeast, H2A.Z was released from the p21 promoter upon DNA 
damage, followed by recruitment of TIP60 (see below) to activate p21 
transcription (Gevry et al., 2007). It is worth mentioning that both H2A.Z and 
TIP60 were recruited to DNA double strand break sites (DSP) (Kawashima et al., 
2007, Kalocsay et al., 2009).  
 
H2A.Z undergoes dynamic redistribution at gene promoters which has 
been found to be necessary for cell fate transitions (Creyghton et al., 2008). 
H2A.Z has also been described as a critical element in cellular differentiation in 
human hematopoietic stem cells (Creyghton et al., 2008) and marine invertebrates 
cells (Arenas-Mena et al., 2007).  
 
As mentioned above, H2A.Z is subjected to post translational 
modifications including acetylation. In chickens, ChIP-Seq studies revealed that a 
triacetylated form of H2A.Z is enriched at the 5' end of active genes, while the 
non-acetylated form was absent from both active and inactive genes during 
interphase. Conversely, at mitosis H2A.Z acetylation was erased, the non-
acetylated form was predominant (Bruce et al., 2005). In yeast, acetylation of 
H2A.Z at lysine 14 was linked to genome-wide gene activity (Millar et al., 2006), 
consistent with the hypothesis that the acetylated form marks active genes (Bruce 
et al., 2005). In mammalian cells, deacetylation of H2A.Z is catalysed by SIRT1, 
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and in yeast this is achieved by Sir2 (the yeast homologue of SIRT1). Sir2 
deacetylates H2A.Z at lysines (K) 4, 7, 11, 13, 15, 115 and 121 (Chen et al., 2006, 
Dryhurst et al., 2004). Interestingly, the acetylation status of H2A.Z regulates its 
turnover by the proteasome.  H2A.Z deacetylation at K115 and K121 promotes its 
degradation via the ubiquitin/proteasome-dependent pathway (Chen et al., 2006, 
Seligson et al., 2009). Consistent with this, yeast genetic studies identified a role 
for H2A.Z in preventing Sir-dependent gene repression (Venkatasubrahmanyam 
et al., 2007), revealing a feedback control between H2A.Z acetylation and SIRT1. 
However, H2A.Z alone is not sufficient to establish an active chromatin structure 
(Arimbasseri and Bhargava, 2008); rather it acts as a chromatin based 
transcriptional memory mark for recently repressed genes to keep these localised 
to the nuclear periphery to promote their rapid reactivation (Brickner et al., 2007, 
Brickner, 2009).  
 
A recent study has demonstrated that both histone PTMs and DNA 
sequences influence H2A.Z occupancy in nucleosomes, indicating that both 
genetic and epigenetic signals regulate H2A.Z targeting to distinct chromatin loci 
(Gervais and Gaudreau, 2009). For example, H3 and H4 acetylation status 
promotes H2A.Z deposition in yeast (Raisner et al., 2005). In addition, in human 
primary hematopoietic stem cells (HSCs), increased levels of H2A.Z were noted 
at the promoter of some genes in association with specific histone modifications 
during cellular differentiation (Cui et al., 2009).  
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1.2.10 Tumour Suppressor p53: Post Translational Modifications 
(PTMs) and its Role in Cancer 
The  transcription factor p53 is referred to as the ³JXDUGLDQRI WKHJHQRPH´ and 
functions as a tumour suppressor protein protecting cells against a range of 
physiological stresses, including oncogene activation, radiation, mitotic stress, 
ribosomal stress and chemical insults (Lane, 1992). Upon cellular stress, p53 is 
activated, and undergoes a complex set of nuclear interactions to regulate the 
transcription of a variety of genes involved in growth arrest, repair, apoptosis, 
senescence or altered metabolism (Vousden and Lane, 2007). p53 has an 
additional cytoplasmic role in controlling cell cycle and apoptosis, through its 
interaction with mitochondrial associated proteins like Bcl-2 and Bax (Galluzzi et 
al., 2008). Because of its involvement in a wide range of cellular events, loss of 
p53 expression or functional abnormalities have been linked to human cancer 
(Goh et al.). For example, the p53 gene is mutated in 50% of human tumours 
(Oren, 1999), making it the most susceptible gene for alterations. However, it is 
likely that all cancers harbour mutations that result in aberrant p53 function.  
 
p53 is subjected to numerous post translational modifications as shown in 
Figure 1.7, including phosphorylation, ubiquitination, acetylation, methylation  
and sumoylation (Meek and Anderson, 2009). Phosphorylation of p53 at Serine 
(S) and threonine (T) sites occurs within the N-terminal transactivation domain 
and the C-terminal regulatory domain (Dai and Gu, 2010). Following cellular 
stress, p53 is phosphorylated by several kinases like ATM, ATR, ChK1/2, such 
phosphorylation of p53 leads to stabilization of the p53 tetramer and enhanced 
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DNA binding and activity (Kruse and Gu, 2009). Phosphorylation at specific sites 
has been linked to specific p53 function; for example, p53 phosphorylation at S46 
is critical for p53 mediated induction of pro-apoptotic genes (Taira et al., 2007) 
and phosphorylation at S392 is required for p53 stabilization (Matsumoto et al., 
2006). 
 
 Ubiquitination which denotes the covalent conjugation of one or more 
ubiquitin molecules to a protein substrate requires the consecutive function of 
three enzymes: an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating 
enzyme and an E3 ubiquitin-ligating enzyme. The ubiquitination of p53 plays a 
key role in its cytoplasmic translocation (Lee and Gu, 2009) and is essential for 
p53 proteasomal degradation (Marine and Lozano, 2010). 
 
 p53 is also subjected to methylation at arginine and lysine residues by 
PRMT5 and several lysine methyltransferases (e.g. SET7/9), respectively (Sims 
and Reinberg, 2008). Interestingly, these modifications can alter the specificity of 
p53 for its target genes (Jansson et al., 2008, Chuikov et al., 2004). p53 
methylation can be either activating or repressing depending on the site of 
methylation (Dai and Gu, 2010, Shi et al., 2007, Huang et al., 2006); and the 
number of covalent post translational modifications at the same site (Dai and Gu, 
2010, Huang et al., 2007). Recently, it has been reported that p53-binding protein 
1 (53BP1) accumulation at DSBs requires H4K20 methylation by the histone 
methyltransferase MMSET in a process involving ƣH2A.X DNA damage 
response pathway (Pei et al., 2011), suggesting a functional link between p53 and 
histone methylation. 
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 Acetylation of p53 is generally associated with increased transcriptional 
activity of p53. Acetylation enhances p53 stability by competing with 
ubiquitination and inhibiting the formation of MDM2/MDM4 repressive 
complexes on target gene promoters. In addition, it enhances p53 transcription 
activity by stimulating cofactor recruitment (Dai and Gu, 2010).  
 Nine acetylation sites in p53 have been described, six lysine residues in 
the C-terminal regulatory domain (K370, K373, K381, K382 and K386) are 
acetylated by CBP/p300, one in the tetramerization domain (K320) acetylated by 
PCAF and two in the DNA binding domain (K120, K164) which appear to be 
targeted by MYST family acetyltransferases and CBP/p300, respectively (Meek 
and Anderson, 2009). Acetylation at the C- terminal domain has been shown to 
enhance p53 binding to DNA sequences and promote p53 transcriptional activity 
and stability (Feng et al., 2005, Kruse and Gu, 2009). Acetylation of p53 at K320 
by PCAF is linked to p53- related cell cycle arrest via enhanced transcription of 
the p21 gene (Knights et al., 2006a). Acetylation of the K120 residue, which is 
located in the DNA binding domain is induced by TIP60 and hMOF and found 
crucial for p53-dependent apoptosis  (Tang et al., 2006a, Li et al., 2009c, Sykes et 
al., 2006), whereas acetylation of K164 by CBP/p300 (Tang et al., 2008) has been 
described as a critical step for  p53-dependent transcription of apoptosis related 
genes (Xu et al., 2009b). 
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Figure 1.7: p53 PTMs. 
 
Overview of p53 domain structure, sites for covalent PTMs and the enzymes 
responsible for each modification are shown on the right side. TAD, 
transactivation domain; PRD, proline rich domain; DBD, DNA-binding domain; 
TD, tetramerization domain; CRD, C-terminal regulatory domain. Reproduced 
with permission from the copyright holder (Elsevier). 
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Involvement of PTMs in p53 activation    
Cellular exposure to stress signals leads to marked elevation in p53 protein within 
a relatively short time. The rapid p53 elevation is achieved by enhanced 
translation of p53 mRNA, (Oren, 1999). Interestingly, p53 is a very labile protein 
whose half-life in some cells is measured in minutes (Rogel et al., 1985). Upon 
cellular stress, acetylation of p53 causes an accumulation of  p53 and an increase 
in the protein half-life (Feng et al., 2005, Kruse and Gu, 2009). p53 activation 
enhances its gene specific, transcriptional activity, which relies on its ability to 
bind defined sequence elements within target genes (Oren, 1999). Once the 
cellular stress ceases, inhibition of  p53 synthesis takes place through p53 binding 
to its own mRNA and p53 binding activity is also negatively regulated (Oren, 
1999).  
 
p53-Mdm2-MdM4 Loop 
Mdm2 inhibits p53 function, in a negative feedback loop mechanism (Chen et al., 
1994). Upon cellular stress, p53 binds specifically to the Mdm2 gene and 
stimulates Mdm2 transcription (Oren, 1999). Mdm2 protein binds p53, represses 
its transcriptional activity and enhances p53 export into the cytoplasm prior to 
complete elimination through proteolytic degradation (Oren, 1999, Alarcon-
Vargas and Ronai, 2002). Interestingly, Mdm2 also possesses a self-ubiquitination 
property, upon cellular stress, Mdm2 is subjected to self-ubiquitination and 
degradation (Alarcon-Vargas and Ronai, 2002).  
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 In mice, inactivation of the Mdm2 gene resulted in early embryonal 
lethality, which is reversed by simultaneous inactivation of p53 (Grier et al., 
2006). Mdm2 is amplified in approximately 7% of human cancers (Alarcon-
Vargas and Ronai, 2002); high expression levels of Mdm2 in tumours led to 
inhibition of p53 and thereby promoted cancer formation without a need for p53 
gene alteration (Oren, 1999). In a cell line model, blocking the binding sites of 
p53 by monoclonal antibodies or competitor peptides results in a dramatic 
stabilization and accumulation of p53 in non-stressed cells (Oren, 1999). Notably, 
PTMs of p53 were found to remarkably oppose the Mdm2-induced inhibitory 
effects on p53. Upon cellular stress, phosphorylation and acetylation of p53 were 
reported to abolish Mdm2 association with p53 (Alarcon-Vargas and Ronai, 2002, 
Feng et al., 2005, Kruse and Gu, 2009).  
 
 Toledo (2007) has described a mechanism (Fig. 1.8) for p53 regulation 
that involves p53, Mdm2 and MdM4. Under normal conditions in unstressed 
cells, p53 protein is kept at low levels as a consequence of Mdm2-mediated 
degradation and MdM4-mediated p53 transactivation domain (TAD) inactivation. 
During cellular stress, Mdm2 degrading activity is shifted to itself and MdM4, 
leading to depletion of both Mdm2 and MdM4 proteins, this builds up p53 protein 
levels and activity, resulting in enhanced p53 transcriptional activity. As soon as 
the cellular stress is relieved p53 returns to the basal pre-stress level (Toledo and 
Wahl, 2007).  
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Figure 1.8: Mdm2, MdM4 and p53 Regulatory Loop. 
 
 
Schematic representation of p53, Mdm2 and MdM4 relationship. Under normal 
condition p53 protein is in low levels under the control of Mdm2 and MdM4. 
Upon cellular stress, Mdm2 activity is shifted to MdM4 and itself, leading to 
depletion of both Mdm2 and MdM4 proteins that build up p53 protein levels and 
activity. This leads to an increase in p53 transcription and enhancement of its 
activity (including Mdm2 transcription). As soon as cellular stress is relieved p53 
levels returns to the basal pre-stress level. Adapted from Toledo (2007). 
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1.2.11 Histone Acetyltransferases (HATs) 
HAT enzymes transfer acetyl groups from acetyl coenzyme A (acetyl-CoA) onto 
the İ-amino group of lysine (K) residues on histones. This neutralizes their net 
positive charge and diminishes their ability to bind to negatively charged DNA. 
This helps to maintain a more opened chromatin configuration, providing 
accessibility for specific transcription factors and the general transcription 
machinery (Glozak and Seto, 2007). 
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Figure 1.9: Histone Acetylation Status of Chromatin  
 
Schematic representation of the potential interplay between SWI/SNF, HATs, and 
HDACs in relationship to chromatin assembly, histone acetylation and 
transcriptional regulation. HATs induce relaxed chromatin which facilitates 
transcriptional factors (TF) access to chromatin. HDACs abrogate acetylation 
(AC) and render chromatin unfavourable for TF. SWI/SNF ensures continuous 
oscillation of nucleosomes between a functional and disrupted structure. HATs 
target the disrupted nucleosome; fix the nucleosome in an inactive conformation 
favourable for TF. Conversely, recruitment of HDACs removes the AC, which 
subsequently is assembled back to functional nucleosomes by SWI/SNF. Where 
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yellow circle, histone protein; red thread, DNA; AC, acetylation; TF, transcription 
factors. 
Histone Acetyltransferase families 
A number of HAT families have been described including the GNAT superfamily 
(such as GCN-5, PCAF), MYST (such as MOZ, MOF, MORF, TIP60, Hbo1), 
p300/CBP, the basal transcription factor TFIIIC etc (Heery and Fischer, 2007, 
Roth et al., 2001). To date, numerous links between HAT deregulation and cancer 
have been reported. In the next part, I will discuss a number of well characterised 
HATs which display altered activity in cancer. 
 
CBP and p300 are large multidomain proteins that interact with a wide 
range of nuclear proteins. Knockout studies have shown that they have distinct 
functions in haematopoiesis in mice (Kasper et al., 2002). CBP and p300 show a 
high degree of conservation and contain a large central HAT domain (Liu et al., 
2008). This domain can target all four core histones and many non histone 
proteins including p53 as described previously above. Reciprocal translocations 
involving the CBP and p300 genes are associated with haematopoietic 
malignancies. This includes the MOZ-CBP fusion protein, which causes acute 
myeloid leukaemia (Troke et al., 2006). Similarly, missense mutation and loss of 
heterozygosity at the p300 gene locus have been reported in colorectal and breast 
cancer (Giles et al., 1998, Gayther et al., 2000). Mutations in the gene encoding 
CBP that inactivates its HAT activity results LQ  µ5XELQVWHLQ-7D\EL V\QGURPH¶
(RTS), a developmental disorder characterised by mental retardation and facial 
anomalies (Roelfsema and Peters, 2007). Patients suffering from this syndrome 
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have a >300 fold increased risk of cancer (Iyer et al., 2004). Simultaneous 
mutations of CBP and p300 have been reported in colorectal, gastric, 
hepatocellular and breast cancers (Iyer et al., 2004). Thus these HATs have a 
clear role in maintaining cancerous growth of mammalian cells. Interestingly, 
small molecule inhibitors that block the HAT function of CBP/p300 (HATi) have 
been described (Balasubramanyam et al., 2003, Eliseeva et al., 2007).  
 
 TIP60 (Tat interactive protein, 60 kDa) the first member described in the 
MYST family was originally identified as a protein interacting with the HIV tat 
gene product (Kamine et al., 1996). It was reported in association with the 
yeast and mammalian NuA4 subunits coactivator complex (Doyon et al., 2004). A 
broad range of functions has been described for TIP60 in both yeast and human 
cells (Doyon et al., 2004, Roth et al., 2001, Thomas and Voss, 2007). Early 
studies showed that TIP60 is a transcriptional co-activator (Cao and Sudhof, 2001, 
Hattori et al., 2008). Importantly, it has a key role in DNA damage response (Sun 
et al., 2011, Squatrito et al., 2006, Sun et al., 2005, Jha et al., 2008), and repair of 
DNA double strand breaks (DSBs) (Murr et al., 2006, Stante et al., 2009, Kusch et 
al., 2004). Interestingly, at DSBs sites, TIP60 was reported to bind to H3K9me3 
(Fischle, 2009); triggering histone acetylation (Xu and Price, 2011) and activating 
DNA DSBs repair (Fischle, 2009). TIP60 also has a critical role in apoptosis 
(Ikura et al., 2000, Tyteca et al., 2006, Xu et al., 2009a, Tang et al., 2006a). It 
enhances p53 dependent expression of apoptosis-related genes such as BAX (Xu 
et al., 2009a), through acetylation of  p53 within the DNA-binding domain at 
lysine 120 (Tang et al., 2006a). In addition, TIP60 has an important role in 
androgen receptor (AR) signalling. AR acetylation was reported by p300, PCAF 
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and TIP60 in vivo (Fu et al., 2004). This was found to promote AR transcriptional 
activity and enhance prostate cancer progression (Halkidou et al., 2003, Lavery 
and Bevan, 2011).  
 
 hMOF (Human Male absent On the First) is another member of the MYST 
family (Thomas and Voss, 2007). It was first described in Drosophila where it 
was reported to enhance the transcription of X-linked genes in males through 
H4K16 acetylation; its loss of function was related to male-specific lethality 
(Hilfiker et al., 1997a, Akhtar and Becker, 2000). In contrast, in human cells, the 
inactive X chromosome is hypoacetylated at H4K16 (Jeppesen and Turner, 1993). 
Knock down of hMOF in HeLa and HepG2 cells caused a dramatic reduction of 
H4K16ac (Taipale et al., 2005). hMOF has a role in DNA damage response; in 
HeLa cells, knocking down of hMOF by RNA interference led to an accumulation 
of cells in the G2 and M phases of the cell cycle (Taipale et al., 2005). Low levels 
of hMOF were additional characteristic of aggressive breast cancer and 
medulloblastomas tumours; correlated with poor overall survival (Giangaspero et 
al., 2006, Pfister et al., 2008).  
 MOZ (monocytic leukemia zinc-finger) and its paralog MORF (MOZ 
related factor) proteins are also members in MYST family (Yang and Ullah, 
2007a). Both proteins have intrinsic histone acetyltransferase activity and are 
important for proper development of murine hematopoietic and bone/neurogenic 
progenitors, respectively (Yang and Ullah, 2007b). MOZ was first described in 
acute myeloid leukemia as a protein lacking the carboxy-terminal domains fused 
with CBP, as a result of an in-frame fusion of the MOZ and the CBP gene 
(Borrow et al., 1996). Moreover, in our lab, we found that MOZ-TIF2 fusion 
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protein has an inhibitory effect on p53 transcriptional activity, mainly through a 
CBP-dependent pathway (Kindle et al., 2005). MORF gene mutations were also 
observed in acute myeloid leukemia and/or benign uterine leiomyomata (Yang 
and Ullah, 2007a). MOZ/MORF complexes are crucial for acetylation of 
chromatin substrates in vivo and essential for DNA replication to occur during S 
phase (Doyon et al., 2006). Although the MYST domains of MOZ and MORF 
target H4 for acetylation, knockout studies reveal the ablation of MOZ results in 
reduction of H3K9/K14 acetylation (Voss et al., 2009). Thus, the substrate 
specificity of the in vivo complexes containing MOZ and MORF are likely to be 
different to the isolated MYST domain.  
HATs acetylates other proteins 
In addition to histones, other nuclear proteins also serve as targets for the lysine 
acetyltransferases described above including many transcription factors such as 
S ȕ-catenin, GATA and HMGI(Y) (Kruse and Gu, 2009, Wolf et al., 2002, 
Sterner and Berger, 2000). This can have profound effects on the stability, 
subcellular localisation, DNA binding or cofactor binding properties of these 
proteins. For example, acetylation of p53 (as described previously in section 
1.2.10) at specific lysines can alter its DNA binding or transactivation functions 
of this protein, and thus affects p53-dependent cell-cycle arrest and apoptosis.  
1.2.12 HATs Inhibitors 
HAT enzymes have important roles in the function of normal cells; however they 
are also clearly important in the growth of tumours. Thus there has been 
considerable interest in the development of small molecule inhibitors of these 
enzymes as possible leads for therapeutic intervention. A number of compounds 
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showing HAT inhibitor activity have been isolated from natural sources, small 
molecule screens or by chemical synthesis (Heery and Fischer, 2007). These 
include lysyl-CoA, H3-CoA, Ȗ-butyrolactones, isothiazolones, Spd-CoA, 
anacardic acid, curcumin, CTK7A, C646, garcinol, plumbagin, EGCG, and gallic 
acid (Selvi et al., 2010). While lysyl-CoA and similar compounds are thought to 
act as competitive inhibitors which compete with Acetyl-CoA for the active site, 
most of the other compounds are likely to be non-competitve inhibitors that act 
allosterically. In the next section, I focus on two natural compounds used in this 
study, curcumin and garcinol.  
 
 Curcumin (Diferuloylmethane)  is a polyphenol, first isolated in 1815 and 
crystallized in 1870 (Ravindran et al., 2009). It is the major yellow pigment 
extracted from turmeric, an ingredient used in curries. It is derived from the 
Curcuma longa Linn (a perennial herb originally cultivated in tropical regions of 
Asia) from which the rhizome is selected and dried to obtain the turmeric 
(Ammon and Wahl, 1991, Somasundaram et al., 2002).  
 
 Curcumin is used as a constituent of many foods, for its colour and 
flavouring properties  (Lin et al., 2000). For generations, extracts from curcumin 
have been used in India and Southeast in herbal medicines; according to tradition, 
in the treatment of inflammation, skin wounds, hepatic and biliary disorders, 
cough, and coryza, as well as certain tumours. Interestingly, the incidence of most 
cancers is low in parts of the world where  the dietary intake of curcumin is high 
(Ravindran et al., 2009); the consumption of an adult may reach up to 200 mg of 
curcumin/day (7.8 µmol/kg of body weight) (Commandeur and Vermeulen, 
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1996). In the western world (depending on diet) only half of this amount was 
detected in daily intake; for example, in France, an intake of 3.4 µmol/kg/day 
has been recorded (Verger et al., 1998).  
 
The anticarcinogenic properties of curcumin have been verified through 
inhibition of tumour initiation and promotion (Ravindran et al., 2009). For 
example, curcumin was found to cause cell apoptosis through altering cell 
membrane curvature and increasing cellular  permeabilization (Barry et al., 2009, 
Epand et al., 2002) and, also, to inhibit cell proliferation, invasion, metastasis and 
angiogenesis (Ravindran et al., 2009). 
 
Curcumin was found to induce growth arrest of several tumour cell lines 
including colorectal, oesophageal, bladder, pancreatic, ovarian and other cell 
lines, highlighting a potential chemotherapeutic potential (Chauhan, 2002, 
O'Sullivan-Coyne et al., 2009, Park et al., 2006, Sahu et al., 2009, Weir et al., 
2007). Most tumour cell lines treated with curcumin arrested in G2/M (Dugas-
Breit et al., 2005, Kutala et al., 2006, Liu et al., 2007, O'Sullivan-Coyne et al., 
2007, Weir et al., 2007, Zheng et al., 2004). However, other cell lines like 
melanoma, prostatic and mantle cell lymphoma were arrested in G1 (Carneiro et 
al., 2010, Chen et al., 2008b, Shishodia et al., 2005). With regard to breast cancer 
cell lines, curcumin treatment opposed tumour cell proliferation of both MCF-7 
and MDA-MB-231 cells through down regulation of angiogenic factor 
transcription, which occur in both ER dependent in independent patterns (Shao et 
al., 2002). In a mouse model, curcumin was reported to reduce MDA-MB-231 
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tumour metastasis and subsequent apoptosis (Bachmeier et al., 2007). In MCF-7 
cells, Curcumin was found to improve chemotherapeutic outcome with tamoxifen 
and mitomycin C (De Gasperi et al., 2009, Zhou et al., 2009). Curcumin treatment 
was also found to elicit p53-dependent apoptosis (Choudhuri et al., 2005). The 
apoptotic cells were mainly arrested in G2 and showed an increase in p53 
expression, correlating with a release of cytochrome C from mitochondria, the 
essential requirement for apoptosis (Choudhuri et al., 2005).  
 
Curcumin was reported to inhibit histone acetylation by p300 and CBP 
both in vitro and in vivo (Balasubramanyam et al., 2004b). Furthermore, it was not 
active against PCAF at similar concentrations. It is unknown whether curcumin 
can inhibit the activity of MYST domain proteins. The phenolic nature of the 
curcumin molecule suggests that it may be very reactive, and thus not very 
specific (Aggarwal and Harikumar, 2009). Consistent with this curcumin inhibits 
other enzymatic activities such as kinases (Zhou et al., 2011). Thus the general 
beneficiary properties of curcumin in targeting rapidly proliferating cells such as 
cancer cells may be related to inhibition of a range of cellular activities.  
 
 Garcinol is a naturally occurring polyisoprenylated benzophenone, 
isolated from Garcinia indica or kokum fruit (indigenous to southern parts of 
India). Garcinol was reported to be highly cytotoxic to HeLa cells, causing a 
down regulation of the majority of genes as demonstrated by gene expression 
microarray analysis (Balasubramanyam et al., 2004a). Interestingly, an inhibitory 
effect on both PCAF and p300 was illustrated (Balasubramanyam et al., 2003). 
This inhibition was later reported to occur via a non-competitive allosteric 
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mechanism (Arif et al., 2007). In order to find more potent, less toxic inhibitors, 
several garcinol derivatives based on isogarcinol, the product of intramolecular 
cyclisation of garcinol, were synthesized. Among 50 isogarcinol derivatives, only 
three have been found highly specific for HAT activity of p300 (Mantelingu et al., 
2007b); LTK-13, LTK-14 and LTK-19, which specifically inhibit p300 HAT 
activity but not PCAF HAT activity (Arif et al., 2009). Recent results from our 
laboratory indicate that garcinol is also a potent inhibitor of MYST domain 
proteins (Messmer et al., in preparation). Garcinol and two of its derivatives 
isogarcinol and LTK14 were kindly provided by Prof. Tapas Kundu for use in this 
study.  
1.2.13 Histone Deacetylases (HDACs)  
Shortly, after the identification and cloning of HDACs, it was established that 
HDACs were recruited to promoters to repress transcription, thereby 
counteracting the activating effects of HATs (De Ruijter et al., 2003). In a 
simplified model, recruitment of HDACs causes decreased histone acetylation that 
(re-compacts) the chromatin and diminishes access by the transcription 
machinery, thereby transcriptional repression, although the exact mechanisms 
remain to be established. 
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Types of HDACs 
Histone deacetylases are classified into four groups based on their homology to 
yeast histone deacetylases (Willis-Martinez et al., 2009) (Table 1.4). Class I 
histone deacetylases: HDAC1, HDAC2, HDAC3 and HDAC8, are homologous to 
yeast RPD3. Class IIa histone deacetylases: HDAC4, HDAC5, HDAC7 and 
HDAC9. Class IIb includes HDAC6 and HDAC10 which share homology with 
yeast Hda1 (De Ruijter et al., 2003). Class III: HDACs are NAD+ dependent and 
commonly referred to as sirtuins (Yang and Seto, 2008). This group comprises 
SIRT 1-7 which are homologues of  yeast Sir2 (Ozdag et al., 2006). HDAC11 
(Class IV) has only partial homology with I and II classes, so is considered as a 
separate type (Yang and Seto, 2008). HDACs have been studied extensively due 
to their important role in cellular function and tumour progression. In the next 
section I will review those members of HDAC family which were included in my 
study.   
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Table 1:4: Classes of Human HDACs 
Class Description Yeast 
Homologue 
I HDAC1, HDAC2, HDAC3 and HDAC8 RPD3 
 
  
IIa HDAC4, HDAC5, HDAC7, HDAC9 Hda1 
 
  
IIb: HDAC6 and HDAC10  Hda1 
   
III SIRT 1-7 Sir2 
 
  
IV HDAC11 (closely related to Class I and II)  
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HDAC1/HDAC2 
 HDAC1 is a class I histone deacetylase (Cai et al., 2000, Willis-Martinez et al., 
2009). In a mouse model, knockout of HDAC1 caused hyperacetylation of 
histones H3 and H4, where loss of function was not compensated by the 
overexpression of HDAC2 and HDAC3, suggesting they have distinct functions  
(Lagger et al., 2002). HDAC1 has a critical role in controlling gene transcription 
and proliferation in embryonic stem cells (Zupkovitz et al., 2006, Lagger et al., 
2002) and transcriptional repression in HeLa cells (Hassig et al., 1998). In 
association with  SUV39H1, it has an important role in permanent chromatin 
silencing in drosophila (Czermin et al., 2001) and controls cellular senescence of 
melanoma cells (Bandyopadhyay et al., 2007). HDAC1 is essential to 
development, as gene deletion is seen to result in death in utero and perinatal 
death in mice (Montgomery et al., 2007).  
 
 HDAC2 is also a class I histone deacetylase (Willis-Martinez et al., 2009). 
It has an important role in controlling acetylation of histones and signalling 
proteins that control transcription (Okazaki et al., 2000, Ashburner et al., 2001, 
Kramer, 2009) including steroid hormone receptors (Bicaku et al., 2008). 
Knockdown of HDAC2 resulted in congenital cardiac abnormalities and neonatal 
death in a mouse model (Montgomery et al., 2007, Zimmermann et al., 2007), 
which suggested a critical role in embryonic development. However, HDAC2 
seems not to be essential for life, as HDAC2-mutant mice exhibit low birth weight 
but survive into adulthood (Zimmermann et al., 2007).  
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 In relation to the transcription factor p53, over expression of HDAC1 in 
melanoma cells was found to impair p53-dependent apoptosis (Bandyopadhyay et 
al., 2004). Similarly, HDAC2 was reported to inhibit p53 expression (Kramer, 
2009). Moreover, knockdown of HDAC2 was reported to enhance p53 induced 
cellular senescence (Harms and Chen, 2007). This proposes an important role for 
both HDAC1 and HDAC2 in regulating tumour cell immortality. 
 
 Immunodetection of HDAC1 and HDAC2 in tissue samples revealed an 
ubiquitous expression in normal glandular cells of gastric and colorectal tissue 
and the nuclei of stromal and inflammatory cells (Weichert et al., 2008a, Weichert 
et al., 2008b) as well as the nuclei of normal prostatic and mammary gland tissue 
(Weichert, 2009). In regards to human tumour tissues, HDAC1 and HDAC2 were 
found to be highly expressed in haematological, gastric, colorectal and prostatic 
tumours (Marquard et al., 2008, Weichert et al., 2008a, Weichert et al., 2008b, 
Weichert et al., 2008c). In addition, high levels of HDAC1 was found in more 
than half of pancreatic tumours studied (Miyake et al., 2008). Importantly, high 
levels of HDAC2 were described as an independent poor prognostic marker in 
oral, prostatic, ovarian, endometrial and gastric cancer (Itoh et al., 2008, Chang et 
al., 2009, Weichert, 2009). 
 
 With regard to breast tissue, HDAC1 was detected in normal luminal but 
not basal cells. High levels of HDAC1 were noted in 40 % of breast cancer cases 
(Krusche et al., 2005) and linked to enhanced MCF-7 cells proliferation (Kawai et 
al., 2003).  
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1.2.14 HDAC inhibitors and Cancer 
A number of natural compounds and chemical derivatives showing inhibitory 
activity against HDACs have been described. HDAC inhibitors can prevent 
histone deacetylation resulting in global histone hyperacetylation (Tanyi et al., 
1999). Thus, they are considered a promising new class of cancer therapeutic 
agents. However, little is known about the non-histone targets of HDAC inhibitors 
and their roles in gene regulation (Hu and Colburn, 2005). Suberoylanilide 
hydroxamic acid (SAHA) for example, is a potent inhibitor of histone deacetylase 
that causes growth arrest, differentiation, and/or apoptosis of many tumour types 
in vitro and in vivo (Butler et al., 2002), such as HCT116 colon cells (Lobjois et 
al., 2009). SAHA was also described to improve the anti-tumour immune 
response of multipotent mesenchymal stromal cells (MSC) (Kruchen et al., 2010) 
and colon cell lines to 5-fluorouacil (Budillon et al., 2005). With regard to breast 
cancer, Munster et al., (2001) found that SAHA caused an inhibition of MCF-7 
cell proliferation and an accumulation of cells in G1 or G2/M in a dose-dependent 
manner. Moreover, withdrawal of SAHA led to re-entry of cells into the cell cycle 
and reversal to a less differentiated phenotype. Other HDACi like trichostatin A 
(TSA) and valproic (VPA) acid have been used as potential cancer therapeutic 
agents. Both TSA and valproic acid were reported to inhibit tumour cell 
proliferation and shift cells into apoptosis in prostatic, neuroblastoma, and 
leukemia cell models (Fortson et al., 2011, Poljakova et al., 2009, Sasaki et al., 
2008). In addition, applying TSA or VPA treatment for H157 human lung cancer 
cell line cells was reported to sensitise the cells for etoposide mediated cell death 
(Hajji et al., 2009). 
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SIRT1 
SIRT1 (silent mating-type information regulation 2 homologue 1) is a class III 
histone deacetylase; it is a mammalian homolog of the Saccharomyces cerevisiae 
chromatin silencing factor Sir2. SIRT1 deacetylates histone and non-histone 
proteins in a nicotinamide adenine dinucleotide (NAD+)-dependent manner 
(Denu, 2005, Cheng et al., 2003). SIRT1 has a wide range of biological functions 
including growth regulation, stress response, tumourgenesis, endocrine signalling, 
and extending cellular lifespan (Kim and Um, 2008, Rahman and Islam, 2011, 
Wang et al., 2011, Domloge et al., 2005). SIRT1 also has a role in facultative 
heterochromatin formation (Vaquero et al., 2004, Vaquero et al., 2007), through 
regulating the histone methyltransferase SUV39H1 (as described in H3k9me3, 
H4K20me3 and their modulators in section 1.2.8). 
 
 One of the main roles of SIRT1 is the deacetylaion of H4K16. Cells 
deficient in SIRT1 were reported to have high H4K16ac levels (Hajji et al., 2009, 
Vaquero et al., 2006). Although SIRT1 is cytoplasmic during most of the cell 
cycle, it was reported to shift to the nucleus during the G2/M transition phase with 
concomitant global attenuation of H4K16 acetylation (Vaquero et al., 2006). 
Moreover, inhibition of SIRT1 was found to reactivate silenced genes (Pruitt et 
al., 2006), suggesting an important role for SIRT1 in gene silencing; and a 
possible therapeutic approach of SIRT1 targeting (Nosho et al., 2009). 
 
 SIRT1 also functions to regulate p53. SIRT1 was reported to deacetylate 
p53, inhibiting its transcriptional activity (Kim et al., 2007) and antagonizing 
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promyelocytic leukemia protein (PML)/p53-induced cellular senescence and 
apoptosis (Langley et al., 2002, Han et al., 2008). Knockdown of SIRT1 resulted 
in hyperacetylation of p53 in mice (Cheng et al., 2003) and induced apoptosis and 
growth arrest in  human epithelial cancer cells (Ford et al., 2005b).  
 
 SIRT1 protein has been detected at high levels in cancer cells, such as the 
prostate cell lines (DU145, LNCaP, 22Rnu1, and PC3) in contrast to normal 
prostate epithelium (Ford et al., 2005a, Jung-Hynes et al., 2009). Interestingly, 
knockdown of SIRT1 resulted in apoptosis of epithelial cancer cells, but not the 
non-cancerous epithelial cells (Ford et al., 2005a). Sirtinol treatment (SIRT1 
inhibitor) caused an inhibition of growth and sensitization for  camptothecin and 
cisplatin in human prostate cells (Kojima et al., 2008). With regard to SIRT1 
detection in tissues, high levels of SIRT1 were detected in malignant ovarian and 
prostate tumours compared to normal glandular tissue (Jang et al., 2009, Jung-
Hynes et al., 2009). SIRT1 expression also correlated with shorter overall survival 
in diffuse large B-cell lymphoma (Jang et al., 2008). 
 
 SIRT1 expression and activity are controlled by a regulatory network of 
proteins, that function on multiple levels (Kwon and Ott, 2008). Upon cellular  
starvation, SIRT1 transcription is induced by p53 (Nemoto et al., 2004). SIRT1 
deacetylase activity is enhanced by active regulator of SIRT1 (AROS), a binding 
partner identified in yeast two-hybrid screens, and potentiates deacetylation of 
p53 (Kim et al., 2007). In contrast, Deleted in Breast Cancer 1 (DBC1) is a 
negative regulator for SIRT1 (Kim et al., 2008, Zhao et al., 2008, Anantharaman 
and Aravind, 2008).  
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DBC1 (Deleted in Breast Cancer 1) 
Deleted in Breast Cancer (DBC1) was first described by Hamaguchi et al. (2002) 
as DBC2, after its ancestor DBC1 (Deleted in Bladder Cancer 1) (Habuchi et al., 
1998), as a tumour suppressor gene mapped to 9q32-33 (Habuchi et al., 1998, 
Nishiyama et al., 1999a, Nishiyama et al., 1999b). DBC1 was identified as a 
candidate tumour suppressor gene at a homozygous deletion region of human 
chromosome 8p21 (Hamaguchi et al., 2002). DBC1 function was first attributed to 
the urokinase-plasminogen pathway (Louhelainen et al., 2006) but was later 
shown to function through modulation of sirtuin deacetylase activity 
(Anantharaman and Aravind, 2008). Kim et al. (2008) identified DBC1 as a 
negative regulator, that directly interacted with SIRT1 both in vivo and in vitro 
(Kim et al., 2008). In the same year, Zhao et al. (2008) also identified DBC1 as a 
negative regulator for SIRT1 in human cells and they showed DBC1- mediated 
repression of SIRT1 that leads to increasing levels of p53 acetylation and 
upregulation of p53-mediated function (Zhao et al., 2008).  
 
 DBC1 may acts as a tumour suppressor as it enhances the function of the 
hyperacetylated p53 and FOXO through inhibiting SIRT1 deacetylase activity 
(Kim et al., 2008, Zhao et al., 2008).  SIRT1 and its modulator DBC1 were targets 
for study in gastric and breast cancer (Cha et al., 2009, Sung et al., 2010). In 177 
gastric cancers tumour tissue microarrays were IHC stained for SIRT1 and DBC1, 
expression of both SIRT1 and DBC1 was significantly associated with reduced 
overall survival and shorter relapse-free interval by univariate analysis (Cha et al., 
2009).  
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1.3 Aims of This Thesis 
        This thesis presents research carried out on two fronts to address molecular 
mechanisms of histone and p53 modifications in cancer:  two related topics 
 
Aim 1 ± Histone and p53 PTMs and their modulators in breast cancer  
The first aim was to perform immunohistochemical analyses to detect the 
comparative levels of histone and p53 PTMS in 880 primary breast tumours, and 
to correlate this with data on expression levels of the enzymes and other 
regulatory proteins that control the deposition of these signals.  The focus of this 
study centred on acetylation of H4K16, an important histone modification that we 
and others have shown is perturbed in cancer cells. Due to the role of the H4K16 
regulatory pathway in controlling p53 acetylation, the extent of selected p53 
modifications in the same tumour set was also determined. These data were then 
correlated with archived data from the tumour set on other biomarkers, 
histopathological variables and patient survival data. 
 
AIM 2 -To Manipulate Global Histone and p53 PTMs in tumour cells using 
HAT inhibitor compounds 
The second aim was to assess the effects of small-molecule inhibitors of 
acetyltransferases on the proliferation and survival of breast cancer cell lines, and 
to examine whether global levels of histone and p53 PTMs can be manipulated by 
chemical intervention. We focussed on the natural HATi compounds curcumin 
and garcinol, as well as garcinol derivatives. This approach included 
immunoflourescence staining of breast cancer cells lines, colony formation 
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assays, western blots and cell cycle analyses and assessment of DNA damage 
responses. This part of the project was designed to provide insight into the effects 
of HATi compounds on cancer cells and their mechanisms of action. 
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2.1 General  
All general laboratory chemicals were analytical grade, supplied by Sigma or 
Fisher Chemical Company Ltd. unless otherwise stated.   
 
2.2 Breast Tumour Tissue 
2.2.1 The Tissue Microarrays (TMAs)  
A tissue microarray (TMA) comprised consecutive series of 880 cases of primary 
breast cancer tumours. The tumours belong to patients diagnosed from 1986 to 
1998 included in the Nottingham Tenovus Primary Breast Carcinoma Series. The 
age of the patient ranged from 18 to 73 years (the mean is 55 years). At the time 
of resection, tumours were incised and immediately placed in formalin to obtain 
optimum tissue fixation. Conventional Haematoxylin and Eosin (H&E) staining, 
followed by pathological examination according to national and international 
standard were done. Data on histological grade, Histological types, tumour size, 
tumour stage, lymph node stage, NPI, vascular invasion were routinely assessed 
and recorded in a data base (http://smrsp2.nottingham.ac.uk/distiller/login.php). 
The histological tumour types of the breast cancer TMA cohort comprised 449 
invasive ductal carcinomas/NOS type, 182 tubular mixed carcinomas, 25 
medullary carcinomas, 83 lobular carcinomas, 28 tubular carcinomas, 8 mucinous 
carcinomas, 6 cribriform carcinomas, 4 papillary carcinomas, 29 mixed no special 
type and lobular carcinomas, 23 mixed no special type and special type 
carcinomas, and 6 miscellaneous tumours. Clinical, histopathological and 
biological data for all these anonymised cases were available from a database 
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managed by Dr. Andrew Green, Nottingham Breast Unit. This study was 
approved by the Nottingham Research Ethics Committee 2 under the title of 
³'HYHORSPHQWRIDPROHFXODUJHQHWLFFODVVLILFDWLRQRIEUHDVWFDQFHU´  
 
2.2.2 Construction of the Tissue Microarray Blocks 
Tissue microarray slides prepared from paraffin-embedded blocks were provided 
by Dr. Des Powe and Dr. Abd El-Rehim as previously described (Rakha et al., 
2006, Abd El-Rehim et al., 2004a, Abd El-Rehim et al., 2004b). The TMAs were 
constructed by sampling a representative site from each breast cancer tumour. 
Each TMA block is formed of 150 cores derived from 150 invasive breast cancer 
block. The orientation of the cores within the array is crucial for the proper 
evaluation of the experiment. The design and orientation of each breast cancer 
TMA are also listed in the data base. A manually-operated tissue puncher/Array 
(Beecher Instrument, Silver Spring, MD, USA) was used for TMA construction 
(Kononen et al., 1998, Camp et al., 2000, Rimm, 2001).  
 
2.2.3 Immunohistochemistry (IHC) Staining and Data Analysis 
Chemical/Solution  
 Xylene 
 Ethanol 
 Tris buffered Saline 
 Hydrogen Peroxide 
 Normal Swine serum 
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 Copper sulphate 
 Haematoxylin (Dako) 
 Envision kit (Dako) 
 
Staining optimization 
 Breast cancer tissue microarrays were prepared and immunohistochemically 
stained with a number of antibodies, which were initially tested and optimized 
using TMA sections including malignant breast tissue and normal kidney tissue to 
check for the exact pattern of staining in both normal and malignant tissue and to 
insure that the staining contains a varied spectrum ranging from high, medium, 
low, and totally negative intensity. The final antibodies dilutions after 
optimization are detailed in Appendix 1.  
 
Protocol for IHC staining: ABC Method ± Sequenza 
7LVVXH VHFWLRQVZHUHSODFHG LQ WKHÛ& LQFXEDWRU IRUPLQXWHV The sections 
were dewaxed by immersing in 2 sequential xylene baths for 5 minutes each; re-
hydrated by immersing in a series of 3 alcohol baths (about 10 seconds in each). 
Sections were then washed well in running tap water. An antigen retrieval step 
was performed by placing the section in a plastic bucket containing citrate Buffer-
Saline pH 6.0 (N.B. EDTA at pH 8.00 could also be used as an alternative antigen 
retrieval). The sections were micro-waved for 10 minutes at high power, followed 
immediately by 10 minutes on 50% power. The following steps were done at RT. 
Sections were immediately flooded with running tap water to stop the retrieval 
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process until they cooled down. Then, slides were loaded onto sequenza plates 
and placed in sequenza trays; ensuring the slides did not dry out. Sequenza 
reservoirs were filled to the middle with Tris Buffered Saline (TBS) pH 7.6 to 
rinse the slides. Blocking of endogenous peroxidase activity was done by 
applying a 0.3% solution of hydrogen peroxide in methanol for 10 minutes, 
IROORZHG E\ ZDVKLQJ ZHOO ZLWK 7%6 ȝO RI 1RUPDO 6ZLQH 6HUXP 166
(diluted 1/5 in TBS) was applied to each slide and incubated for 10 minutes; 
followed by LQFXEDWLRQ ZLWK ȝO RI SULPDU\ DQWLERG\ RSWLPDOO\ GLOXWHG LQ
NSS/TBS) to each slide for 45 minutes. The sections were washed well in TBS. 
6OLGHVZHUHLQFXEDWHGZLWKȝORIELRWLQ\ODWHGVHFRQGDU\&DQWLERG\GLOXWHG
1/100 in NSS/TBS) for 30 minutes at RT. The slides were washed again in TBS 
IROORZHG E\ LQFXEDWLRQ ZLWK ȝO RI SUHIRUPHG $B Complex (AB) for 55 
minutes at RT. AB was prepared at least 30 minutes prior to use to ensure 
adequate binding of the 2 components - diluted 1/100 in NSS/TBS). Another 
wash with 7%6 IROORZHG E\ DSSO\LQJ ȝO RI IUHVKO\ SUHSDUHG OLTXLG
Diaminobenzidine (DAB) solution for 8-PLQXWHVSUHSDUHGE\GLOXWLQJȝORI
liquid DAB chromogen per ml of substrate buffer). Another wash with TBS; 
IROORZHGE\LQFXEDWLRQZLWKȝORIFRSSHUVXOSKDWHVROXWLRQIRU-10 minutes at 
RT. Last wash in TBS; followed by addinJȝORIIUHVKO\ILOWHUHGKDHPDWR[\OLQ
for 2 minutes only. Then, the slides were washed well in tap water. The slides 
were removed from sequenza plates and placed face up into a cover slipping rack, 
rinsed in running tap water, dehydrated in alcohols, cleared in xylene and finally 
mounted with DPX. 
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Protocol for IHC staining: Envision kit (Dako) Method ± Sequenza 
Tissue sections were placed LQWKHÛ&LQFXEDWRUIRUPLQXWHV. Sections were 
dewaxed by immersing in 2 sequential xylene baths for 5 minutes each; re-
hydrated by immersing in a series of 3 alcohol baths (about 10 seconds in each). 
Sections were washed well in running tap water. An antigen retrieval step was 
performed here (see above). The following steps were done at RT. Slides were 
loaded onto the sequenza plates and placed in sequenza trays; ensuring the slides 
do not dry out. Sequenza reservoirs were filled to the middle with Tris Buffered 
Saline (TBS) pH 7.6 to rinse the slides. Blocking endogenous peroxidase activity 
step was done; followed by washing well with TBS. Blocking unspecific antibody 
binding site was done by adding ȝO166GLOXWHGLQ7%6WRHDFKVOLGHfor 
10 min; followed by ȝO RI SULPDU\ DQWLERG\ for 30 minutes. Slides were 
washed with 7%6 ȝO RI (QYLVLRQ $ applied for 30 minutes at RT from 
GURSSHU ERWWOH $QRWKHU ZDVK LQ 7%6 ȝO RI IUHVKO\ SUHSDUHG (QYLVLRQ &
solution were applied for 6 minutes at RT (C is prepared 1/50 C to B Substrate 
EXIIHU 6OLGHV ZHUH ZDVKHG ZHOO LQ 7%6 IRU  PLQ ȝO RI IUHVKO\ Iiltered 
haematoxylin applied for 6 minutes. Slides were washed well in tap water; 
removed from sequenza plates and placed in a rack in the water; dehydrated in 
alcohols; and cleared in xylene; mounted with DPX.  
 
Scoring of IHC reactivity.  
TMAs were scored using high-resolution digital images (NanoZoomer; 
+DPDPDWVX3KRWRQLFV:HOZ\Q*DUGHQ&LW\8.DW;PDJQL¿FDWLRQXVLQJD
web-based interface (Distiller; Slidepath Ltd., Dublin, Ireland). Unsuitable TMA 
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cores, which were lost, fragmented or rolled out were excluded.  IHC scoring was 
performed by the modified Histo-score (H-score)(McCarty et al., 1985), which 
involves semi-quantitative assessment for both the intensity and percentage of 
staining. The H-score is calculated as 0 X negative % + 1 X weak % + 2 X 
moderate % + 3 X strongly stained %. The range of possible scores is between 0-
300. This method is superior to using either the conventional intensity or 
percentage scoring scheme.  
 
2.2.4 Statistical analysis 
Ordinary statistics 
Statistical analysis was done using SPSS 15.0 statistical software (SPSS INC., 
Chicago, IL, USA). Data were dichotomized into high and low groups based on 
median H-score. Identical analysis on continuous non-categorical data was 
performed, which showed similar results, suggesting that dichotomization had not 
weakened the evidence for an association in this instance. Standard cut-offs were 
used for the well established prognostic variables, previously published on the 
same patient series (Abd El-Rehim et al., 2005, Elsheikh et al., 2009). All factors 
were used as dichotomous covariates with the exception of grade, NPI and 
phenotypic groups proposed by Nielsen et al. (2004) that were categorized into 
three groups. Distribution of the expression level of all the markers used in our 
study with other variables was analyzed using Pearson Chi-square statistic. Mann-
Whitney-Wilcoxon test was used for two-level variables and Kruskal-Wallis for 
more than two-level variables. To assess the correlation of each of the biomarkers 
with tumour clinicopathological variables, biological and histone PTMs markers, 
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the LQWHUYDO E\ LQWHUYDO 3HDUVRQ¶V r and .HQGDOO¶V WDX-b correlation coefficient 
tests were performed for categorical data; and Spearman test was applied on 
continuous data. All p values were two-sided. Given that 16 different biomarkers 
were assessed in this study, the chance of getting type 1 errors was increased. We 
therefore applied a Bonferroni correction, increasing the significance threshold of 
p in X2 test from 0.05 to 0.003 (by dividing the p value on the number of the 
studied biomarkers). 
 
 Survival analysis was evaluated using Kaplan-Meier curves and log-rank 
tests. Median follow-up was defined as follow-up period for those patients still 
alive and disease-free at their latest hospital visit. Differences between survivals 
were calculated using a log rank test. Cox proportional hazard model (Cox, 1972) 
determined the influence of the markers used in the study, when adjusted to 
conventional clinicopathological prognostic variables, on breast cancer specific 
survival (BCSS) and/or disease free survival (DFS). Post hoc tests were used in 
the situation where we obtained a significant omnibus F-test, with a factor that 
consists of three or more means, and additional exploration of the differences 
among means is needed to provide specific information, on which means are 
significantly different from each other (any correlation with grade, stage and 
NPI).  
 
Clustering of tissue microarray data 
Cluster analysis of histone and p53 PTMs marks were done with two clustering 
algorithm: K-means and the partitioning around medoids (PAM) (arc software) 
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kindly performed by Dr. Daniel Soria. Both methods run for clusters ranging from 
2 to 20 clusters. Six validity indices tests were followed to determine the best 
number of clusters. The used indices are Calinski and Harabasz, Hartigan, Scott 
and Symons, Marriot, TraceW, and TraceW-1B. The number of  groups 
considered in each index was chosen according to the rules previously reported 
(Wiley, 1990).  
 
2.3 Cell Culture 
2.3.1 Reagents 
DMEM and RPMI media, L-glutamine, penicillin/streptomycin, foetal bovine 
serum (FBS) and Trypsin- EDTA were purchased from GIBCO, Invitrogen 
Corporation. Phosphate Buffer Saline (PBS) tablets were purchased from Oxoid 
Ltd. 
 
2.3.2 Cell Line Maintenance 
The cell lines indicated in Table 2.1 were grown in the appropriate media in 
sterile plasticware (TPP, Helena Biosciences, Tyne and Wear) at 37 ºC, in a 
humidified atmosphere containing 5% CO2. Cells were grown to confluence in 7.5 
cm2 flasks, 10 or 20 cm2 dishes. Cells were grown in 5, 10 and 20 ml of culture 
media and passaged at 100% confluency for a maximum of 30 passages; after 
which they were discarded. For passaging cells, medium was aspirated; cells were 
washed twice with sterile PBS at room temperature. 1-4 ml 1x trypsin/0.5 mM 
EDTA (ethylenediamine tetra-acetic acid) (GIBCO) was added for 1 min and 
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incubated at 37 ºC prior to being aspirated. Cells were then resuspended in an 
appropriate volume of culture medium. 
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Table  2:1: Mammalian Cell Lines Used in the Study. 
Cell line Origin Growth medium 
MCF-7 Human Invasive ductal Carcinoma DMEM + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
   
MDA-MB-231 Human invasive Lobular carcinoma DMEM + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
   
MRC-5 Human  embryonic lung fibroblast DMEM + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
   
Saos2 Human Osteosarcoma, p53- null RPMI-1640 + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
   
U20S Human Osteosarcoma DMEM + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
   
HEK293 Human embryonic Kidney RPMI-1640 + 2 mM L-Glutamine + 1% Penicillin/streptomycin + 10%FCS 
The table is showing the origin of cell lines used in the study and the composition of their growing media. DMEM, 'XOEHFFR¶VPRGLILHGHDJOH
medium (GibcoBRL); RPMI-1640, Roswell Park Memorial Institute 1640 medium (GibcoBRL). 
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2.3.3 Freezing Down Cells for Liquid Nitrogen Stocks 
A near 100% confluent 10ml dish (containing 4-6 x 106) was used to make stocks 
for storage. The cells were washed twice with 5ml 1xPBS, harvested by adding 
2ml 1x trypsin for one minute at 37ºC.  Trypsin was aspirated; cells were 
resuspended in 10 ml media, centrifuged for 5min at 1500 rpm. The supernatant 
were removed; the cells were again resuspended in 1ml culture media containing 
10% DMSO, 40% FCS and 50% DMEM. The date; identity of cell line; passage 
number were recorded. The cells were gradually frozen by incubation at-20 for 
1hr and -80ºC overnight. Finally, the cells were transferred to liquid nitrogen for 
long term storage.  
 
2.3.4 Thawing Cells from Liquid Nitrogen Stocks 
Cells were immediately thawed by immersion in 37 ºC water bath for 5 minutes. 9 
ml of media was added, cells were centrifuged and resuspended in 10 ml full 
cultural media. Cells were allowed to attach overnight (37ºC, 5% CO2) before 
media was replaced and cells were passaged as described above. 
   
2.3.5 Harvesting adherent cells 
Adherent cells were dislodged from tissue culture dishes using a cell scraper. 
Tissue culture media containing cells was aspirated and centrifuged (5 min, 1500 
rpm) at 4°C. The supernatant was discarded and the pellet was resuspended in 5 
ml 1x PBS; centrifuged again (5 min, 1500 rpm) at 4°C twice, the supernatant was 
discarded and pellet was incubated in 100 µl lysis buffer on ice for 30 min. 
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Following vigorous vortexing, the lysed cells were transferred to clean lapelled 
tubes, and frozen at -20 °C.  
 
 An alternative method for cell harvesting was performed as follow: cells 
were washed twice with 5 ml 1x PBS; were incubated with 1x trypsin at 37°C for 
1 min. Trypsin solution was aspirated and cells were resuspended in 5m 1x PBS; 
centrifuged (5 min, 1500 rpm) at 4°C. The supernatant was discarded and the 
pellet was incubated in 100µl Lysis buffer on ice for 30 min. Following vigorous 
vortexing, the lysed cells were transferred to clean labelled tubes and frozen at -
20°C. 
 
2.4 Biochemical Techniques 
2.4.1 Solutions and Buffers 
 4x SDS-PAGE sample buffer: 200 mM Tris-HCl pH6.8, 40% (v/v) 
glycerol, 2% (w/v) SDS, 5% (v/v) -mercaptoethanol, 0.4% (w/v) 
bromophenol blue. N.B. 400 mM dithiothreitol sometimes was used in 
replacement for ( -mercaptoethanol). 
 10-x SDS-PAGE running buffer: 250 mM Tris-HCL, 2.5 M glycine, 1% 
(w/v) SDS 
 SDS-PAGE stacking gel: 1ml volume: 680 µl H2O, 170 µl 30% 
acrylamide mix (National Diagnostic, Hull), 130  µl 1M Tris-HCL pH 6.8, 
10 µl 10% (w/v) SDS, 10 µl 10% (w/v) ammonium persulphate (APS), 1 
O7(0('111¶1¶-Tetramethyl-ethylendiamine) 
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 SDS-PAGE resolving gel: different concentrations of acrylamide were 
used (as illustrated in Table 2.5) according to the molecular weight of the 
proteins to be detected.  
 High glycine transfer buffer:  48 mM Tris-HCL, 380 mM glycine, 0.1% 
(w/v) SDS, 20% (v/v) methanol 
 RIPA Lysis buffer: 50mM Tris-HCl pH7.4, 150 mM NaCl, 1% NP-40, 
0.25% Na-deoxycholate, 1mM PMSF, 1x Complete mini protease 
inhibitor tablet (Roche) per 10 ml, 1x Pierce phosphatase inhibitor  
 PBST: Phosphate buffer saline, 0.02% Tween-20   
 ECL detection reagents. 
Solution A Stock: 0.296 gm p-coumaric acid (Sigma) in 20 ml DMSO 
Solution B Stock: 0.89g Aminophthalhdrazide (Luminol) (Sigma) in 20 ml 
DMSO 
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Table 2:2: Solution Compositions for preparing Resolving Gels for Tris-
glycine SDS-Polyacrylamide Gel Electrophoresis. 
% of acrylamide in Resolving Gel 6% 8% 12% 15% 
Protein Size for separation (kDa) 150-300 100-250 30-100 10-50 
C
om
po
n
en
ts
 
H2O ( l) 2,600 2,300 1,600 1,100 
30% acrylamide mix ( l) 1,000 1,300 2,000 2,500 
1.5 M Tris-HCl pH 8.8 ( l) 1,300 1,300 1,300 1,300 
10%(w/v) SDS ( l) 50 50 50 50 
10% (w/v) (APS) ( l) 50 50 50 50 
TEMED 4 3 2 2 
Volume (µl) required for 5ml resolving gel 
 
Recipes for preparation of 5ml resolving gel for gels with different acrylamide 
contents. Where SDS, Sodium dodecyl sulphate; APS, Ammonium persulphate; 
TEMED, N, N, N, 'N-tetramethylethylenediamine. Appropriate molecular weight 
ranger (in kilo Daltons) for different acrylamide concentrations is also shown. 
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2.4.2 Antibodies 
Antibodies used in the study are detailed in Appendix 1 
 
Validating the Specificity of the Antibodies Used in the Study 
The anti-H3K18ac, H3K9me3 and H4K20me3 antibodies used in this work have 
passed the test used in an assessment of histone ±modification antibody quality 
study  (Egelhofer et al., 2011). The test included western blot analyses to test the 
antibody cross reactivity with unmodified histone in nuclear or whole-cell 
extracts, dot blot and chip-chip/seq tests. In addition, the specificity of H2A.Z 
antibody was confirmed. As shown in Appendix 2B the antibody targeted the 
histone variant H2A.Z but not the H3/H4core histone (Appendix 2B). 
 
2.4.3 Total Protein Assay 
The protein concentration of cell-free extracts was measured using Bio-Rad 
protein assay reagent according to the manufacturer¶V instructions. Briefly, ȝRI
VDPSOH ZDV PL[HG ZLWK  ȝ protein assay reagent and 798 ȝ G+2O in a 
cuvette and incubated at RT for 15 min. The reaction between protein and copper 
in the alkaline solution and the Folin reagent is reduced by the copper-treated 
protein leads to colour development. Then, its absorbance was measured at 595 
nm (A595 nm). Protein concentration was determined by measuring against diluted 
BSA standards of known concentration. 
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2.4.4 Protein Separation and Transfer to Nitrocellulose
 
SDS PAGE electrophoresis was carried out according to standard protocols. 
Samples were prepared by mixing 1 volume 4X loading buffer with 3 volumes of 
protein extract; Samples were boiled for 5 min at 100 °C, followed by 
centrifugation at 8000 rpm for 30s immediately prior to loading. ȝJ of each 
VDPSOH DQG ȝO RI marker were loaded on 6-15% SDS-PAGE gels. Gels 
containing samples were electrophresed in Biorad Protean II system in 1x SDS-
PAGE running buffer at 150 V. The separated protein samples are transferred by a 
wet transfer apparatus (Bio-Rad Laboratories), onto nitrocellulose paper (Hybond 
P; Amersham Biosciences UK Limited) by wet blotting for 90 minutes in running 
buffer (formed of 1x methanol; 1x high glycine transfer buffer; and 3x distilled 
water) at constant current at 100 V, the duration may extend to over night at 30 V 
for large proteins.  
 
2.4.5 Western Blotting and Immunodetection 
Nitrocellulose membranes were stained in Ponceau S solution (Sigma) (0.1% 
(w/v) Ponceau S in 5% (v/v) acetic acid in dH2O) for 5 min and then washed in 
distilled H2O to monitor the efficiency of protein transfer. The following 
incubation steps were done at RT on a rocking platform. Nitrocellulose 
membranes were incubated in 20 ml blocking buffer (5% dried milk in 1x PBS) 
for 10 minutes, to block non-specific antibody binding sites. After removal of the 
blocking buffer, primary antibody diluted in milk was added (in a sealed bag) for 
a duration ranging from 1 hour at room temperature to O/N at 4 °C, depending on 
the primary antibody. Membranes were washed 3 times (5minutes, rocking) in 
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0.5% tween in PBS (PBST) before adding Secondary HRP-conjugated antibody 
(in a concentration ranging from 1:5000 to 1:20,000) in sealed bags for one hour. 
Excess /unbound secondary antibody was washed by three washes with PBST. 
Ptotein:antibody immunocomplexes were detected by ECL detection. The 
membrane was incubated for one minute face down in 10 ml ECL developer (22 
µl solution A, 50 µl Luminol, 6 µl H2O2, 1ml of 1M Tris pH 8.5, 9 ml dH2O). 
Excess reagent was drained and the membrane was wrapped in saran wrap. The 
membrane was placed in x-ray film cassette, exposed (10 sec-5 min) to 
autoradiograph film or chemiluminescence was measurement with Las 4000® 
(Fujifilm). 
 
2.4.6 Immunocytochemistry and Fluorescence Microscopy  
Mammalian cells were seeded into 2 ml cultural media (as described in table 2.1) 
in 24 well plates containing coverslips and cultured in a 5% CO2 incubator. If 
required for the experiment, chemical reagents such as HAT inhibitors, etoposide 
or vehicle (DMSO) were added to the medium at least 3 hours after seeding to 
ensure proper cell attachment.  After 24 hr, coverslips were washed gently twice 
with PBS and then fixed with PBS containing 4% paraformaldehyde for 10 min at 
RT. The following incubation steps were done at RT. Cells were then washed five 
times with PBS. After removing PBS, cells were permeablised by incubation with 
0.2% Triton- X100 in PBS for 2 min at RT, and washed again five times with 
PBS. Non-specific interactions were blocked by incubation with 3% BSA in PBS 
for 30min. Cells were incubated with primary antibody for 1 hr, then washed 
again five times with PBS. Cells were incubated with Alexa fluor® fluorophore-
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conjugated secondary antibody (1:500 Alex-594 in 3% BSA) for 30 min. Then 
cells were washed again five times with PBS. To stain nuclei, cells were 
LQFXEDWHGZLWKȝJPO+RHFKVWLQ3%6)LQDOO\WKHVOLGHVZHUHZDVKHG
five times in PBS. The coverslips were taken out using a non-toothed forceps and 
needle, and excess PBS was dried by touching the coverslip on a piece of tissue. 
7KHFRYHUVOLSVZHUHLQYHUWHGRQPRXQWLQJPHGLDȝORIJO\FHUROLQ3%6
Excess mounting media underneath the slide was dried out with a piece of tissue; 
slide edge was sealed by nail polish. 
 
 A Zeiss LSM 510 META confocal microscope was used to image the 
mammalian cells. Flourescence from the 488, 594 secondary antibodies were 
detected using 488, 543nm laser excitation at 2% power and the long  pass 505 
filter for emission. The Hoechst counter stain for DNA was measured using a 
mercury bulb. The lenses used were 40x/1.3, 63x/1.4 oil lenses (Zeiss). 
 
2.4.7 Bivariate Flow Cytometric Analysis of the Cell Cycle 
Bromodeoxyuridine (BrdU), an analogue of the DNA base thymidine, is used in 
this protocol for effective analysis of the cell cycle.  BrdU competes with 
thymidine for uptake during DNA synthesis. Thus, only cells that have been 
actively synthesising DNA during the time that BrdU is present will be positive 
for it. Therefore, the percentage of cells in G0/G1, S and G2/M can be determined 
by simultaneous staining for BrdU (using a labelled Ab) and DNA content (using 
propidium iodide). 
 1x PBS 
Chapter Two: Material and Methods 
 
101 
 10 mM BrdU Stock Solution 
 70 % ethanol (ice-cold) 
 2M HCl  
 PBST-BSA (PBS with 0.1 % Tween20 and 0.1% BSA) 
 FITC conjugated Mouse anti-BrdU antibody (BD Biosciences) 
 Propidium iodide solution (1 mg/ml) prepared in water  
 Ribonuclease A solution 1mg/ml prepared in water  
Cells were incubated with 20µM BrdU at 37 °C. Media was removed and kept in 
same tube as cells (for analysing apoptotic cells), washed with 4ml 1x PBS 
solution and then incubated with 4ml trypsin to detach cells. Trypsin was 
aspirated; 10ml media were added. Cells were centrifuged at 2000 rpm for 5 min.  
Cells were washed once with 20 ml cold 1 x PBS. Cells were fixed in 400 µl ice-
cold 70 % ethanol (with gentle vortexing) for 30 min on ice or overnight in the 
fridge. Another spinning at 1900 rpm for 5 min, followed by washing twice with 2 
ml cold PBS. Cells were incubated with 400 µl 2 M HCl for 20 min at RT with 
frequent mixing. 2 ml 1x PBS solution was added followed by spinning at 1900 
rpm for 5 min, and then washed twice with 2 ml PBST-BSA. 20 µl FITC-
conjugated anti-BrdU antibody were added directly to 100 µl PBST-BSA, left for 
60 min at RT (in the dark).  Cells were washed once with 2 ml 1x PBS ( if another 
antibody was used in combination with anti-BrdU, the samples were incubated for 
30  min with a secondary antibody covering the far red spectrum e.g. Alexaflour-
633 or Alexaflour-647 followed by washing once with PBS). Cells were 
resuspended in 500 µl 1x PBS; 10µl ribonuclease A was added for 15 min; and 
finally 1 µl PI was added to each tube.  1 hour after PI incubation measurement 
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was carried out using a FACS Aria flow cytometer, FACS Diva software (BD 
Biosciences); analysis of results was done with the WinMDI package 
(http://facs.scripps.edu).  
 
2.4.8 Colony formation study 
MCF-7 cells (20,000 cells) were seeded in 6 cm2 ml dishes, left for 6 hrs to attach. 
Cells were then treated for 24 hours with either Garcinol (20 µM), or LTK14 (20 
µM) alone or in combination with Etoposide (5 µM). After washes, cells were 
incubated for an additional 12 days to allow colony formation. The cultured cells 
were fixed in methanol and stained by 10% Giemsa in PBS. The number and size 
of colonies were estimated using Image J software. Unpaired t test was used to 
measure data pooled from three independent experiments. 
 
2.5 Bacterial Manipulations 
2.5.1 Reagents, cells, media, supplements  
Bacterial strain: E. coli DH5  (Stratagen, Texas, USA) bacterial strain was used 
for plasmid transformations and maxi DNA preparations.  
Bacterial Cell Culture  media: Luria Bertani medium (LB): 10g/L Tryptone 
(OXOID Ltd), 5g/L yeast extract (OXOID Ltd), 10 g/L NaCl (Fisher Scientific) 
was prepared in deionised water pH 7.0 and sterilised by autoclaving at 121oC for 
20 minutes (min). For LB agar, 15 g bacto-agar (OXOID Ltd) was added to 1 litre 
of LB medium prior to sterilization. For LB agar plate 20-25 ml molten agar 
medium (55oC) were poured into each Petri dish. Solidified agar plates were dried 
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under UV in a laminar flow hood for 20 min to eliminate excess moisture and 
stored at 4 ºC.  
Sterile antibiotics were added to liquid LB or molten LB agar medium at ~55 ºC 
as required, at the following concentrations.  
Ampicillin (100 g/ml) 1,000x stock solution: 100mg/ml in 50% ethanol. 
Antibiotics were sterilised by filtration through a 0.2 µm filter (Millipore). 
 
2.5.2 Culture of E. coli DH5Į 
DH5  cells were streaked for single colonies on LBA plates (containing antibiotic 
if required) and grown overnight at 37 ºC.  After 24hrs, 5-10ml LB in a sterile 
Erlenmeyer flask was inoculated with a single colony and cultured at 37 ºC.  
 
2.5.3 Preparation of Escherichia coli (E. coli) competent cells. 
The Calcium chloride/Rubidium chloride method was used for making E. coli 
DH5  competent for DNA transformation. A single colony from a fresh streak of 
cells was used to inoculate 5ml LB. After overnight growth at 37 ºC the culture 
was diluted at 1:100 ratio in LB  medium at 37 ºC, until it reached an optical 
density (at 600 nm) of 0.5. The log phase cells were incubated on ice for 10 
minutes in a pre-chilled 50 ml falcon tube. Cells were harvested by centrifugation 
at 2400 rpm for 10 minutes at 4 ºC. The supernatant was removed, the cell pellets 
were gently resuspended in 20 ml ice cold Buffer 1 (on ice). Centrifugation was 
repeated (2400 rpm for 10 minutes at 4 ºC); the pellet was resuspended in 2 ml 
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ice-cold Buffer B and the cell suspension combined. Prior to storing at -80 ºC, 
200 l competent cells aliquots in Microfuge tubes were snap frozen on dry ice.  
Buffer 1: (30 mM KCl; 100mM RbCl; 10mM CaCl2, 50 mM MgCl2, 
15%glycerol; adjust to pH 5.8 using 0.2 M glacial acetic acid) 
Buffer 2: (10 mM MOPS; 75 mM CaCL2, 10 mM RbCl, 15% glycerol; adjust to 
pH 6.5 using 1M filter sterilised KOH). 
 
2.5.4 Plasmid DNA Transformation into E. coli  cells 
Plasmid DNA was used to transform competent DH5Į E. coli cells as follows. 
Firstly, the competent host cells were removed from -80 C and thawed on ice. For 
each of the transformations, 1 µl of plasmid DNA was mixed with a 100 l 
volume of cell suspension, and incubated on ice for a further 45 minutes.  The 
cells were heat shocked in a water bath at 42 C for 2 minutes before returning to 
ice for 2 min.  400 l of LB was added aseptically and the transformed cells 
incubated at 37 C for 1 hour on a shaking incubator. Transformation mixes were 
spun at 13,000 rpm for 1 minute to pellet the cells, 400 l of supernatant was 
removed and the pellet resuspended in the remaining media. The bacteria were 
spread onto LB agar plates containing the appropriate antibiotic and incubated 
overnight at 37 C. 
 
 The plasmids used in this study were wild type and mutant full length p53 
cloned into pcDNA3 as described in (Rodriguez et al., 2000), kindly provided by 
Professor Ronald Hay (University of Dundee), as shown in Table 2.2. 
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Table 2:3: Plasmids Used in the Study. 
Plasmid Source 
pcDNA3 Invitrogen 
  
p53 Professor Ronald Hay, University of Dundee  
  
p53K372-3R Professor Ronald Hay, University of Dundee 
  
p53K381-2R Professor Ronald Hay, University of Dundee 
  
p53K386R Professor Ronald Hay, University of Dundee 
  
p53K6R Professor Ronald Hay, University of Dundee 
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2.6 Molecular biology techniques 
2.6.1 Plasmid Purification from E.coli 
For large-scale preparation of plasmid DNA, 200ml cultures were inoculated with 
1/100 fold dilution of suspended cells and left to replicate overnight at 37°C, 250 
rpm. To isolate the plasmid DNA from these cells the QIAGEN Plasmid Maxi Kit 
protocol was used with the following amendments: To precipitate plasmid DNA, 
centrifugation was carried out at 7000 rpm for 15 min and after addition of 
isopropanol; the pellet was washed with 75% ethanol; dried by vacuum 
evaporation and finally resuspended in sterile water. 
 
2.6.2 Determination of Nucleic Acid Concentration 
The concentrations and purity of plasmid DNA preparations were determined 
using the Nanodrop ND-1000 UV-Vis Spectrophotometer. A260/A280 values 
were also calculated and were useful indicators of sample purity. For uncut DNA 
plasmids, 1µg was then run on a 0.8% agarose gel to allow estimation of the ratio 
of supercoiled to nicked DNA.  
 
2.6.3 Sequencing of Plasmid DNA  
Plasmid DNA for sequencing was sent to Geneservice Ltd (MRC, Medical 
solutions plc, Nottingham, UK). Samples were sequenced using Big Dye V3.1 
chemistry and an AB13730xl Automated Sequencer. 
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2.6.4 Calcium Phosphate-Mediated Transfection of Adherent 
Cells 
Adherent SaOs2 (p53 deficient) cells were seeded at 1-2x106 cells/ plate 24 hours 
prior to transfection. 50-80% subconfluent cells were transfected by using the 
calcium phosphate coprecipitation method (CalPhosTM Mammalian Transfection 
Kit- Clontech, Basingtoke, UK). 1-3 hr prior to transfection cells were washed 
with sterile 1X PBS and 10 ml of fresh medium added. Cells were transfected 
with 10µg of pcDNA3 (p53, p53K372-3R, p53K381-2R, p53K386R and 
p53K6R) expression vectors. Expression of p53 proteins was confirmed by 
western blots using anti-p53 antibody. For each condition, a DNA mastermix 
containing sterile water, DNA and 12.5% (v/v) 2M calcium solution was 
prepared; added dropwise to an equivalent volume of 2X Hepes Buffered Saline 
(HBS) while vortexing. Solutions were incubated at room temperature (RT) for 20 
min. 200µl was subsequently added dropwise to the 10 ml of medium present in 
the plate. After 16 hours of incubation at 37°C, cells were washed twice with 1X 
PBS; then maintained in DMEM for another 24 hours. Cells were then washed 
with 1X PBS and harvested in PBS for subsequent protocols, e.g. wetern blots.  
 
2.6.5 Data bank analysis 
The NCBI databases and BLAST program was used for DNA and protein 
sequence verifications.  
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2.6.6 RNA interference 
RNA interference (RNAi) is a post-transcriptional process used to induce 
temporary gene silencing. Where a double-stranded RNA molecules triggers a 
sequence specific mRNA degradation of homologous single-stranded target 
RNAs and the translated products (Tuschl and Borkhardt, 2002). Interference of 
RNA initiates by the conversion of dsRNA into 21-23 nucleotide fragments by 
the RNase III enzyme, Dicer. These short RNA nucleotide fragments are called 
small interfering RNAs (siRNAs), containing two nucleotide single-stranded 
overhangs at the 3' end and bearing 5'-monophosphate and 3'- hydroxyl groups 
which are crucial for the degradation of the target RNAs complementary to the 
siRNA sequence. Then, the siRNAs incorporated into the RNA-induced silencing 
complex (RISC), in an ATP-dependent step (in this step siRNA duplex is 
unwound into single strands), that guide the RISC to recognize and cleave the 
target RNA (Schwarz et al., 2002). In this study, we silenced SUV420H2 gene 
using siSUV420H2 (Dharmacon). INTERFERinTM (Polyplus Transfection) was 
used as the transfection reagent. 2,000,000 MCF-7 cells per 6 cm2 dishes were 
plated 24 hrs prior to transfection. The following steps were done at room 
temperature. 1.1 µl siRNA was mixed with 399 µl DMEM media, followed by 
adding 15 µl INTERFERin with continuous vortexing for 10 min. The culture 
media was removed from the plate and replaced with fresh media, to which the 
mix was added. The final concentration of siRNA oligos in each plate was 5 nM. 
As a control reaction for the experiment, cells were subjected to transfection with 
scrambled siRNA in order to detect cellular effects caused by the transfection 
event or delivery process. After 24 hrs, garcinol treatment was added for 24 
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hours, followed by western blotting for detecting the levels of H4K20me3 in the 
MCF-7 cells. 
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3.1 Evaluation of the H4K16ac Regulatory Axis as a Novel 
Biomarker Set in Breast Tumours 
In a previous study, we assessed the occurrence of global histone PTMs in an 
archived set of 880 paraffin-embedded breast tumour biopsies using 
immunohistochemistry of tissue microarrays (TMAs). This study revealed that 
global histone PTM levels in breast tumours correlate with tumour phenotypes, 
prognostic factors, and patient outcome (Elsheikh et al., 2009). µLow¶ levels 
(below the median) of 7 different histone PTMs were associated with advanced 
stage tumours, and correlated with a significantly poorer long term survival. 
Similar observations have been reported in prostate tumours (Seligson et al., 
2005), renal cell carcinoma (Mosashvilli et al., 2010, Liu et al., 2010) and bladder 
cancer (Dudziec et al., 2011). Thus, it has been suggested that assessment of 
histone PTM levels may be a useful prognostic indicator predictive of clinical 
outcome in solid tumours (Seligson et al., 2005, Elsheikh et al., 2009). This is 
consistent with the findings that H4K16ac and H4K20me3 PTMs are very low or 
absent in  most cancer cell lines, and are thus considered hallmarks of cancer 
(Fraga et al., 2005). In contrast these marks are readily detected in normal tissues 
or non-transformed cells (Jones et al., 2008). As our previous study indicated 
decreased H4K16 acetylation in even early stage tumours (Elsheikh et al., 2009), 
we reasoned that this might be one of the early epigenetic changes to occur in 
tumour cells. Thus, it was decided to use TMAs to determine the expression of the 
H4K16ac regulatory axis, i.e. the enzymes that control H4K16 acetylation status 
and their cofactors. Therefore, the hypothesis under investigation here is that 
factors that regulate H4K16 acetylation might also be altered in their expression 
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or function in breast tumours, and might therefore be useful cancer biomarkers or 
offer new leads to discover novel therapeutic targets. 
 
3.1.1 Enzymes that Regulate H4K16 Acetylation: The H4K16ac 
Axis 
A number of in vitro studies have revealed that MYST domain proteins such as 
hMOF, TIP60, MOZ/MYST3 and MORF/MYST4 are capable of acetylating 
histone H4 at K16 (Troke et al., 2006), although there is still some controversy in 
the field regarding whether all of these enzymes can regulate this PTM in vivo. 
The human homolog of the Drosophila MOF (males absent on the first) protein 
has been suggested to be responsible for the majority of H4K16 acetylation in 
vivo under normal growth conditions (Taipale et al., 2005). In support of this, 
hMOF knock down by siRNA in HeLa and HepG2 cells showed a strong 
reduction in H4K16 acetylation, with inhibitory effects on the cell cycle (Taipale 
et al., 2005). The Drosophila MOF is a component of the male specific lethal 
(MSL) and non-specific lethal (NSL) complexes and is required for dosage 
compensation in flies (Hilfiker et al., 1997b). However, its role in mammalian 
cells remains unclear. Nonetheless, it has been shown that down-regulation of 
hMOF in mammalian cells results in a global decrease in H4K16 acetylation 
(Taipale et al., 2005). In addition, another study showed that ablation of hMOF 
led to a decreased expression of the tumour suppressor gene TMS1, accompanied 
by changes in nucleosome positioning within its promoter. Interestingly, this 
silencing of TMS1 was reversed by re-expression of hMOF (Kapoor-Vazirani et 
al., 2008). Similarly, ablation of MOF in mouse fibroblasts was associated with 
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G2/M arrest, aberrant chromosomal segregation and defective repair of DNA 
damage (Li et al., 2011). As hMOF has been shown to be downregulated or 
deleted at a high frequency in breast tumours or medulloblastomas (Pfister et al., 
2008), we considered this protein as a possible central player in the H4K16ac 
regulatory axis. 
 
 Other MYST proteins have also been shown to acetylate H4. The MYST 
domain of TIP60 can acetylate H4K16 (Kimura and Horikoshi, 1998), although 
this is likely to be in response to cell stress such as DNA damage. Consistent with 
this, in Chapter 5, I will show that treatment of cells with DNA damaging agents 
led to increased TIP60 expression and concomitant H4K16 acetylation. The MOZ 
and MORF (or MYST3 and MYST4) proteins have also been reported to acetylate 
H3 and H4 at several sites including H4K16 (Kitabayashi et al., 2001). Data from 
our lab has shown that the MYST domain of MOZ can acetylate H4 at K16 
(Collins et al., in preparation). However, some studies have suggested full-length 
MOZ acetylates H3 preferentially when associated with the ING5 protein 
complex (Doyon et al., 2006). This suggests that the MYST domain substrate 
preference may be modulated by other domains in MOZ/MYST3 or by cofactors. 
Indeed, recent results from our group have discovered a second H3 
acetyltransferase activity in MOZ/MYST3 (Deeves et al., in preparation). 
Nonetheless, there is clear evidence that H4K16 may be a target for MOZ and 
TIP60 under some conditions. 
 
Deacetylation of H4K16 has been reported to be catalyzed by the Class III 
NAD-dependent HDAC SIRT1 (Vaquero et al., 2006). SIRT1 is negatively 
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regulated by a cofactor termed Deleted in Breast Cancer (DBC1) which blocks its 
HDAC function (Zhao et al., 2008, Kim et al., 2008). Thus loss of DBC1, which 
is frequently deleted in breast tumours, would in theory result in increased activity 
of SIRT1 and thus hypoacetylation of H4K16. Thus DBC1 was also considered a 
possible factor within the H4K16ac regulatory axis (Fig. 3.1). 
 
DBC1 has also been reported to block the activity of the histone 
methyltransferase SUV39H1 (Li et al., 2009e). SUV39H1 is responsible for 
H3K9 trimethylation (Rea et al., 2000), which is a histone PTM associated with 
transcriptional silencing and DNA repair (Tachibana et al., 2005). and localises to 
transcriptionally silent heterochromatin (Bhaumik et al., 2007). The N-terminus of 
SUV39H1 interacts with the heterochromatin protein HP1 , (Melcher et al., 
2000). The presence of H3K9me3 in chromatin stabilises the recruitment of 
heterochromatin proteins (HP1 - ), which bind this PTM via the chromo domain 
to promote silencing (Bannister et al., 2001). The activity of the SET domain of 
SUV39H1 is impaired by acetylation of K226, although it is not clear which 
acetyltransferases mediate this modification. In contrast SIRT1 can remove the 
acetyl group from K226, thus acting as a positive regulator of SUV39H1 and 
promoting deposition of H3K9me3 in chromatin. The negative regulator DBC1 
blocks the activity of SUV39H1, by binding to its catalytic domain (Li et al., 
2009e). Moreover, SIRT1 deacetylates SUV39H1 at its catalytic SET domain, 
resulting in increased activity, higher levels of the H3K9me3 modification and 
impaired localization of heterochromatin protein1 (Vaquero et al., 2007) (Fig. 
3.1). 
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Thus, MOF, TIP60, DBC1, SUV39H1 and possibly MOZ/MYST3 are all 
potentially part of the H4K16 regulatory axis which crosstalk to other PTMs such 
as H3K9me3 and H4K20me3. We therefore decided to explore the expression of 
hMOF, DBC1, TIP60, SUV39H1 as well as the incidence of H3K9me3 in breast 
tumours and correlate this within previous data on histone PTMs and archived 
information on other clinico-pathological factors.  
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Figure 3.1: The H4K16ac Axis. 
 
 
hMOF, TIP60 and possibly other MYST domain histone acetyl transferases 
acetylate H4K16, whereas SIRT1 deacetylates H4K16; The SET domain of the 
methyl transferase SUV39H1 is negatively regulated by acetylation at K266, 
although the HAT that catalyses this unknown; SIRT1 can also deacetylates 
SUV39H1 at K266, thus stimulating its ability to trimethylate H3K9 (H3K9me3) 
a repressive mark in chromatin; the regulatory protein Deleted in Breast Cancer 
(DBC1) can bind and  inhibit both SIRT1 and SUV39H1.  
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3.1.2 TMA profiling of the H4K16ac Regulatory Axis in Breast 
Tumours 
Tissue microarrays representing core sections from 880 breast tumour cores were 
provided by the Nottingham Breast Unit. The TMAs were stained for the presence 
of four chromatin regulators (hMOF, SIRT1, DBC1 and SUV39H1) as well as 
H3K9me3 and H4K16ac. The antibodies used are described in Appendix 1, and 
all were optimized by IHC staining of optimization slides (TMA slides that lost 
numerous tissue cores) with different primary antibody dilutions, which further 
increased/decreased according to the staining outcome. The final antibody dilution 
and method for antigen retrieval (Appendix 1) were determined when the staining 
outcome, and the majority of the tissue cores showing some level of staining. IHC 
staining was performed as described in Materials and Methods (Section 2.2.3). 
Any damaged samples were discounted. A standard H-score system was used for 
evaluating the staining intensity for all marks (Elsheikh et al., 2009).  
 
 
 Two antibodies were used to detect H4K16ac in TMAs (Abcam, ab1762) 
and (Upstate, 06762). Data from the first antibody was reported in El Sheikh et 
al., (2009), while data obtained with the second antibody (Upstate) is reported 
here. The specificity of this antibody was verified using  dot blot  assays with H4 
1-22 peptides acetylated at K5, K8, K12 and K16, or unacetylated H4 (personal 
communication; Sian Deeves). Immunoreactivity for the above biomarkers was 
generally detected in the nuclei of the examined tissue; except for SUV39H1, 
which showed additional cytoplasmic reactivity. H-score was done according to 
only the nuclear reactivity. Representative examples of breast cancer tumour 
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tissue cores presenting with low or high levels of staining for each antibody are 
shown in Figure 3.2 left and central column. Histograms illustrating the frequency 
for H-score for each mark plotted against the number of cases are shown in Figure 
3.2, right column. The histone PTM H4K16ac gave a zero score in more than 10% 
of tumours (90 out of 760 cases) although the median H-score was 100. This is 
consistent with our previous data using another H4K16ac antibody as reported in 
El Sheikh et al. (2009), and is consistent with other reports of a reduction of this 
histone PTM in breast and medulloblastoma tumours (Pfister et al., 2008). 
Interestingly, 40 cases were also recorded as H-score =zero for hMOF, the 
primary acetyltransferase for H4K16 in cell line studies. Similarly, DBC1 
expression absent in around 10% of tumours, and 90 tumours also had zero H-
score for the global levels of H3K9me3. In contrast, fewer tumours were negative 
for SIRT1, which may be indicative of its essential role in cells (Fig. 3.2). 
 
 For further analysis of the distribution of the H4K16ac regulatory axis, 
IHC staining levels were studied with respect to various tumour 
clinicopathological and biological parameters. To facilitate comparison, the data 
was categorised into low or high detection levels. The median H-score was used 
WRFDWHJRULVHGDWDLQWRµORZ¶(Below or equal the PHGLDQRUµKLJK¶OHYHOVWDLQLQJ 
(Above the median), as described in previous studies from the Nottingham Breast 
Unit (Habashy et al., 2008a, Habashy et al., 2009, Zhang et al., 2009, 
Aleskandarany et al., 2010).  
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Figure 3.2: Detection of the H4K16ac Regulatory Axis in Breast Cancer 
TMAs as determined by IHC. 
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Representative examples of breast tumour tissue cores presenting with low (left 
hand column) or µhigh¶ H-scores (central column) for expression of the H4K16ac 
regulatory axis. H4K16ac (A, B); hMOF (D, E); SIRT1 (G, H); DBC1 (J, K); 
H3K9me3 (M, N); and SUV39H1 (P, K). The right hand column (C, F, I, L, O, R) 
shows the combined H-scores for each biomarker in this tumour set. Original 
magnification is x20, further magnifications are presented below.  
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H4K16ac Regulatory Axis in Relationship to Breast Cancer Histologic 
Tumour Types  
H-VFRUHGDWDZDVXVHGWRFDWHJRULVHWXPRXUVDVµKLJK¶RUµORZ¶OHYHOGHWHFWLRQIRU
each of the H4K16-related biomarkers. The numbers for each category in relation 
to tumour type is shown in Table 3.1. No striking associations were apparent, 
although for most tumour types the numbers in the study are too low for 
meaningful statistical analysis. However, we noted a tendency for association of 
several of the biomarkers tested with lobular tumour type. 48 out of 77 (62%) of  
hMOF stained lobular tumours ZHUH µ+LJK¶ VFRUH, which also had a tendency 
(73%) to score high for H4K16ac. In contrast, 43 out of 61 (70%) of SIRT1-
VWDLQHG OREXODU WXPRXUV ZHUH µORZ¶ VFRUH Invasive duct carcinoma/NOS type 
tumours scored tended to have lower levels of H4K16ac axis members. Medullary 
type tumours also tended to have lower levels of H4K16ac axis members, 
although fewer tumours were of this type were present in the sample. DBC1 levels 
did not show considerable variation among different tumour histopathological 
types. Furthermore, all mucinous tumour cases examined (6 cases) had high levels 
of both H3K9me3 and SUV39H1.  
 
H4K16ac Regulatory Axis in Relationship to Breast Cancer Phenotypic 
Groups  
Concerning breast cancer tumour phenotypes proposed by Nielson and colleagues 
(Nielsen et al., 2004), significant differences in H4K16ac and its regulator, the 
hMOF expression levels were noted where the p value in X2 test were below 
0.003 (p<0.003 (Table 3.2). In particular, H4K16ac and hMOF tend to be low in 
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the poor prognostic HER2 type (p=0.002 and p<0.001). This proposes an 
association between low levels of H4K16ac regulatory axis components and 
tumour types associated with poor prognosis. 
 
 Similar results were obtained when correlating the data with breast cancer 
tumour phenotypes proposed by Abd El-Rehim and colleagues (Abd El-Rehim et 
al., 2005), (Table 3.3). Considerable differences were noted in the H4K16ac 
regulatory axis (Table 3.3). H4k16ac and hMOF levels were found predominantly 
low in HER2 tumours. All other marks except H3K9me3 were also low in HER2. 
In addition, hMOF and SIRT1, the H4K16ac regulators, tended to be low in basal 
tumours, especially those expressing normal p53. SUV39H1, the H3K9 
methylation regulator, also tended to be low in basal-p53 normal tumours.  On the 
other hand, although H3K9me3 levels did not show considerable differences 
among HER2 or basal tumours, significant differences in H3K9me3 and its 
regulator SUV39H1 levels were noted among luminal type B tumours (Tumour 
class characteristics is shown in Fig. 1.2). 
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Table 3:1: H4K16ac Regulatory Axis detection levels in Relationship to Tumour Histo-Pathological Types. 
 
H4K16ac  hMOF  SIRT1  DBC1  H3K9me3  SUV39H1 
LD HD  LD HD  LD HD  LD HD  LD HD  LD HD 
Invasive Ductal/NOS Type 212 162  255 131  207 117 
 
176 140  177 140  131 97 
Invasive papillary 1 2  3 0  1 2  1 2  0 3  1 1 
NST& Lobular 13 13  6 12  12 9  10 12  8 9  9 4 
NST& Special 10 11  9 12  5 9  6 10  8 5  9 4 
Classical lobular 29 48  21 56  43 18  33 27  21 34  15 32 
Tubular 9 14  11 13  8 9  8 9  7 9  4 8 
Tubular mixed 70 91  76 83  81 47  58 70  65 59  47 54 
Medullary 14 6  16 6  14 5  10 8  15 3  10 5 
Mucinous 2 5  2 5  3 1  2 2  0 6  0 5 
Cribriform 4 2  4 2  1 3  2 3  1 1  2 1 
Miscellaneous 2 1  3 1  2 1  2 1  1 0  2 1 
Total 721  735  598  592  572  442 
LD, low detection; HD, high detection; NOS, no other specified. 
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Table 3:2: H4K16ac Regulatory Axis detection levels in Relationship to Tumour Phenotype groups of Breast Cancer as defined by 
Nielsen et al (Nielsen et al., 2004). 
 
Nielsen classes of breast cancer 
(Nielsen et al., 2004) 
H4K16ac  hMOF  SIRT1 
LD HD p  LD HD p  LD HD p 
Class   0.002    <0.001    0.775 
HER2 41 24  
 
52 16   42 19  
Luminal 182 224  189 222  202 126 
Basal-like 43 29  57 17  34 22 
Total 543  553  445 
 
Nielsen classes of breast cancer 
(Nielsen et al., 2004) 
DBC1  H3K9me3  SUV39H1 
LD HD p  LD HD p  LD HD p 
Class   0.846    0.088    0.009 
HER2 31 25   22 25   23 17  
Luminal 162 177  179 169  123 131 
Basal-like 38 21  47 26  31 12 
Total 454  468  337 
LD, low detection; HD, high detection; all p values are calculated by X2 test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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Table 3:3: H4K16ac Regulatory Axis detection levels and Phenotype groups of Breast Cancer as defined by Abe El-Rehim et al (Abd El-
Rehim et al., 2005). 
Abd El-Rehim classes of 
breast cancer 
H4K16ac  hMOF  SIRT1  DBC1  H3K9me3  SUV39H1 
LD HD  LD HD  LD HD  LD HD  LD HD  LD HD 
Luminal A 16 21  11 26  18 17  18 12  12 20  12 15 
Luminal B 16 16  17 16  15 9  14 13  17 9  14 5 
Luminal N 40 47  45 42  42 36  41 37  29 49  35 30 
HER2 20 10  23 7  16 8  18 9  9 16  12 6 
Basal-p53 altered 11 9  12 7  7 6  10 6  10 5  9 1 
Basal-p53 normal 13 14  22 4  14 8  11 13  11 11  13 6 
Not classified 58 59  69 53  63 37  55 44  48 46  44 30 
Total 350  356  296  301  292  232 
LD, low detection; HD, high detection. 
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Correlation of H4K16ac Regulatory Axis with Clinicopathological Factors 
Complete clinical and follow-up data for 835 of the 880 patient samples. Analysis 
of the data revealed a number of significant correlation with the biomarkers tested 
in this study (Table 3.4 and 3.5). In particular, tumour grade tended to correlate 
negatively with H4K16ac and hMOF (p<0.001 and p<.001 respectively). Low 
grade tumours were more likely to express high levels of H4K16ac and its 
regulators. Conversely, high-grade tumours were found to be less likely to express 
H4K16ac and its regulatory axis. In contrast, SIRT1 expression did not appear to 
correlate with tumour grade (Table 3.4). 
 
 Regarding Nottingham Prognostic Index (NPI), there was a tendency 
towards high H4K16ac detection in the good and moderate prognostic groups and 
low scores for this PTM in the poor prognostic group. Generally, H4K16ac was 
negatively correlated with NPI (p=0.011). Consistent with that, high hMOF 
expression was detected in more than half of the tumours within a good prognosis 
group and it tended to be low in a considerable part of the moderate and poor 
prognostic groups (p<0.001) (Table 3.4). A significant difference in SUV39H1 
levels was also noted among various NPI categories. High SUV39H1 levels were 
found to be negatively correlated with NPI (p<0.001); where 58% (n=161) of the 
tumours of the good NPI category were found to be high in SUV39H1, 71% 
(n=56) of the poor category were low in SUV39H1 (Table 3.5).  
 
 A negative correlation was found for hMOF expression in large tumours 
(>5cm), as 63% scored as low for hMOF, although this was not observed for 
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H4K16Ac. Conversely, SIRT1 showed a trend toward  positive correlation with 
tumour size (p=0.03), where big tumours (>5cm) tended to express higher SIRT1 
levels (Table 3.4) which is consistent with a  role for SIRT1 in proper growth and 
development in mice embryo (Cheng et al., 2003). High SUV39H1 levels 
negatively correlated with tumour size (p=0.017), where big tumours (>5cm) 
tended to express low SUV39H1 levels (Table 3.5), which was consistent with the 
identification of growth retardation in a mouse model when SUV39H1 was over 
expressed (Czvitkovich et al., 2001).  
 
Correlation with other cancer biomarkers 
Comparison of H-scores for our biomarker set to a range of other cancer 
biomarkers (14 biomarkers) for the 880 tumours detected a number of significant 
correlations (Table 3.5). The biomarkers showing significant correlation with 
H4K16ac, hMOF and SIRT1 are reported in Figure 3.4 whereas correlation data 
for H3K9me3, DBC1 and SUV39H1 are shown in Table 3.6. I have reported all 
significant correlations, but due to the large volume of data, I will summaries the 
main point we can extract from our data. 
 
 High scores for H4K16ac and hMOF expression were significantly 
associated with high levels of luminal cytokeratins CK7/8 and CK19 and low 
levels of basal cytokeratin 5/6 and CK14 (Table 3.4). This is consistent with the 
data in Table 3.2 showing a tendency for luminal tumours to have high scores for 
H4K16ac and hMOF; and the tendency for basal tumours to have low scores for 
both biomarkers. Steroid hormone receptors i.e. estrogen, progesterone and 
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androgen receptors which are usually good prognostic indicators in breast 
tumours, also correlated with high levels of hMOF and H4K16ac, in contrast to 
SIRT1 which did not show a correlation with steroid receptor status. Similarly 
forkhead-box A1 (FOXA1), previously described as a growth repressor in breast 
cancer (Habashy et al., 2008b), and BRCA1, the tumour suppressor gene BRCA1 
(Lee et al., 2010) showed a tendency to positive correlation with high H4K16ac 
and hMOF (Table 3.4). In addition, both hMOF and H4K16 Ac showed a negative 
correlation with c-MYC (Cheng et al., 2006) and the mutated form of p53. 
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Table 3:4: H4K16ac, hMOF and SIRT1 Detection Levels in relationship to 
Tumour Clinicopathological Parameters; Biological factors. 
Parameter 
H4K16ac hMOF SIRT1 
Total LD HD p Total LD HD p Total LD HD p 
Age 722   0.237 736   0.388 599   0.272 
<50  123 129   145 113   133 84  
>50  244 226   262 216   245 137  
 
            
Grade 722   <0.001 736   <0.001 599   0.015 
I  63 95   73 88   69 59  
II  106 130   104 137   132 57  
III  198 130   230 104   177 105  
             
Stage 720   0.876 734   0.505 597   0.994 
1  110 238   262 226   247 144  
2  90 82   102 75   95 55  
3  34 35   41 28   35 21  
             
NPI  720   0.011 734   <0.001 597    
Good  110 143   114 145   127 70 0.759 
Moderate  198 172   221 155   201 117  
Poor  57 40   70 29   49 33  
             
Size  722   0.086 736   <0.001 599   0.03 
< 5cm  224 235   239 233   256 132  
> 5cm  143 120   168 96   122 89  
             
LN Metastasis 720   0.417 734   0.144 597   0.528 
Negative  241 238  
 262 226   247 144  
Positive  124 117  
 143 103   130 76  
             
ER receptor 668   0.001 680   <0.001 555   0.272 
Low  126 88   160 60   122 66  
High  207 247   217 243   227 140  
             
PR receptor  658   0.017 671   <0.001 549   0.195 
Negative  169 138   211 99   162 88  
Positive  163 188   164 197   182 117  
             
AR receptor  618   <0.001 631   <0.001 517   0.229 
Negative  159 101   174 86   138 75  
Positive  157 201   170 201   186 118  
             
P53 (Altered) 664   0.030 676   <0.001 552   0.344 
Negative  237 245   247 242   247 150  
positive  105 77   123 64   100 55  
             
CK7/8  693   0.005 708   <0.001 581   0.503 
Negative  145 107   163 93   128 75  
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Positive  208 233   228 224   237 141  
             
CK18  593   0.407 602   0.012 505   0.026 
Negative  92 91   112 69   108 46  
positive  212 198   217 204   213 138  
             
CK19 690   0.037 702   0.003 575   0.200 
Negative  79 57   90 45   77 38  
positive  272 282   303 264   286 174  
             
CK5/6 699   0.013 713   <0.001 584   0.074 
Negative  260 273   275 267   295 160  
Positive  98 68   123 48   74 55  
             
CK14  676   0.051 691   <0.001 567   0.179 
Negative  266 267   282 261   291 165  
positive  83 60   109 39   65 46  
             
c-MYC 340   0.001 343   0.045 276   0.010 
Low  145 99   160 88   131 72  
High  39 57   71 24   35 38  
             
nBRCA1   504   <0.001 512   <0.001 430   0.016 
Low  137 79   140 79   130 62  
High  110 178   137 156   136 102  
             
FOXA1   581   <0.001 591   <0.001 486   0.141 
Low  176 132   214 98   169 100  
High  117 156   130 149   125 92  
             
FHIT 438   0.016 445   0.019 372   0.484 
Low  133 112   142 112   131 82  
High  84 109   87 104   99 60  
             
EGFR 483   0.008 494   0.265 460   0.063 
Low  203 196   216 191   228 143  
High  30 54   50 37   63 26  
 
LD, low detection; HD, high detection; LN, lymph node; ER, estrogen receptor, 
PR, progesterone receptor; AR, androgen receptor; all p values are calculated by 
X2 test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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DBC1, the negative regulator for SIRT1 exhibited striking associations with other 
biomarkers. Although DBC1 has been previously reported functionally interact 
with estrogen receptor (Trauernicht et al., 2007) and androgen receptors (Milne et 
al., 2007), no significant correlations in expression for these proteins were 
detected. :HGLGQRWHDWHQGHQF\IRU µKLJK¶'%&LQORZJUDGH WXPRXUV 7DEOe 
3.5). 
 
 Low expression of SUV39H1 was associated with poor prognostic index 
(NPI), large tumour size, low expression of steroid receptors and was negatively 
correlated with luminal cytokeratins CK18 and CK19. SUV39H1 showed a 
positive association with FOXA1 and tumour suppressor FHIT; and inverse 
correlation with the poor prognostic marker FGFR (Haugsten et al., 2010). In 
addition, SUV39H1 and its product H3K9me3 levels were found to score lower in 
Grade III tumours (Table 3.5).  
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3:5: H3K9me3, DBC1 and SUV39H1 Detection Levels in relationship to 
Tumour Clinicopathological Parameters; Biological factors. 
Clinico- 
Pathological 
data 
DBC1 H3K9me3 SUV39H1 
Total LD HD p Total LD HD p Total LD HD p 
Age 593   0.302 573   0.231 442   0.516 
<50  114 98   103 100   82 75  
>50  195 186   201 169   148 137  
 
            
Grade 593   0.005 573   0.035 442   0.002 
I  51 78   59 67   47 60  
II  103 84   87 91   65 78  
III  155 122   158 111   118 74  
             
Stage 590   0.638 572   0.545 440   0.263 
1  197 188   208 173   143 145  
2  77 71   70 70   61 51  
3  33 24   25 26   25 15  
             
NPI  590   0.057 572   0.156 440   <0.001 
Good  93 107   95 100   67 94  
Moderate  165 146   172 131   122 101  
Poor  49 30   36 38   40 16  
             
Size  593   0.108 573   0.494 442   0.017 
< 5cm  185 185   199 175   135 146  
> 5cm  124 99   105 94   95 66  
             
LN Metastasis  590   0.312 572   0.157 440   0.100 
Negative 
 197 188   208 173   143 145  
Positive 
 110 95   95 96   86 66  
             
ER receptor 551   0.127 534   0.107 417   <0.001 
Low  100 79   99 76   89 44  
High  187 185   181 178   132 152  
             
PR receptor  550   0.038 529   0.014 411   0.006 
Negative  145 113   140 99   110 71  
Positive  141 151   141 149   110 120  
             
AR receptor  512   0.076 497   0.003 386   0.008 
Negative  124 95   125 86   98 60  
Positive  146 147   132 154   112 116  
             
p53 (Altered) 553   0.098 529   0.080 409   0.162 
Negative  198 199   191 182   155 145  
positive  88 68   91 65   63 46  
             
CK7/8  576   0.306 555   0.111 430   0.096 
Negative  114 99   111 84   87 64  
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Positive  185 178   184 176   141 138  
             
CK18  42   0.048 481   0.506 378   0.008 
Negative  84 62   74 67   71 39  
positive  169 177   177 163   135 133  
             
CK19 753   0.343 547   0.029 424   0.028 
Negative  60 50   63 38   51 29  
positive  240 223   229 217   176 168  
             
CK5/6 580   0.191 558   0.148 431   0.081 
Negative  227 217   221 205   168 161  
Positive  76 60   76 56   58 44  
             
CK14  561   0.130 536   0.066 415   0.524 
Negative  242 204   213 205   172 152  
positive  55 60   70 48   48 43  
             
c-MYC 275   0.546 258   0.066 210   0.098 
Low  99 109   116 71   101 60  
High  32 35   36 35   25 24  
             
nBRCA1   428   0.004 412   <0.001 331   <0.001 
Low  115 79   110 75   100 44  
High  108 126   95 132   82 105  
             
FOXA1   481   0.206 464   <0.001 355   <0.001 
Low  140 124   157 100   131 72  
High  106 111   93 114   62 90  
             
FHIT 372   0.024 359   0.240 292   0.014 
Low  120 90   109 102   95 72  
High  75 87   70 78   54 71  
             
EGFR 397   0.321 389   0.508 238   0.021 
Low  169 161   165 152   112 114  
High  37 30   38 34   10 2  
 
LD, low detection; HD, high detection; LN, lymph node; ER, estrogen receptor, 
PR, progesterone receptor; AR, androgen receptor; all p values are calculated by 
X2 test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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Relationship to histone marks and their modulators 
H4K16ac regulatory axis levels showed a correlation with most histone PTMs and 
modulators used in this study. Remarkably, high levels of H4K16ac were 
positively correlated with eight (H3K9ac, H3K18ac, H4K12ac, H4K16ac 
(abcam), H3K4me2, H3K9me3, H4R3me2 and H3K56ac) histone PTMs marks  
with highly significant p values (p<0.001) as shown in Table 3.6. Interestingly, 
high levels of a number of those histone PTMs, including H4K16ac (abcam 
antibody) have been already reported in association with favourable prognosis in 
breast cancer (Elsheikh et al., 2009). In addition, high levels of H4K16 correlated 
with high levels of histone acetyltransferase TIP60, hMOF and MORF and with 
high levels of the methyltransferase SUV39H1 (p<0.001). Strikingly, the DNA 
damage marker, H3K56ac (Masumoto et al., 2005, Vempati et al., 2010) was also 
correlated with high level of H4K16ac in a highly significant p value (p<0.001). 
 
 High levels of hMOF correlated with all histone PTMs marks studied in 
this work (Table 3.6). Specifically, with high levels of the active gene marks 
H3K9ac (Lindeman et al., 2010); the transcriptional activation mark H3K4me3 
(Ruthenburg et al., 2007); H3K18ac; H4K12ac and as expected with H4K16ac 
(p<0.001). The positive correlation with histone acetylation marks other than 
H4K16 could be explained by either redundancy in hMOF activity or due to 
enhanced expression of other HATs. The DNA damage mark H3K56ac was 
positively correlated with hMOF which is consistent with the role for hMOF in 
the DNA damage response (Taipale et al., 2005). hMOF was also correlated with 
high levels of most HATs in our study, such as TIP60 and MORF (p=0.015 and 
p<0.001 respectively). Consistent with our hypothesis, although the p values were 
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not significant, hMOF levels were negatively correlated with HDACs (HDAC1, 
HDAC2 and SIRT1) levels. hMOF was found positively correlated with the 
repressed gene mark H3K9me3 (Derks et al., 2009, Snowden et al., 2002) and 
with the high levels of H3K9me3 modulator, the histone methyltransferase 
SUV39H1 (Bhaumik et al., 2007) (p=0.01 and 0.001 respectively). hMOF was 
found positively correlated with, H4K20me3 and H4R3me2 histone methylation 
marks, which might be a sign of histone PTMs cross talk, which is consistent with 
the reported ordered and interdependent deposition of acetylation and arginine 
methylation during histone PTMs during gene transcription (Daujat et al., 2002). 
 
 SIRT1 levels were correlated with a number of histone acetylation and 
methylation marks used in the study (Table 3.6). Although the differences in 
SIRT1 levels among some of them were not statistically significant, high levels of 
SIRT1 were positively correlated with the repressed gene marker H3K9me3 
(Tachibana et al., 2005) which is consistent with the role of SIRT1 in inducing 
gene repression (Pruitt et al., 2006, Nosho et al., 2009); and H3K4me3 (p=0.003), 
the active gene mark (Tserel et al., 2010). Regarding HATs, differences in SIRT1 
levels were not significant among any of them except MORF (p=0.003). As 
expected, SIRT1 was positively correlated with HDACs. Where, SIRT1 positively 
correlated with both HDAC1 and HDAC2 (p=0.012; 0.018 respectively), which is 
consistent with their deacetylase activity. Interestingly, DBC1 the negative 
regulator for SIRT1 was found positively correlated with SIRT1 in highly 
significant value (p<0.001).  
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Table 3:6: H4K16ac, hMOF and SIRT1 Detection Level and Histone PTMs 
and their Modulators. 
Histone and 
Histone 
Modulators 
H4K16ac hMOF SIRT1 
Total LD HD p Total LD HD p Total LD HD p 
H3K9ac 500   <0.001 511   <0.001 428   0.151 
Low  165 96   185 82   152 80  
High  83 156   119 125   118 78  
  
 
   
 
   
 
  
H3K18ac 506   <0.001 516   <0.001 431   0.017 
Low  159 99   188 74   156 77  
High  93 155   119 135   112 86  
 
     
 
   
 
  
H4K12ac 484   <0.001 494   <0.001 414   0.017 
Low  172 104   194 83   158 79  
High  70 138   100 117   99 78  
             
H4K16ac 
(Abcam) 
519   <0.001 528   <0.001 444   0.106 
Low  220 143   238 135   203 117  
High  42 114   66 89   70 54  
             
H4K16ac 
(Millipore) 
    741   <0.001 558   0.028 
Low      247 133   187 101  
High      173 188   153 117  
             
H3K4me2 489   <0.001 498   <0.001 421   0.039 
Low  169 95   181 83   155 81  
High  78 147   117 117   105 80  
             
H4K20me3 462   0.002 474   0.009 408   0.065 
Low  52 27   56 23   54 25  
High  182 201   221 174   192 137  
             
H3K9me3 531   <0.001 543   0.010 519   0.001 
Low  199 83   174 112   185 93  
High  75 174   130 127   127 114  
             
H4R3me2 554   <0.001 563   0.003 470   0.003 
Low  189 134   211 117   197 95  
High  86 145   123 112   97 81  
 
            
H3k56ac 569   <0.001 584   <0.001 467   0.415 
Low  194 102   196 107   148 97  
High  109 164   124 157   131 91  
 
            
MORF 491   0.001 504   <0.001 474   0.003 
Low  143 105   151 101   168 76  
High  104 139   113 139   129 101  
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TIP60 545   0.162 194   0.015 166   0.332 
Low  155 50   72 19   49 36  
High  137 68   66 37   43 38  
 
            
hMOF 741   <0.001     566   0.259 
Low  247 173       189 128  
High  133 188       156 93  
 
            
SUV39H1 411   0.001 423   0.001 393   0.324 
Low  135 80   140 81   135 78  
High  91 105   98 104   119 61  
 
            
HDAC1  513   <0.001 524   0.420 475   0.012 
Low  150 109   155 115   161 83  
High  106 148   149 105   128 103  
             
HDAC2  559   0.078 568   0.016 547   0.018 
Low  134 154   126 120   161 79  
High  109 162   195 127   178 129  
 
            
SIRT1 558   0.082 566   0.259     
Low  146 120   189 128      
High  142 150   156 93      
 
            
DBC1 318   0.065 331   0.463 308   <0.001 
Low  104 69   103 73   131 35  
High  74 71   89 66   79 63  
 
LD, low detection; HD, high detection; all p values are calculated by X2 test. 
Bonferroni correction test was applied and reduced the (p) value of significance to 
0.003. 
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High DBC1 levels were correlated with high levels of SIRT1; histone acetylation 
and methylation marks as shown in Table 3.7, which is consistent with its 
inhibitory role for the SIRT1 deacetylase activity (Kim et al., 2008). 
 
  
A remarkable relationship between changes in H3K9me3 levels and the level of 
other histone PTMs and histone modulators was noticed. H3K9me3 levels 
correlated with all histone acetylation and methylation marks studied in this work. 
Specially, with high H3K4me2 levels, which is consistent with their tendency for 
substantial decrease during transcription (Wang et al., 2001, Li et al., 2002, 
Nishioka et al., 2002a). The rest of positive correlations with histone PTMs might 
be explained via H3K9me3 central role in a variety cellular function, and its 
involvement in diverse pathways. In addition, although H3K9me3 has been 
previously described as a repressed gene mark (Tachibana et al., 2005); when 
H3K9me3 and other histone PTMS were explored in  cancer cell lines derived 
from different tissues; Immunoprecipitation (IP) study revealed H3K9me3 
association with active genes rather than being a repressive mark as previously 
described (Wiencke et al., 2008). Consistent with H3K9me3 role in DNA damage 
(Sun et al., 2009), high levels of H3K9me3 correlated with high levels of 
H3K56ac and hMOF levels (p<0.001 and 0.010).  High H3K9me3 levels were 
also correlated with high expression level of MORF (p<0.001), but not TIP60. 
H3K9me3 was found positively correlated with all HDACs where the p values 
were (p=0.004, p<0.001 and p= 0.001 respectively) for HDAC1, HDAC2 and 
SIRT1. This is really consistent with their role in inducing global gene repression 
(Wang et al., 2009b). As expected H3K9me3 expression level has been found 
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positively correlated (p<0.001) with its positive regulator, the histone 
methyltransferase SUV39H1 (Bhaumik et al., 2007); this is really consistent with 
the SUV39H1 role in inducing gene repression (O'Carroll et al., 2000, Rea et al., 
2000, Bhaumik et al., 2007). 
 
   High SUV39H1 levels were found correlated with high level of all histone 
acetylation and methylation marks (Table 3.7). This suggests a close biological 
relationship between those histone marks and SUV39H1, or the involvement in 
same cellular pathways. For example, the positive correlation with the DNA 
damage mark H3K56ac (p=0.011) is consistent with SUV39H1 role in DNA 
damage response (Zhu et al., 2007). With regard to HATs, differences in 
SUV39H1 levels were significant among number of HATs. For example, 
SUV39H1 levels positively correlated with both MORF and hMOF levels 
(p<0.001 and p=0.001). But did not with  high TIP60, although TIP60 was 
previously reported to attach to H3K9me3 during the repair of DNA double-
strand break (Fischle, 2009). Consistently with the literature (Macaluso et al., 
2003, Macaluso et al., 2006), high levels of SUV39H1 correlated with high 
HDAC1 levels (p=0.042), which consistent with their interaction in vivo in 
Drosophila and their involvement in the permanent silencing of transcription in 
particular areas of the genome (Czermin et al., 2001). Similarly, HDAC2 levels 
were also correlated with high SUV39H1 (p=0.007).  
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Table 3:7: H3K9me3, DBC1 and SUV39H1 Detection Level and Histone 
PTMs and their Modulators. 
Histone and 
Histone 
Modulators 
DBC1 H3K9me3 SUV39H1 
Total LD HD p Total LD HD p Total LD HD p 
H3K9ac 425   0.004 417   <0.001 329   0.004 
Low  135 94   133 80   109 64  
High  89 107   88 116   75 81  
  
 
   
 
   
 
  
H3K18ac 454   0.004 420   <0.001 329   <0.001 
Low  131 92   142 73   113 59  
High  91 110   77 128   71 86  
 
 
 
   
 
   
 
  
H4K12ac 410   0.011 396   <0.001 311   <0.001 
Low  134 101   148 69   113 64  
High  79 96   63 116   57 77  
             
H4K16ac 
(Millipore) 
585   0.189 531   <0.001 411   0.001 
Low  169 144   199 75   135 91  
High  136 136   83 174   80 105  
             
H3K4me2 414   0.012 407   <0.001 318   <0.001 
Low  132 97   141 75   115 56  
High  85 100   72 119   63 84  
             
H4K20me3 394   0.048 390   <0.001 301   0.043 
Low  40 26   48 19   34 17  
High  159 169   158 165   131 119  
             
H3K9me3 461   0.514     400   <0.001 
Low  131 119       144 73  
High  110 101       73 110  
             
H4R3me2 474   0.131 452   <0.001 355   0.010 
Low  160 130   172 97   129 80  
High  91 93   71 112   71 75  
 
            
H3k56ac 534   0.137 462   <0.001 382   0.011 
Low  151 125   150 102   120 79  
High  128 130   90 120   88 95  
 
            
MORF 428   0.043 467   <0.001 388   <0.001 
Low  124 97   144 98   118 83  
High  98 109   88 137   77 110  
 
            
TIP60 526   0.110 442   0.083 361   0.386 
Low  141 120   116 92   91 74  
High  128 137   114 120   104 92  
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hMOF 593   0.304 543   0.010 423   0.001 
Low  178 160   174 130   140 98  
High  128 127   112 127   81 104  
 
            
SUV39H1 382   0.489 400   <0.001     
Low  110 101   144 73      
High  88 83   73 110      
 
            
HDAC1  434   0.009 475   0.004 364   0.042 
Low  131 99   145 100   110 81  
High  92 112   107 123   83 90  
             
HDAC2  477   0.290 531   <0.001 405   0.007 
Low  105 102   138 89   107 72  
High  145 125   138 166   106 120  
 
            
SIRT1 308   <0.001 519   0.001 393   0.324 
Low  131 79   144 96   135 119  
High  35 63   134 145   78 61  
 
            
DBC1     461   0.514 382   0.489 
Low      131 110   110 88  
High      119 101   101 83  
LD, low detection; HD, high detection; all p values are calculated by X2 test. 
Bonferroni correction test was applied and reduced the (p) value of significance to 
0.003. 
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H4K16ac regulatory axis and patient outcome 
Our previous study identified H3K18 acetylation status as a significant 
independent prognostic indicator of patient survival (El Sheikh et al., 2009). A 
priority of this study was to determine whether components of the H4K16 
regulatory axis show a correlation with patient outcome in breast cancer, and 
might therefore represent useful biomarkers in assessment of the disease. We 
therefore assessed the components of the H4K16 axis for their effects on patient 
outcome. Kaplan Meier curves analysing the whole breast cancer TMA cohort 
revealed that tumours scoring high for either H4K16ac, hMOF or SUV39H1 
associated (Fig. 3.3) with increased breast cancer specific survival (BCSS) and 
longer disease free survival after surgical excision of the tumour (DFS). In 
contrast, no association with patient outcome was observed for SIRT1, DBC1 or 
H3K9me3 levels. Multivariate analysis using the Cox proportional regression 
model (Cox, 1972) showed that the prognostic effects of H4K16ac, SUV39H1 or 
hMOF were dependent on other key prognostic factors in breast cancer including 
histological grade, tumour size and tumour stage (Table 3.8). hMOF appears to be 
a good indicator of patient outcome and correlates well with H4K16 acetylation 
status (Table 3.6) . However, unlike other histone PTMs, H3K9me3 did not show 
an association with patient outcome, in contrast to its regulator SUV39H1. 
However, these results were a stimulus to undertake cluster analyses to determine 
if these markers together could give improved prognostic value. 
 
 Analysing the whole cohort of breast cancer TMA with respect to revealed 
that three out of six marks  (H4K16ac, hMOF and SUV39H1) were found 
associated with both favourable breast cancer specific survival (BCSS) and longer 
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disease free survival (DFS). In pDUWLFXODU WKH µKLJK¶ +.DF JURXS WHQGHG WR
live longer than the low-H4K16ac (p  ,Q DGGLWLRQ µKLJK¶ +.DF ZDV
also associated with longer disease-free interval after tumour excision as 
compared to the low H4K16ac group (p=0.020) (Fig. 3.3).  
 
With regard to hMOF, high detection levels of hMOF showed highly 
significant associations with favourable BCSS and DFS (p=0.001). This is 
consistent with the importance of hMOF protein level as a marker for good 
tumour outcome and patient survival. 
 
Kaplan Meier curves revealed a trend towards low level expression of 
SIRT1 in association with longer BCSS and DFS, although the differences were 
not statistically significant. A similar trend was observed for high expression of 
DBC1, the negative regulator for SIRT1 although again the association was not 
statistically significant.  
 
                Although trimethylation of H3K9 showed no association with patient 
outcome, the methyltransferase responsible for this PTM i.e. SUV39H1 appears to 
be a favourable prognostic indicator.  High level expression of SUV39H1 was 
significantly associated with both longer BCSS and DFS (p=0.010 and p=0.015 
respectively). 
 
  Multivariate analysis by using Cox proportional regression model (Cox, 
1972) showed that the prognostic effect of  H4K16ac regulatory axis members on 
survival was dependent on other key prognostic factors in breast cancer including 
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histological grade, tumour size, tumour stage and lymph node stage. However, the 
diverse association between the members of H4K16ac regulatory axis and patient 
outcome was a stimulus for further assessment of this pathway in breast tumours. 
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Figure 3.3: H4K16ac Regulatory Axis and Patient Outcome. 
 
Kaplan-Meier curves for levels of H4K16ac regulatory axis in breast bancer TMA 
with respect to Breast cancer specific survival (BCSS) and disease free survival 
(DFS) The green and blue colours represent in order high and low detection group 
for each marker, the Y axis represent survival probability, X axis represent time 
relapse in months.  
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Table 3:8: Cox proportional Hazard Model Showing Hazard Ratios for 
BCSS and DFS conferred by H4K16ac, hMOF, SUV39H1 and 
clinicopathological variables 
A 
BCSS 
Variable Hazard Ratio 95% CI p 
     
Tumour size (cm) 0.633 0.310 to 1.009 0.054 
    
Tumour stage 1.439 1.310 to 2.689 0.001 
    
Grade 2.215 1.428 to 4.070 0.001 
    
H4K16ac (high) 0.556 0.539 to 1.674 0.859 
    
hMOF (high) 0.577 0.598 to 2.147 0.701 
    
SUV39H1 0.521 0.943 to 3.230 0.076 
 
B 
DFS 
Variable Hazard Ratio 95% CI p 
     
Tumour size (cm) 0.632 0.292 to 0.974 0.041 
    
Tumour stage 1.44 1.338 to 2.795 <0.001 
    
Grade 2.213 1.415 to 4.054 0.001 
    
H4K16ac (high) 0.557 0.607 to 1.927 0.790 
    
hMOF (high) 0.576 0.947 to 3.218 0.712 
    
SUV39H1 0.520  0.074 
 
A, H4K16ac, hMOF and SUV39H1 are dependent of other prognostic factors in 
breast cancer with respect to breast cancer specific survival (BCSS); (B), and 
disease free survival (DFS); CI, confidence interval ; p, X2 p value.  
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Cluster analysis of H4K16ac regulatory axis  
To explore the relationship between individual components of the H4K16ac 
regulatory axis with regard to patient survival, an unsupervised cluster analysis 
was performed. This work was performed with the assistance of Dr. Daniel Soria, 
(School of Computer science, Nottingham University). Two different algorithms 
were used for cluster analysis: the K-means and the partitioning around medoids 
(PAM) methods. Both methods run for clusters ranging from 2 to 20 clusters. Six 
validity indices tests were followed to determine the best number of clusters. The 
used indices are Calinski and Harabasz, Hartigan, Scott and Symons, Marriot, 
TraceW, and TraceW-1B. The number of groups considered in each index was 
chosen according to the rules previously reported (Wiley, 1990).  
 
Initial attempts to perform, cluster analysis on all markers i.e. H4K16ac, 
hMOF, SIRT1, DBC1, H3K9me3 and SUV39H1 was unsuccessful due to lower 
number of samples scored for DBC1. Therefore, DBC1 was discarded from the 
analysis. Cluster analysis with the remaining 5 markers yielded 4 common cluster 
groups, obtained from 301 cores stained for each marker. However, SIRT1 
distribution among the cluster groups had no striking effect. So, SIRT1 was also 
discarded from the cluster; which retained 46 more cores. Finally, the established 
cluster groups (N=347) were based only on four marks: H4K16ac, hMOF, 
H3K9me3 and SUV39H1 distributed on three common cluster groups. The cluster 
numbers yielded in K-means algorithms was found consistent in 4 (Hartingen, 
Scott, TraceW, and TraceW-1B) out of the 6 validity indices tests (Fig. 3.4). 
Moreover, the cluster numbers obtained by PAM algorithms were validated by 
the 6 validity indices tests (Fig. 3.5). Remarkably, cluster 2 which is characterized 
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by high level of SUV39H1, hMOF and H4K16ac was found to be correlated with 
low tumour grades and better survival (Fig. 3.6), consistent with the hypothesis 
these markers may be useful indictors in breast tumours.     
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Figure 3.4: K-means Clustering Algorithm for Breast Cancer Tumour TMA in Regards to H4K16ac Regulatory Axis detection Levels 
and Validity Indices tests. 
 
A, Boxplots for H4K16ac, hMOF, H3K9me3 and SUV39H1 grouped by K-means algorithm; B, Four out of six validity indices tests indicate 3 
clusters.
Chapter Three: Evaluation of Histone PTMS in Breast Cancer TMA 
 
150  
 
Figure 3.5: PAM Clustering Algorithm for Breast Cancer Tumour TMA in Regards to H4K16ac Regulatory Axis Detection Levels and 
Validity Indices Tests. 
 
A, Boxplots for H4K16ac, hMOF, H3K9me3 and SUV39H1 grouped by K-means algorithm; B, All validity indices tests indicate 3 clusters. 
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Figure 3.6: Common Clustering of H4K16ac Regulatory Axis, Cluster 2 
Correlates with Favourable Tumour Grade and Better Survival. 
 
A, Boxplots for H4K16ac, hMOF, H3K9me3 and SUV39H1 grouped by common 
clusters, Cluster 2 is characterized by high levels of H4K16ac, hMOF and 
SUV39H1 in comparison to other two clusters; B, Cluster 2 correlates with the 
favourable grades I and II, cluster 1 and 3 correlate with ominous grade III; C, 
unadjusted Kaplan-Meier curves for H4K16ac regulatory axis common clusters is 
showing cluster 2 correlating with favourable patient outcome. 
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Summary of Findings:  The H4K16ac Regulatory Axis in Breast tumours 
In this Chapter we examined expression levels in breast tumours of proteins or 
histone PTMs that are functionally related to H4K16 acetylation. The H-score 
data for each tumour was categorised as high or low and correlated with tumour 
histological/phenotypic types, clinicopathological factors, and tumour biological 
markers. In addition, we examined the relationship of the H4K16 axis with patient 
outcome. The data indicates hMOF, the factor that contributes to the 
establishment of H4K16 acetylation, tends to correlate with this PTM, as might be 
expected from the proposed functional relationship. Moreover, tumours that score 
high for H4K16ac tend to also have high levels of H3K56ac as well as other 
µDFWLYH¶ PDUNHUV +.DF DQG DOVR +.PH ,Q JHQHUDO +.DF DQG LWV
positive regulators tend to show an association with favourable tumour grade, 
tumour type and other favourable clinicopathological markers. Most importantly, 
cluster analysis using hMOF, SUV39H1, H3K9me3 and H4K16ac defined a 
patient group that had shown significantly improved post-operative survival and 
lower recurrence of the disease. 
 
 H4K16ac has been variously implicated as a marker of active genes and 
DNA repair, but also has a role in establishment of gene repression. The 
acetylation of histone H4K16 specifically disrupts the formation of higher-order 
chromatin structures (Shogren-Knaak et al., 2006). The opened chromatin 
configuration provides accessibility for specific transcription factors and the 
general transcription machinery (Glozak and Seto, 2007). In yeast, H4K16ac is a 
prerequisite for the methylation of H3K79 by the DOT methyltransferase (Altaf et 
al., 2007). Together with H3K56ac, these PTMs repel the recruitment of the Sir3 
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repressor and thus halt the spread of repressive heterochromatin into active genes 
(Oppikofer et al., 2011). However, H4K16ac is also important to establish 
repressive chromatin. In yeast, recent evidence indicates that acetylated H4K16 
repels the recruitment of Sir3 to chromatin, but, stimulates recruitment of Sir2-4 
dimers. Subsequent deacetylation of H4K16 by Sir2-4 can then promote 
recruitment of the Sir2-3-4 holocomplex (Oppikofer et al., 2011). The 
understanding of this pathway in human cells is less advanced, therefore it is 
possible that other Sirtuin proteins may be involved, and their expression in breast 
tumours should be investigated. 
 
 Acetylation of H4K16 is a critical step during cell replication; particularly, 
it has been observed during S-phase just prior to H4K20 di-methylation in early 
replicating chromatin domains. This epigenetic label then persists on the 
chromatin throughout mitosis and become deacetylated during early G1-phase 
(Fidlerova et al., 2009). Knock down of hMOF activity, the H4K16ac regulator, in 
a HeLa cell line cells, resulted in accumulation of cells in the G2 and M phases of 
the cell cycle (Taipale et al., 2005). Both H4K16ac and H3K56ac have been 
implicated in repair of DNA damage (Raisner and Madhani, 2008) and have been 
seen to be enriched in ƣH2A.X foci along with TIP60 (Kusch et al., 2004) 
(Rossetto et al., 2010), a MYST domain acetyltransferase that can also acetylate 
H4K16 (Miyamoto et al., 2008).  
  
 It is therefore intriguing that H4K16 acetylation appears reduced in most 
cancer cell lines and in tumour tissues in TMA studies, particular in those 
tumours with poorest prognosis. This may reflect a global increase in repressive 
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chromatin needed to silence tumour suppressor genes and apoptotic gene 
pathways. It might also indicate a failure in the DNA damage repair and genome 
maintenance processes, or indicate more rapid turnover of this PTM in 
proliferating tumour cells, due to enhanced activity of NAD-dependent HDACs. 
As H4K16 acetylation is globally attenuated in G2/M (Vaquero et al., 2006), low 
level may indicate a high proportion of tumours cells undergoing mitosis. 
µ&OLSSDVHV¶KDYHEHHQLGHQWLILHGLQ\HDVWWKDWFDQUHPRYHKLVWRQH1-terminal tails 
(Best and Carey, 2010, Bannister and Kouzarides, 2011). Deregulation of such 
enzymes in tumours might lead to global loss of histone N-terminal tails (and 
their associated PTMs) and failure of genome regulation as observed in many 
tumour cells. Resolving these mechanisms will be the goals of future studies.  
 
 hMOF is the major enzyme responsible for H4K16ac establishment in 
normal cells (Kapoor-Vazirani et al., 2008, Gupta et al., 2008). Ablation of hMOF 
results in defective cell cycle progression, reduced transcription of certain genes 
and impaired DNA damage response after irradiation (Rea et al., 2007). 
Optimisation of hMOF antibody concentration to be used in IHC staining revealed 
that the working concentration was 1/8. This is relatively high concentration 
suggesting low antibody sensitivity. Our results demonstrate that low level hMOF 
expression is associated with poorly differentiated high grade tumours.  
 
 SIRT1 has a wide range of biological functions, as it participates in 
growth regulation, stress response, tumourgenesis, endocrine signalling and 
control of cellular lifespan (Kim and Um, 2008). It functions by promoting gene 
silencing (Nosho et al., 2009) and thus inhibition of SIRT1 can reactivate silenced 
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genes (Pruitt et al., 2006), suggesting it as an attractive therapeutic target (Nosho 
et al., 2009). SIRT1 coordinates facultative heterochromatin formation (Vaquero 
et al., 2004) through its ability to deacetylate H4K16 and SUV39H1 during 
heterochromatin formation (Hajji et al., 2009, Vaquero et al., 2006, Vaquero et 
al., 2007). While SIRT1 has been reported to be cytoplasmic during most of the 
cell cycle, it shifts to the nucleus during the G2/M transition phase, corresponding 
with global attenuation of H4K16 acetylation in mammalian fibroblasts (Vaquero 
et al., 2006). Mouse embryonic fibroblasts (MEFs) deficient in SIRT1 exhibit 
increased levels and mislocalised H4K16ac during S phase (Vaquero et al., 2006). 
We did not detect a strong association of nuclear SIRT1 expression in tumours 
with patient outcome, tumour grade, tumour phenotype or other biomarkers. 
However, this highlights the importance of screening for proteins that regulate 
SIRT1 activity, such as the negative regulator Deleted in Breast Cancer (DBC1) 
(Kim et al., 2008; Zhao et al., 2008b; Anantharaman and Aravind, 2008).      
 
DBC1 and SIRT1 expression in breast tumours showed a positive 
correlation consistent with a recent study that showed elevated level of both 
SIRT1 and DBC1 in breast cancer (Sung et al., 2010). Previous studies have 
reported associations of DBC1 and SIRT1 expression in breast tumours, although 
using far fewer cases than in this study, i.e. 28 tumours (Sung et al., 2010) or 110 
tumours (Lee et al., 2011). Sung et al. (2010) reported higher SIRT1 and DBC1 
protein levels in breast tumour tissue compared to their matched normal tissue; 
Lee et al., (2011) reported a positive correlation between SIRT1 and DBC1 in 
breast tumour tissue. In addition, our results indicated that most tumours express 
SIRT1 possibly reflecting its vital role in tissue growth and development, and the 
Chapter Three: Evaluation of Histone PTMS in Breast Cancer TMA 
 
156   
hazardous effects of SIRT1 over expression in ovarian and prostate tumours  
(Jang et al., 2009, Jung-Hynes et al., 2009). SIRT1 levels were found highly 
expressed in malignant ovarian epithelial tumours and prostate cancer. In 
addition, it was associated with poor prognosis in large B cell lymphoma and 
gastric carcinoma (Jang et al., 2008, Cha et al., 2009). When SIRT1 and DBC1 
levels were assessed in fresh frozen breast cancer tissue; the study revealed that 
their over expression in breast cancer tumour tissue was correlated with both 
favourable and unfavourable clinicopathological factors, suggesting their 
pleiotropic functions as a potential tumour promoter and tumour suppressor in 
tumourgenesis (Sung et al., 2010). Although, the study was done on smaller sized 
population (28 cases); it could explain the conflict in our results that showed high 
grade tumours tending to express low SIRT1 levels; however, smaller tumours 
(<5cm) tend to express low SIRT1 level. Thus, the role of SIRT1 in breast 
tumours remains unclear.  
 
 The DBC1 protein (Hamaguchi et al., 2002) is reported to be a key 
negative regulator of SIRT1 (Zhao et al., 2008, Kim et al., 2008). DBC1- 
mediated repression of SIRT1 leads to increased p53 acetylation and upregulation 
of p53-mediated function (Zhao et al., 2008) and is thus considered to function  as 
a tumour suppressor (Kim et al., 2008, Zhao et al., 2008). When SIRT1 and 
DBC1 expression levels were explored in gastric carcinoma by TMA in 177 
gastric tumours, DBC1 positive tumours correlated with SIRT1 positive tumours; 
DBC1 was found to be significantly correlated with advanced tumour stage, 
shorter overall survival and disease-free survival  (Cha et al., 2009). In addition, 
Lee et al. (2011) reported that high DBC1 and SIRT1 levels in breast cancer 
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tissue were associated with advanced tumour grade, shorter survival and distant 
metastatic relapse in breast cancer tissue, suggesting them as significant 
prognostic indicators for breast carcinoma patients. 
 
 A previous study by the Breast Cancer Pathology Research Group at 
Nottingham University using the same breast tumour archive analysed the 
relationship between tumour type, epithelial cell lineage, hormone and growth 
factor receptors Abd El-Rehim et al. (2005). This study identified six classes of 
breast tumour using cluster analyses. Soria et al. (2010) validated these data with 
different clustering algorithms and identified novel breast cancer sub-groups. 
Elsheikh et al. (2009) used cluster analysis to show that breast tumours can be 
separated into biologically and prognostically distinct groups depending on their 
histone modification pattern. However, the histone PTMs examined in that study 
were chosen at random as opposed to having a biological or functional basis. In 
this study cluster analysis of components of the H4K16ac regulatory axis showed 
that breast cancer tumours can be classified into biologically and prognostically 
distinct groups, where high levels of H4K16ac, hMOF and SUV39H1 group were 
correlated with favourable tumour grade and breast cancer specific survival. Our 
findings suggest that SUV39H1, in particular has prognostic value, although one 
of its targets 3meH3K9 did not show an association with survival. Thus, 
methylation of H3 may be subject to redundancy in that other enzymes may also 
target this residue. Alternatively, SUV39H1 may have other functions outside of 
H3 methylation which are important for tumour suppression. 
 
Chapter Three: Evaluation of Histone PTMS in Breast Cancer TMA 
 
158   
3.2 : Histone Variants in Breast Cancer 
Histone variants perform specialised functions in the cell, and are increasingly 
topical as important regulators of nuclear processes. In particular variants of the 
H2A histone have recently been identified as performing specific functions within 
chromatin as outlined in Chapter 1 (1.2.9). However relatively few studies have 
assessed whether histone variants such as H2A.Z and macroH2A expression 
levels are altered in tumours. For this reason we next turned our attention to study 
the expression of these histones in breast tumours. This study was performed in 
collaboration with Prof. Stefan Dimitrov, University of Grenoble, who provided 
specific antibodies for the study. 
.   
 Macro H2A is involved in a number of cellular functions including  
nucleosomal remodelling (Angelov et al., 2003), inactive X chromosome 
(Costanzi and Pehrson, 1998), transcription repression (Angelov et al., 2003, 
Doyen et al., 2006, Ouararhni et al., 2006), and heterochromatin formation in 
association with heterochromatin markers (histone H3K27me2 and H327me3) 
(Araya et al., 2010). In addition, it has a potential role in tumour progression. 
Knocking down of mH2A in melanoma cells resulted in significantly increased 
proliferation and migration in vitro and growth and metastasis in vivo (Kapoor et 
al., 2010).  
 
 H2A.Z has been described as a marker for active genes, although like 
most regulatory proteins it can have both positive and negative roles in gene 
regulation (Marques et al., 2010).  In yeast, H2A.Z replaces H2A at active genes 
and is inserted into chromatin by Swr1 and Swr1-like complexes, where it induces 
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biophysical changes in the nucleosome (Placek et al., 2005). In addition to roles 
in transcription initiation and elongation, H2A.Z is required for heterochromatin 
integrity (Rangasamy et al., 2003), guarding against heterochromatin propagation 
(Shia et al., 2006). H2A.Z has also a role in DNA damage repair (Ahmed et al., 
2007, Gevry et al., 2007) and for recruitment of transcription factors (Fu et al., 
2008, Draker and Cheung, 2009, Lemieux et al., 2008). Acetylation of H2A.Z 
were linked to genome-wide gene activity in yeast (Millar et al., 2006), chicken 
(Bruce et al., 2005) and mammalian cells (Chen et al., 2006). Genome wide 
studies have found that acetylated H2A.Z is enriched at the boundaries of active 
and poised genes (Valdez-Mora 2011). 
 
Deacetylation of H2A.Z in mammalian cells is catalysed by SIRT1, which 
regulates H2A.Z turnover via ubiquitin/proteasome-dependent pathway (Chen et 
al., 2006, Seligson et al., 2009) (Fig. 3.7). Conversely, H2A.Z was found to 
prevent SIR-dependent gene repression in yeast (Venkatasubrahmanyam et al., 
2007), suggesting a feedback relationship between H2A.Z acetylation and SIRT1. 
H2A.Z was reported to inversely localize with H3K9me3 and its modulators 
SUV39h1 at heterochromatin loci (Bulynko et al., 2006). In summary, 
H2A.Z plays a pivotal role in gene regulation and its acetylation has functional 
links with the H4K16ac pathway.  
.  
 In this next section, I assess the levels of mH2A, H2A.Z and the 
acetylated form of H2A.Z (H2A.Zac) in breast tumours and explore their 
association with clinicopathological parameters, other biomarkers and patient 
outcome.    
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Figure 3.7: Histone PTMs, HATs and HDACs Relationship 
 
H2A.Z inversely localizes with H3K9me3 and its modulators SUV39h1 at 
heterochromatin loci. H2A.Z is subjected to acetylation/deacetylation by Histone 
acetyltransferases (HATs). Deacetylation of H2A.Z in mammalian cells is 
catalysed by SIRT1, which regulates H2A.Z turnover via ubiquitin/proteasome-
dependent pathway. At the same time, H2A.Z prevents SIRT1-dependent gene 
repression.    
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3.2.1 Detection of Histone Variants in Breast Tumour TMAs 
The TMA set used in the previous section was also IHC stained for the presence 
of histone variants mH2A, H2A.Z and the pan-acetyl form of H2A.Z. The 
antibodies used were provided by Prof. Stefan Dimitrov (U. Grenoble). Working 
dilutions and the method of antigen retrieval are described in Appendix 1. The 
staining patterns observed were close to homogeneous in most of the examined 
cores; with variation in staining intensity between different cases (Fig. 3.8, 3.9 
and 3.10A and B). Evaluation of the stained cores showed immunoreactivity in all 
tumour cells for both mH2A and H2A.Z (Fig. 3.8 and 3.9). Positive reactivity was 
also noted in the nuclei of myoepithelial, stromal and inflammatory cells (Fig. 3.8 
and 3.9). However, cores stained for H2A.Zac showed an attenuated 
immunoreactivity in myoepithelial, stromal and inflammatory cell nuclei relative 
to tumour cells (arrows in Fig.3.10). H-scoring for all cores stained revealed 760, 
774 and 600 valid cores for mH2A, H2A.Z and H2A.Zac respectively. 
Histograms illustrating the frequency for H-score for each mark plotted against 
the number of cases are shown in Figure 3.8C, 3.9C and 3.10C. Fifty cores were 
totally negative for mH2A. However, only ten cores were negative for both 
H2A.Z and H2A.Zac.  
 
 As in the previous section, H-score data was used to dichotomize the 
tumour cores into two groups (low and high) according to the median values (Fig. 
3.8C). Any H-score between zero and the median value was considered to be in 
the low detection group, any score above median to 300 was considered among 
the high detection group. 
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Figure 3.8: Detection of mH2A in Breast Cancer TMAs as determined by IHC  
 
 
Breast tumour tissue cores presenting with low level (A) or high level (B) of mH2A; distribution of H-scores of breast cancer cores stained for 
mH2A (C). Non- tumourous tissue is low for mH2A (arrows). Original magnification is X20. 
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Figure 3.9: Detection of H2A.Z in Breast Cancer TMAs as determined by IHC 
 
Breast tumour tissue cores presenting with low level (A) or high level (B) of H2A.Z; distribution of H-scores of breast cancer cores stained for 
H2A.Z (C). Original magnification is X20. 
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Figure 3.10: Detection of H2A.Zac in Breast Cancer TMAs as determined by IHC 
 
 
Breast tumour tissue cores presenting with low level (A) or high level (B) of H2A.Zac; distribution of H-scores of breast cancer cores stained for 
H2A.Zac (C). Myoepethelial cells are low in H2A.Zac staining (Arrows). Original magnification is X20. 
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Histone Variants in Relationship to Breast Cancer Histologic Tumour Types  
The data indicated associations of H2A variants with tumour histopathological 
types (Table 3.9). Low detection levels of mH2A and H2A.Z were seen among 
invasive ductal/ NOS and medullary tumours, where 233 out of 378 (62%) and 
233 out of 383 (61%) invasive duct/ NOS tumours were low for mH2A and 
H2A.Z respectively. In medullary tumours, 17 out of 22 (77%) and 18 out of 21 
(86%) scored low for mH2A and H2A.Z respectively. In addition, low H2A.Z 
levels were encountered among the well differentiated tubular and mucinous 
tumours, for example 16 out of 32 (69%) tubular type tumours and 6 out of 7 
(86%) of mucinous tumour tumours were low in H2A.Z. In contrast, classical 
lobular tumours were more likely to exhibit high expression levels of both mH2A 
and H2A.Z i.e. 43 out of 73 (59%) of lobular tumours scored high for mH2A; 47 
RXWRIVWDLQHGµKLJK¶IRU+$=,QWHUHVWLQJO\+$=DFGHWHFWLRQOHYHOV
did not show considerable variation among most tumour histopathological types, 
with the exception of mucinous and cribriform tumours, which tended to express 
low level of H2A.Zac. Indeed, 5 out of 6 cases of mucinous tumour and 3 out of 4 
cases of cribriform tumour low in H2A.Zac. 
 
Histone Variants in Relationship to Breast Cancer Phenotypic Groups  
Significant differences in both mH2A and H2A.Z levels were observed (p<0.001) 
ZLWKUHJDUGWR1LHOVHQ¶VWXPRXUSKHQRW\SHV7KHSRRUSURJQRVWLFPDUNHUV+(5
and basal tumour types were characterized by low levels of both mH2A and 
H2A.Z (Table 3.10). These results suggest an association between low detection 
levels of both marks with specific classes of breast cancer characterized by poor 
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prognosis. In regards to H2A.Zac, no statistically significant differences were 
observed among Nielson classes. 
 
 Corresponding to breast cancer tumour phenotypes proposed by Abd El-
Rehim and colleagues (Abd El-Rehim et al., 2005), considerable differences were 
noted among basal tumours stained for mH2A H2A.Z and H2A.Zac. Both basal 
groups tended to express low levels for mH2A, H2A.Z and H2A.Zac irrespective 
of whether p53 was normal or altered (Table 3.10). In addition, 14 out of 24 
(58%) of HER2 tumours were found tending to show low levels of H2A.Zac. 
These results show further association between Low detection levels of histone 
variants with poor prognostic breast cancer classes.  
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Table 3:9: Histone Variants detection levels in Different Tumour Histo-
Pathological Types. 
 
mH2A  H2A.Z  H2A.Zac 
LD HD  LD HD  LD HD 
Invasive Ductal/NOS Type 233 145  232 151  141 161 
Invasive papillary 2 2  2 1  3 0 
NST& Lobular 15 10  10 16  12 8 
NST& Special 14 5  8 12  8 6 
Classical lobular 30 43  33 47  23 30 
Tubular 8 13  16 7  11 7 
Tubular mixed 84 80  76 85  68 63 
Medullary 17 5  18 3  8 6 
Mucinous 2 5  6 1  5 1 
Cribriform 5 0  4 2  3 1 
Miscellaneous 2 1  2 2  1 3 
Total 721  734  569 
LD, low detection; HD, high detection; NOS, no other specified. 
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Table 3:10: Histone Variants detection levels and Phenotype groups of Breast Cancer as defined by Nielsen and Colleagues 
(Nielsen et al., 2004). 
Nielsen classes of 
breast cancer (Nielsen 
et al., 2004)  
mH2A H2A.Z H2A.Zac 
Total LD HD p Total LD HD p Total LD HD p 
Neilson Groups    <0.001 596   <0.001 425   0.717 
HER2  45 21   36 20   24 33  
Luminal  209 199   218 230   150 166  
Basal-like  54 18   71 21   30 22  
 
 LD, low detection; HD, high detection; all p values are calculated by X2 test. Bonferroni correction test was applied and 
reduced the (p) value of significance to 0.003. 
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Table 3:11: Histone Variants detection levels and Phenotype groups of 
Breast Cancer as defined by Abe El-Rehim and Colleagues (Abd El-Rehim et 
al., 2005). 
Abd El-Rehim classes of 
breast cancer 
mH2A  H2A.Z  H2A.Zac 
LD HD  LD HD  LD HD 
Luminal A 20 17  15 22  12 22 
Luminal B 16 14  13 20  15 11 
Luminal N 50 40  47 42  33 52 
HER2 15 12  16 14  14 10 
Basal-p53 altered 14 6  12 3  10 5 
Basal-p53 normal 24 2  16 6  15 8 
Not classified 74 48  43 45  56 46 
Total 352  314  309 
LD, low detection; HD, high detection 
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Expression of H2A Variants Correlates with Breast Cancer 
Clinicopathological Factors and Biological markers  
Analysis of histone variants expression in relationship to clinicopathological 
variables revealed a number of significant differences and correlations (Table 
3.12). In particular, high mH2A levels were negatively correlated with tumour 
grade (p<0.001);  where, 220 out of 323 (68%) of grade III tumours tended to 
show low level of mH2A, and 86 out of 158 (54%) of grade I showed high levels 
of mH2A. Consistent with that, mH2A levels were also found to negatively 
correlate with NPI (p=0.009), in that moderate and poor categories scored low for 
mH2A. However, no significant pattern of mH2A expression was detected in 
relation to patient age, tumour size or nodal metastasis (Table 3.12).  
 
 High levels of H2A.Z were also negatively correlated with tumour grade 
(p<0.001); where 211 out of 331 (64%) of grade III tumours tended to show low 
levels of mH2A. However, no significant differences in H2A.Z level were 
detected among different patient age, NPI categories, tumour stage or tumour size.  
 
 Concerning acetylated H2A.Z levels, advanced tumour stage was found to 
positively correlate with H2A.Zac (p=0.002), as, 64% of stage 3 tumours were 
high in H2A.Zac. High H2A.Zac levels were also significantly correlated with 
poor NPI (p=0.009) and nodal metastasis status (p<0.001). However, no 
correlation was observed for H2A.Zac with patient age, tumour grade or tumour 
size.  
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Histone Variants Correlate with Breast Cancer Biological Markers 
Our analysis also indicated other statistically significant associations for H2A 
variants in relationship to other biological markers in breast tumours (Table 3.12). 
Remarkably, high levels of both mH2A and H2A.Z, (but not H2A.Zac) were 
positively correlated with steroid receptors. Interestingly, H2A.Z has been 
reported to be an estrogen regulated gene (Hua et al., 2008) and to be important 
for estrogen receptor alpha signalling in breast cancer cells (Svotelis et al., 
2009b). 
 
 Tumours with high scores for mH2A and H2A.Z were found more likely 
to express luminal cytokeratins, whereas, tumours negative for CK7/8 and CK18 
showed low mH2A levels (p=0.010 and 0.001 respectively); and low H2A.Z 
levels (p<0.001, p<0.001 and p=0.001 respectively). On the other hand, both 
variants were inversely correlated with basal cytokeratin, i.e. CK5/6 positive 
tumours, whereas H2A.Z levels showed a tendency to be low in p53 altered 
tumours. These results again suggest an association between the low levels of 
H2A variants levels with poor prognostic tumour types such as basal tumour. 
Conversely, mH2A showed a positive association with FOXA1 (p<0.001), a 
breast tumour growth repressor (Habashy et al., 2008b). 
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Table 3:12: Relation between Histone Variants Detection levels and Clinico-
pathological Parameters and Biological Factors. 
Parameter 
mH2A H2A.Z H2A.Zac1 
Total LD HD p Total LD HD p Total LD HD p 
Age 722   0.028 735   0.034 570   0.029 
<50  155 94   216 150 
 
 112 90  
>50  258 215   192 177 
 
 172 196  
 
            
Grade 722   <0.001 735   <0.001 570   0.377 
I  72 86   83 76   73 61  
II  121 120   114 131   91 90  
III  220 103   211 120   120 135  
             
Stage 719   0.311 733   0.056 567   0.002 
1  276 205   286 203   206 169  
2  90 78   84 91   55 78  
3  45 25   38 31   21 38  
             
NPI  719   0.009 733   0.141 567   0.007 
Good  127 128   132 128   112 90  
Moderate  220 145   220 156   144 145  
Poor  64 35   56 41   26 50  
             
Size  722   0.450 735   0.116 570   0.208 
< 5cm  261 193   251 216   188 179  
> 5cm  152 116   157 111   96 107  
             
LN Metastasis 
  
733   0.018 719   0.465 567   <0.001 
Negative  286 203   276 205   206 169  
Positive  122 122   135 103   76 116  
             
ER receptor 669   <0.001 681   <0.001 532   0.403 
Low  149 61   153 68   89 88  
High  233 226   225 235   173 182  
             
PR receptor  663   0.003 673   <0.001 528   0.527 
Negative  196 111   201 116   120 123  
Positive  188 168   175 181   141 144  
 
            
AR receptor  621   <0.001 631   <0.001 494   0.108 
Negative  189 69   170 94   109 103  
Positive  181 182   171 196   128 154  
             
CK7/8  695   0.010 707   <0.001 557   0.142 
Negative  159 93   169 87   104 92  
Positive  238 205   225 226   173 188  
             
CK18  595   0.001 604   <0.001 475   0.211 
Negative  119 55   120 65   71 67  
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positive  231 190   208 211   158 179  
             
CK19 691   0.004 703   0.001 552   0.500 
Negative  92 43   94 44   52 51  
positive  306 250   300 265   224 225  
             
CK5/6 701   0.016 713   <0.001 559   0.008 
Negative  295 241   278 265   196 224  
Positive  107 58   118 52   82 57  
             
CK14  679   0.509 690   0.013 548   0.045 
Negative  312 221   294 248   204 223  
positive  85 61   96 52   69 52  
             
p53 (Altered) 671   0.043 678   0.001 531   0.271 
Negative  269 219   256 239   189 197  
positive  115 68   119 64   66 79  
             
c-MYC 337   0.005 342   0.265 301   0.111 
Low  156 87   145 60   108 116  
High  45 49   102 35   44 33  
             
nBRCA1   507   0.005 514   0.180 395   0.042 
Low  144 80   120 101   73 109  
High  149 134   146 147   105 108  
             
FOXA1   576   <0.001 592   0.398 456   0.015 
Low  199 112   176 137   115 147  
High  126 139   153 126   106 88  
             
FHIT 437   0.010 443   0.018 339   0.338 
Low  146 99   140 112   81 110  
High  92 100   86 105   67 81  
             
EGFR 400   0.019 491   0.143 383   0.015 
Low  196 167   215 191   152 164  
High  27 10   51 34   22 45  
LD, low detection; HD, high detection; NPI, Nottingham Prognostic Index; LN, 
lymph node; ER, estrogen receptor, PR, progesterone receptor; AR, androgen 
receptor; all p values are calculated by X2 test. Bonferroni correction test was 
applied and reduced the (p) value of significance to 0.003. 
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Correlation of H2A Variants with Histone PTMs and their Modulators 
H2A variant scores were found to correlate with a range of other histone PTMs 
and their modulators (Table 3.13). MacroH2a was positively associated with 
histone acetylation and methylation PTMs, as well as the acetyltransferases 
MORF, hMOF and CBP. In addition, mH2A was also positively correlated with 
SUV39H1, but showed no apparent association with deacetylases such as 
HDAC1, HDAC2 or SIRT1.  
 
 With regard to H2A.Z, high detection levels were correlated with high 
levels of mH2A and several histone PTMs marks (Table 3.13), all of which tend 
to be associated with favourable outcome (El Sheikh et al., 2009). Interestingly, 
the positive correlations with all active gene marks H4K16ac, H4K20me3 are 
consistent with the role of H2A.Z in gene activation; e.g. in yeast where H2A.Z 
and H4K16ac were present in nucleosomes at the promoters of active genes 
(Guillemette and Gaudreau, 2006, Shia et al., 2006). Furthermore, high H2A.Z 
levels were also correlated with high expression levels of the DNA damage mark 
H3K56ac (Vempati et al., 2010) (p<0.001) as well as hMOF and CBP (p<0.001 
for both). 
 
 With regard to the acetylated form of H2A.Z (Table 3.13), few significant 
correlations were observed (after application of Bonferroni correction), with the 
exception of a positive correlation with TIP60 expression. Interestingly, H2A.Z is 
implicated in the repair of DNA double strand break (DSB) (Kawashima et al., 
2007, Kalocsay et al., 2009), and TIP60 is required for H2A.Z incorporation into 
nucleosomes (Svotelis et al., 2009a). 
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Table 3:13: Correlation between Histone Variants Levels and Histone PTMs 
and their Modulators. 
Histone and 
Histone 
Modulators 
mH2A H2A.Z H2A.Zac 
Total LD HD p Total LD HD p Total LD HD p 
mH2A     728   0.001 541   0.435 
Low      248 167   159 171  
High      148 165   104 107  
 
 
 
   
 
   
 
  
H2A.Z         541   0.014 
Low          159 142  
High          103 137  
 
 
 
   
 
   
 
  
H3K9ac 500   <0.001 511   0.113 395   0.056 
Low  184 80   152 113   90 120  
High  105 131   127 119   95 90  
  
 
       
 
  
H3K18ac 507   <0.001 515   <0.001 400   0.511 
Low  183 74   162 100   93 114  
High  118 132   117 136   86 107  
 
 
 
       
 
  
H4K12ac 486   <0.001 492   <0.001 378   0.254 
Low  193 89   173 103   92 122  
High  84 120   92 124   77 87  
             
H4K16ac 
(Millipore) 
718   <0.001 747   0.417 408   0.021 
Low  258 109   211 169   127 168  
High  151 200   200 167   62 51  
             
H3K4me2 488   <0.001 498   0.006 385   0.146 
Low  185 79   158 109   91 124  
High  103 121   110 121   82 88  
             
H4K20me3 465   <0.001 474   0.001 363   0.545 
Low  67 12   55 24   26 34  
High  205 181   198 197   132 171  
             
H3K9me3 536   <0.001 541   0.495 432   0.004 
Low  194 94   158 127   96 134  
High  129 119   143 113   111 91  
             
H4R3me2 556   <0.001 563   0.087 439   0.213 
Low  215 113   189 139   122 149  
High  108 120   121 114   83 85  
 
            
H3k56ac 584   <0.001 586   <0.001 478   0.054 
Low  222 80   189 114   133 122  
High  115 167   135 148   99 124  
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MORF 502   <0.001 504   0.342 395   0.032 
Low  175 79   140 117   80 120  
High  125 123   140 107   97 98  
 
            
TIP60 554   0.485 193   0.057 425    <0.001 
Low  158 116   61 30   124 96  
High  160 120   56 46   76 129  
 
            
hMOF 728   <0.001 755   <0.001 534   0.104 
Low  270 138   279 145   159 158  
High  141 179   139 192   96 121  
 
            
CBP 720   <0.001 708   <0.001 516   0.318 
Low  251 149   249 143   145 142  
High  157 163   143 173   110 119  
 
            
SUV39H1 421   <0.001 421   0.190 363   0.009 
Low  158 64   121 99   78 118  
High  98 101   101 100   88 79  
 
            
HDAC1  515   0.039 523   0.447 404   0.326 
Low  156 107   152 118   106 109  
High  129 123   140 113   88 101  
             
HDAC2  558   0.104 567   0.130 447   0.079 
Low  150 92   130 116   82 113  
High  178 138   186 135   124 128  
 
            
SIRT1 562   0.108 566   0.020 449   0.089 
Low  209 131   179 168   123 152  
High  124 98   133 86   90 84  
 
            
DBC1 327   0.087 594   0.016 274   0.153 
Low  111 66   185 122   72 72  
High  82 68   147 140   56 74  
LD, low detection; HD, high detection; all p values are calculated by X2 test. 
Bonferroni correction test was applied and reduced the (p) value of significance to 
0.003. 
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H2A variants and patient outcome  
Kaplan Meier curves correlating H2A variants to patient outcome were generated 
as described earlier and are illustrated in Figure 3.11. Patients presenting with 
high scores for H2A.Z showed improved survival breast cancer specific survival 
(BCSS) and longer disease free survival (DFS) (p=0.011 for both); which is 
consistent with the association of higher H2A.Z expression with favourable 
prognostic indicators. However acetylated H2AZ showed a reverse relationship, 
with a marginally poorer survival for high scoring patients. Although the results 
were not statistically significant (p=0.171 and p=0.165 for BCSS and DFS 
respectively), they are consistent with the observation that high H2A.Zac 
correlates with advanced tumour stage, poor NPI and tumour tendency for nodal 
metastasis. Patients who showed high detection levels of mH2A at time of 
diagnosis tended to have marginally better breast cancer specific survival (BCSS) 
and longer disease free survival (DFS) in comparison to low score mH2A-group. 
However, the differences between the two groups were not statistically 
significant.  
 
 Multivariate analysis by using Cox proportional regression model (Cox, 
1972) showed that only the prognostic effect of H2A.Z was independent of other 
key prognostic factors in breast cancer including histological grade, tumour size 
and tumour stage (Table 3.10). Taken together, we conclude that mH2A and 
H2A.Z show a trend to being markers of more favourable outcome in breast 
cancer, whereas high levels of acetylated H2A.Z may be indicative of worse 
prognosis.  
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Figure 3.11: High H2A.Zac level correlates with better patient survival.  
 
Kaplan-Meier curves for levels of histone variants in Breast Cancer TMA with respect to breast cancer specific survival (BCSS) and disease free 
survival (DFS) The green and blue colours represent in order high and low detection groups for each marker, the Y axis represent survival 
probability, X axis represent time relapse in months. 
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Table 3:14: Cox proportional Hazard Model Showing Hazard Ratios for 
BCSS and DFS conferred by H2A.Z and clinicopathological variables 
A 
BCSS 
Variable Hazard Ratio 95% CI p 
     
Tumour size (cm) 0.535 0.352 to 0.813 0.003 
    
Tumour stage 2.226 1.733 to 0.2.860 <0.001 
    
Grade 2.368 1.665 to 3.368 <0.001 
    
H2A.Z (high) 0.625 0.411 to 0.951 0.028 
 
B 
DFS 
Variable Hazard Ratio 95% CI p 
    
Tumour size (cm) 1.902 1.245 to 2.906 0.003 
    
Tumour stage 2.238 1.738 to 2.883 <0.001 
    
Grade 2.338 1.639 to 3.333 <0.001 
    
H2A.Z (high) 0.609 0.399 to 0.928 0.021 
 
A, H2A.Z prognostic effect is independent of other prognostic factors in breast 
cancer with respect to breast cancer specific survival (BCSS); (B), and disease 
free survival (DFS); CI, confidence interval ; p, X2 p value. 
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Summary of Findings:  The Histone H2A Variants in Breast tumours 
As described in the introduction, H2A variants appear to participate in many 
aspects of cellular function. mH2A was previously reported in association with 
malignant tumours progression and metastasis (Kapoor et al., 2010) whereas 
H2A.Z over expression was reported to  promote cellular proliferation in ER 
negative breast cancer cells (Svotelis et al., 2010) and independently increased the 
prognostic power of biomarkers currently in clinical use (Hua et al., 2008). Hence 
we tried to explore their immunoreactivity in a large set of breast cancer TMA 
(880) to point out their relation with conventional clinical and histopathological 
breast cancer variables and tumour outcome. Optimisation of Histone H2A 
variant antibodies concentration to be used in IHC staining revealed that the 
working concentration for H2A.Zac was 1/5. This is relatively high concentration 
suggesting low antibody sensitivity. However, the antibodies were highly specific 
according to tests supplied by our collaborator S Dimitrov, and western blots 
comparing detection of H2AZ but not core histones (Appendix 2B). 
 
 7KH GDWD LQGLFDWH WKDW µKLJK¶ OHYHOV RI P+$ VKRZ DQ DVVRFLDWLRQ ZLWK
other favourable prognostic markers good tumour outcome biomarker, whereas 
low mH2A levels were correlated with the ominous high grade tumours and poor 
NPI categories. This appears to be consistent with reports that mH2A can 
suppress melanoma tumour cell growth, whereas knock down of mH2A results in 
enhanced tumour growth and metastasis (Kapoor et al., 2010). However we did 
not detect a significant association of mH2A with patient outcome, thus it is 
unlikely to be a very useful marker in this disease.  
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 The data also revealed negative association of H2A.Z in relation to tumour 
grade which is consistent with the reported role of H2A.Z in relation to cellular 
differentiation. However, the positive correlation between H2A.Z and nodal 
metastasis was not consistent with H2A.Z being a biomarker for good tumour 
outcome. With regard to H2A.Zac, high levels were correlated with advanced 
tumour stage, poor NPI, older age group and nodal metastasis, proposing it as a 
biomarker of poor tumour outcome. Thus, global H2A.Z acetylation may increase 
during tumour progression. 
 
 The expression levels of H2A variants revealed an association with 
specific tumour classes, as determined by expression of biomarkers such as 
luminal and basal cytokeratins and HER2.  High levels of both mH2A and H2A.Z 
were correlated with luminal type tumours and luminal type specific cytokeratin. 
Conversely, they showed a negative correlation with basal type-specific 
cytokeratins. 
  
 Interestingly, high levels of mH2A and H2A.Z correlated with high levels 
of ER, PR and AR receptors levels, which may be consistent with H2A.Z 
HVVHQWLDO UROH LQ WUDQVFULSWLRQ RI (5Į-dependent genes (Svotelis et al., 2009b, 
Gevry et al., 2009) and the induction of H2A.Z expression by ER  (Hua et al., 
2008). H2A.Z and mH2A also correlated with high levels of several tumour 
suppressor genes, transcription factors and cell cycle regulators. For example, 
high mH2A levels were correlated with the tumour suppressor gene BRCA1 (Lee 
et al., 2010) the growth suppressor FOXA1 (Habashy et al., 2008b) and FHIT, a 
tumour suppressor protein (Syeed et al., 2010). Conversely, p53-altered tumours 
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were associated with low levels of H2A.Z (p=0.001). However, it is not clear 
whether these apparent associations have any functional basis. 
 
 Interestingly, whereas fewer significant associations were reported for 
H2A.Zac, this marker tended to display opposite associations to mH2A or H2A.Z. 
For example, high levels of H2A.Zac were negatively correlated with the tumour 
suppressor nBRCA1 and FOXA1 expression. In addition, high levels of H2A.Zac 
correlated with EGFR expression, a poor prognostic biomarker in breast cancer 
(Abd El-Rehim et al., 2004b).  
 
 With regard to core histone PTMs, mH2A and H2A.Z showed a 
significant positive association, with the exception of H4K16ac. This may 
possibly reflect functional associations of H2A variants and core histone PTMs. 
For example, mH2A has been reported to function in transcription repression 
(Ouararhni et al., 2006), and to be functionally associated with H3K9me3 
(Tachibana et al., 2005) and its modulator SUV39H1 (Bhaumik et al., 2007). 
  
 High H2A.Z levels were positively correlated with H3K18ac, H4K12ac, 
H3K4me3 and H4K20me3, all of which are good prognostic indicators in breast 
tumours (Elsheikh et al., 2009). Although H2A.Z has been shown to colocalise 
with H4K16ac at the promoters of active genes (Guillemette and Gaudreau, 2006, 
Shia et al., 2006) we did not detect a significant correlation of H2A.Z expression 
with H6K16ac. However, it is unclear whether changes in H2A.Z occupancy at 
active promoters reflect changes in the overall cellular levels of H2A.Z or a 
relocalisation to active genes. Thus there may not be a relationship between 
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H2A.Z levels and H4K16 acetylation. Increased H2A.Z levels have also been 
correlated with the DNA damage response (Pillus, 2008, Gevry et al., 2007) and 
H2A.Z has been implicated in repair of DNA double strand breaks (DSB) 
(Kawashima et al., 2007, Kalocsay et al., 2009). Acetylation of H2A.Z by Tip60, 
another protein induced in response to DSBs, is required for incorporation of 
H2AZ into nucleosomes (Svotelis et al., 2009a). DNA damage also results in 
increased acetylation of  H3K56 (Masumoto et al., 2005, Vempati et al., 2010) 
and H4K16 at sites of DNA damage (Krishnan et al., 2011), although the HATs 
responsible for this are not yet clear.  In this study we found that H2A.Z 
expression in breast tumours was positively correlated with H3K56 acetylation 
levels (p <0.001)). Moreover, a strong positive correlation between acetylated 
H2A.Z and TIP60 was observed. We also detected significant positive 
correlations with the H2A.Z deacetylase SIRT1 (Chen et al., 2006, Seligson et al., 
2009) and DBC1, the SIRT1 negative regulator (Kim et al., 2008). These findings 
may support the functional relationship between TIP60, SIRT1 and DBC1 in 
regulating the acetylation of H2A.Z and its incorporation into nucleosomes at 
active genes or DSBs.  
  
 Assessing the relationship of H2A variants to patient survival, I would like 
to highlight two points. First, high detection level of H2A.Z in breast cancer 
tumours appears to be moderately associated with good prognosis in regard to 
both BCSS and DFS.  H2AZ expression was found to be an independent predictor 
of survival and to provide significant prognostic information independent of 
conventional prognostic variables like tumour grade, tumour stage and size. 
However, this result contrasts with a study using a smaller number (500 cases) of 
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breast tumour samples that reported high H2A.Z levels as a poor prognostic factor 
in breast cancer, although enhanced H2A.Z expression by estrogen have been 
reported (Hua et al., 2008). The reason for this discrepancy is unknown, but might 
be explained by differences in the preparation of samples, or the antibody used. 
Second, H2A.Zac levels differs from H2A.Z in relationship to the correlation with 
clinicopathological factors, biological variables and patient survival that further 
support the impact of PTMs on H2A.Z functions. 
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4.1  p53 Post Translational Modifications (PTMs) 
4.1.1  Acetylation of p53 in breast cancer 
The tumour suppressor protein p53 is probably functionally compromised in most 
tumours, either directly through p53 gene mutations, or indirectly through 
alterations to regulatory systems that are required for p53 function. Post 
translational modifications of p53 are now known to be important in the 
regulation of its functions both in the nucleus and the cytoplasm. In this chapter, I 
investigated whether acetylated forms of p53 can be detected in breast tumours 
using TMA, and used this approach to assess whether we can detect altered p53 
acetylation in breast cancer. 
 
 Acetylation of p53 at lysine 120 (K120ac) has been shown to be catalysed 
by TIP60/hMOF (Tang et al., 2006a, Li et al., 2009c), which was found to be 
required for p53 proapoptotic function (Tang et al., 2008), such as BAX 
expression (Xu et al., 2009a). This modification occurs within the p53 DNA 
binding domain and has been reported to alter the ability of p53 to bind DNA 
(Sykes et al., 2006), it has also a well defined cytoplasmic function other than its 
conventional nuclear function (Green and Kroemer, 2009). Acetylation of the C-
terminal activation domain  is generally considered to promote the transcriptional 
activity of p53 (Dai and Gu, 2010), such as acetylation of K373 which is driven 
by CBP/p300 and reversed by HDAC1 (Meek and Anderson, 2009). Acetylation 
of K373 leads to hyperphosphorylation of p53 NH2-terminal residues and 
enhances the p53 activity toward the apoptotic pathway (Knights et al., 2006b). 
Furthermore, CBP/p300 HATs were reported to acetylate p53 at lysine 386 
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(K386) which was reported to enhance p53 sequence-specific binding to DNA 
and its transcriptional activity in tissue culture system. Finally, acetylation 
augments p53 stability through the mutual exclusion of acetylation and 
ubiquitination, which is involved in p53 turnover by the proteasome (Feng et al., 
2005). In the next section, an evaluation of p53 acetylation at three different 
lysine residues (K120, K373 and K386) in breast tumours is presented.   
 
4.1.2  Detection of p53 Acetylation in Breast Tumour Tissue 
The breast cancer TMA cohort (880 tumour cores) was IHC stained (Materials 
and Methods, section 2.2.3) with commercial anti-acetyl p53 antibodies targeting 
specific p53 acetylation sites at K120, K373 and K386. The working 
concentration and antigen retrieval methods used for each antibody are listed in 
Appendix 1. IHC staining with the three antibodies revealed immune reactivity in 
breast tumour, stromal myoepithelial and inflammatory cells; which vary in 
pattern and intensity. The reactivity was mainly nuclear for p53K373ac and 
p53K386ac stained tissue cores with p53K373 solely nuclear and p53K386 
showing nuclear with some cytoplasmic background (Fig. 4.2 and Fig.4.3). 
p53K120ac stained tumour cores showed strong nuclear and cytoplasmic 
reactivity but for some tumours staining was almost exclusively cytoplasmic (Fig. 
4.1A, B, C and D). As acetylation of p53 at K120 has a well defined cytoplasmic 
function, assessment for cytoplasmic p53K120 immunoreactivity was also 
evaluated alongside the nuclear staining. As described in the previous chapter 
scoring of the immunoreactivity of the three p53 acetylation marks was done by 
modified H-score. The valid breast cancer tissue cores were further categorised 
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into low and high detection groups according to the H-score median values. As 
before, where H-score values between zero and the median were considered to be 
in low detection group (LD) and values above the median to 300 were considered 
in the high detection group (HD). Histograms showing frequency of H-score 
plotted against the number of cases are shown in Figure 4.1, right column.  
Strikingly, the intensity of immunoreactivity for nuclear p53K120ac differs from 
the cytoplasmic compartment, which was reflected in the distribution of 
frequency in both histograms (Fig. 4.1E and F). 
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Figure 4.1: Detection of p53K120 Acetylation Mark in Breast Cancer as determined by IHC.   
 
Breast tumour tissue cores presenting with low (A) and high (C) levels for p53K120ac; further magnifications are presented below (B and D). 
Both nuclear (blue arrows) and cytoplasmic staining (red arrows) for p53K120ac were observed (D). Original magnification is X20. Distribution 
of nuclear (E) and cytoplasmic (F) H-score of breast cancer TMA stained for p53K120ac.  
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Figure 4.2: Detection of p53K373 Acetylation Mark in Breast Cancer as determined by IHC. 
 Breast tumour tissue cores presenting with low (A) and high (C) levels for p53K373ac; further magnifications are presented below (B and D). 
Original magnification is X20. Distribution of H-score of breast cancer TMA stained for p53K373ac (E). 
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  Figure 4.3: Detection of p53K386 Acetylation Mark in Breast Cancer as determined by IHC. 
 
 
Breast tumour tissue cores presenting with low (A) and high (C) levels for p53K373ac; further magnifications are presented below (B and D). 
Original magnification is X40. Distribution of H-score of breast cancer TMA stained for p53K386ac (E).
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p53 PTMs Detection Levels in Relationship to Breast Cancer Histological 
Types  
p53 acetylation marks were found to vary among different tumour 
histopathological types as shown in (Table 4.1). In particular, low levels of 
nuclear p53K120ac were observed in invasive duct, invasive papillary, medullary 
and mucinous and cribriform tumours; while, 8 out of 10 (80%) of tubular 
tumours expressed high levels of nuclear p53K120ac. Concerning cytoplasmic 
p53K120ac, low levels have been noted among 28 out of 47 (60%) of classical 
lobular, 11 out of 16 (69%) of medullary and 3 out of 4 (75%) of mucinous 
tumours.  
 
 With regard to p53K373ac, conversely to cytoplasmic p53K120ac, high 
levels have been noted in 44 out of 59 (75%) of lobular tumours. Both tubular and 
cribriform tumours also tended to show high levels of p53K373ac. Where 11 out 
of 16 (69%) of tubular tumours and 3 out of 4 (75%) cribriform tumours were 
high for p53K373ac levels. However, almost all (15 out of 16 tumours) medullary 
and all mucinous (3 cases) tumours were low in p53K373ac levels. 
 
 p53K386ac levels have been also shown to vary considerably among 
tumour histopathological types, high levels have been noted in 42 out of 68 (64%) 
of lobular, 14 out of 20 (70%) of tubular and most mucinous (5 out of 6) and 
cribriform (4 cases) tumours. However, low levels were observed in 14 out of 19 
(74%) of medullary tumours and more than half (57%) of invasive ductal/NOS 
tumours.  
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 These results illustrate that tumour histological types differ in their p53 
acetylation levels. Moreover, medullary tumours always tend to show low levels 
of p53 acetylation. Finally, high levels of p53K373ac and p53K386ac have been 
observed in well differentiated tumours; however, p53K120 acetylation levels did 
not correlate with tumour grade regardless of the staining was nuclear or 
cytoplasmic.   
 
 p53 PTMs in Relationship to Breast Cancer Phenotypic Groups 
Regarding breast cancer tumour phenotypes proposed by Nielson et al (Nielsen et 
al., 2004), significant differences in nuclear p53K120ac levels were noted 
(p<0.001). Low nuclear p53K120ac levels were observed in 67% of HER2 and 
72% of basal subtypes, whereas, no significant differences were observed among 
luminal type tumours. Similar trends were obtained from nuclear levels of both 
p53K373ac and p53K386ac (p<0.001 for both) as shown in Table 4.2. 
Remarkably, high levels of nuclear p53K386ac were observed in 208 out of 281 
(74%) of luminal tumours. With regard to cytoplasmic p53K120ac, no significant 
differences were noted among Neilson phenotypes. The tendency for bad 
prognostic HER2 and basal tumours to show low detection levels of nuclear p53 
acetylation marks and loss of H4K16 acetylation may indicate dysfunction of 
HATs in those tumours. This data suggests that nuclear p53 acetylation may be a 
useful indicator of tumour type. Conversely, cytoplasmic p53K120ac does not 
seem related to breast cancer phenotypic groups.  
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 With regard to p53 acetylation levels in tumour classes proposed by Abd 
El-Rehim et al  (Abd El-Rehim et al., 2005), nuclear p53K120ac levels were low 
in both luminal N class and both HER2 and basal classes. Cytoplasmic 
p53K120ac levels were also low in both luminal N and HER2 classes; however, 
10 out of 16 (60%) of p53-altered (mutated) class showed tendency towards high 
p53K120ac. This suggests a difference in the subcellular distribution of 
p53K120ac in different tumour classes, especially in relation to p53 mutations. 
With regard to p53 acetylation at K373 and K386, high levels of both marks were 
observed in luminal A and N classes; however, low levels were seen in basal 
classes (Table 4.3).  
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Table 4:1:p53 PTMs Detection Levels in Relationship to Tumour Histopathological Types. 
Histopathological type 
p53K120ac (N)  p53K120ac (C)  p53K373ac  p53K386ac 
LD HD  LD HD  LD HD  LD HD 
Invasive Ductal/NOS Type 162 114  136 140  174 129  184 139 
Invasive papillary 3 1  3 1  1 2  2 1 
NST& Lobular 13 7  11 9  12 8  6 11 
NST& Special 6 8  6 8  10 6  11 4 
Classical lobular 24 23  28 19  15 44  26 42 
Tubular 2 8  5 5  5 11  6 14 
Tubular mixed 53 56  48 61  50 69  61 77 
Medullary 13 3  11 5  15 1  14 5 
Mucinous 3 1  3 1  3 0  1 5 
Cribriform 3 0  2 1  1 3  0 4 
Miscellaneous 0 4  2 2  4 0  2 0 
Total 507  507  563  615 
LD, low detection; HD, high detection; NOS, no other specified. 
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Table 4:2: p53 PTMs detection levels in Relationship to Tumour Phenotype Groups of Breast Cancer as defined by Nielsen and 
Colleagues (Nielsen et al., 2004). 
Nielsen classes of breast 
cancer (Nielsen et al., 2004)  
p53K120ac (N) p53K120ac (C) p53K373ac p53k386ac 
Total LD HD p Total LD HD p Total LD HD p Total LD HD p 
Neilson Groups 373   <0.001 373   0.484 422   <0.001 505   0.003 
HER2  31 15   22 24   36 22   31 14  
Luminal  135 142   132 145   135 174   73 208  
Basal-like  36 14   30 20   41 14   46 33  
LD, low detection; HD, high detection; all p values are calculated by X2 test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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Table 4:3: p53 PTMs Detection Levels and Phenotype Groups of Breast Cancer as defined by Abe El-Rehim and Colleagues (Abd El-
Rehim et al., 2005). 
Abd El-Rehim classes 
of breast cancer 
p53K120ac 
(N) 
 p53K120ac 
(C) 
 p53K373ac  p53K386ac 
LD HD  LD HD  LD HD  LD HD 
Luminal A 14 15  12 17  11 17  12 22 
Luminal B 16 10  13 13  13 14  15 11 
Luminal N 44 25  41 28  29 50  33 52 
HER2 16 6  14 8  12 14  14 10 
Basal-p53 altered 10 6  6 10  11 5  10 5 
Basal-p53 normal 14 9  13 10  15 8  15 8 
Not classified 44 37  43 38  41 44  56 46 
Total 266  284  309 
LD, low detection; HD, high detection; N, nuclear; C, cytoplasmic. 
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p53 PTMs Correlate with Breast Cancer Clinicopathological factors  
Statistical analysis of p53 acetylation marks in relationship to breast cancer 
clinicopathological variables revealed a number of significant results (Table 4.4). 
In particular, high nuclear p53K120ac levels negatively correlated with NPI 
(p=0.001); where, 70% of stage 3 tumours and 69% of poor prognostic NPI group 
were low in p53K120ac levels. Consistently, low p53K120ac levels correlated 
with nodal metastasis (p=0.014). However, cytoplasmic localisation of 
p53K120ac did not correlate with NPI. With regard to p53 acetylation at K373, 
high levels inversely correlated with tumour grade (p<0.001), where grade I and 
II (favourable grades) were more likely to show high levels of p53K373ac; 
conversely, 60% of grade III tumours were low in p53K373ac. Similarly, high 
levels of p53K386ac were inversely correlated with tumour grade (p<0.001); 
where, grade I and II were more likely to express high levels of p53K386ac; 
conversely 61% of grade III tumours were low in p53K386ac levels. In addition, 
high levels of p53K386ac inversely correlated with NPI categories (p<0.001); 
where 60% of tumours in the good category were showing high levels of 
p53K386ac and 59% of tumours in the poor category were showing low levels of 
p53K386ac. These results may consider p53 acetylation being favourable 
prognostic indicators. 
 
p53 PTMs Correlate with Breast Cancer Biological Markers  
Complementary to the abovementioned work, a set of correlations between p53 
acetylation and a group of breast cancer biological markers were also assessed 
(Table 4.4). In particular, high levels of nuclear p53K120ac significantly 
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correlated with well known markers for good outcome, such as high ER receptor 
expression and high levels of FOXA1 expressions (p<0.001 for both) which 
suggests it as a potentially active form of p53.  
  
 Concerning acetylation at K373, high levels significantly correlated with 
luminal type-specific markers, the cytokeratins CK7/8 and CK18 (p<0.001, and 
p=0.001 respectively) and high levels of the hormone receptors estrogen, 
progesterone and androgen where the p value was <0.001 in all of them. Low 
levels of p53K373ac correlated with the basal type tumour marker CK5/6 
(p<0.001), which consistent with the low p53K373ac levels in basal type tumour 
classes as shown in Table 4.2 and Table 4.3 . In addition, a number of favourable 
outcome related-tumour biological markers also correlated with high levels of 
p53K373ac such as, the transcription factor c-MYC and the tumour suppressor 
genes BRCA1 (Lee et al., 2010) and EGFR; moreover, high levels the p53 
dependent apoptotic marker BCL2. However, these results were not statistically 
significant. Collectively, these results suggest p53K373ac as a potential marker 
for good outcome in breast cancer.  
 
 With regard to p53 acetylation at K386, high detection levels were also - 
like K373- found to significantly correlate with luminal type-specific markers the 
cytokeratins CK7/8 and CK18 (p<0.001 and p<0.001 respectively), and high 
levels of the hormone receptors estrogen, progesterone and androgen with highly 
significant p values (p<0.001 for all). In relationship to favourable outcome 
related-tumour biological markers, high p53K386ac levels also correlated with 
high levels of the tumour suppressor genes BRCA1 (p=0.001) and BCL2 levels 
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(p=0.007). Together, these results are consistent with the hypothesis that active 
i.e. acetylated p53 correlated with biological markers for good outcome, inversely 
correlated with markers of poor prognosis in breast cancer tumours and has a 
close relationship with steroid hormone signaling and apoptosis.  
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Table  4:4: Relation between p53 PTMs Detection levels and Clinico-pathological Parameters and Biological Factors. 
Parameter 
p53K120ac (N) p53K120ac (C) p53K373ac p53K386ac 
Total LD HD p Total LD HD p Total LD HD p Total LD HD p 
Age 507   0.014 507   0.040 564   0.309 616   0.230 
<50  114 69   102 81   106 93   116 102  
>50  168 156   153 171   185 180   198 200  
 
                
Grade 507   0.020 507   0.950 564   <0.001 616   <0.001 
I 
 
52 57 
 
 54 55   55 70   55 92  
II 
 
83 78 
 
 80 81   77 99   87 102  
III 
 
147 90 
 
 121 116   159 104   172 108  
 
 
               
Stage 504   0.031 504   0.032 561   0.218 614   .619 
1  170 158   154 174   195 169   87 129  
2  73 50   64 59   63 76   180 140  
3  37 16   35 18   32 26   46 32  
                 
NPI  504 75 90 0.001 504   0.128 561   0.317 614   <0.001 
Good  155 112   75 90   90 99   87 129  
Moderate  50 22   135 132   155 138   180 140  
Poor  43 29   43 29   45 34   46 32  
                 
Size  507   0.149 507   0.089 564   0.477 616   0.055 
< 5cm  164 142   146 160   184 171   196 208  
> 5cm  118 83   109 92   107 102   118 94  
                 
LN Metastasis 504   0.014 504   0.029 561   0.131 614   0.199 
Negative  170 158   154 174   195 169   201 204  
Positive  110 66   99 77   95 102   112 97  
                 
ER receptor 471   <0.001 471   0.051 527   <0.001 575   <0.001 
Low  113 43   88 68   118 62   113 65  
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High  151 164   151 164   150 197   178 219  
 
                
PR receptor 472   0.094 472   0.534 523   <0.001 567   <0.001 
Negative  131 88   110 109   152 97   148 101  
Positive  135 118   127 126   113 161   139 179  
                 
AR receptor  435   0.073 435   0.073 484   <0.001 533   <0.001 
Negative  119 75   119 75   140 70   130 88  
Positive  130 111   130 111   107 172   139 176  
                 
p53 (Altered) 470   0.023 470   0.529 524   0.149 567   0.041 
Negative  180 156   170 166   185 191   199 212  
positive  86 48   68 66   81 67   89 67  
 
                
c-MYC 259   0.225 259   0.008 299   0.043 284   0.233 
Low  93 89   66 116   133 86   118 91  
High  44 33   41 36   39 41   38 37  
                 
CK7/8  494   0.419 494   0.390 550   0.011 597   <0.001 
Negative  99 83   89 93   118 86   129 79  
Positive  174 138   158 154   164 182   76 213  
                 
CK18  428   0.076 428   0.122 480   0.001 520   <0.001 
Negative  79 47   69 57   90 59   100 54  
positive  165 137   145 157   148 183   65 201  
                 
CK19 491   0.356 491   0.379 547   0.006 589   0.010 
Negative  60 44   50 54   65 38   64 39  
positive  213 174   195 192   217 227   238 248  
                 
CK5/6 497   0.059 497   0.331 554   <0.001 599   0.094 
Negative  198 173   184 187   196 221   225 227  
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Positive  78 48   66 60   88 49   83 64  
                 
CK14  484   0.076 484   0.050 537   0.011 575   0.165 
Negative  214 154   193 175   202 208   225 221  
positive  58 58   50 66   78 49   72 57  
                 
nBRCA1   368   0.026 368   0.288 400   0.007 447   0.001 
Low  107 62   85 84   100 83   113 82  
High  105 94   107 92   91 126   106 146  
                 
FOXA1   412   <0.001 412   0.326 458   0.024 498   0.005 
Low  146 84   110 120   145 122   155 118  
High  81 101   92 90   85 106   101 124  
                 
FHIT 304   0.379 304   0.041 340   0.182 396   0.004 
Low  98 74   94 78   90 96   124 104  
High  72 60   58 74   66 88   68 100  
                 
EGFR 340   0.451 340   0.010 378   0.015 421   0.502 
Low  158 122   133 147   162 150   178 168  
High  35 25   39 21   24 42   38 37  
                 
BCL2 216   0.111 216   0.404 232   0.014 279   0.007 
Low  77 61   67 71   84 67   103 74  
High  36 42   40 38   32 49   43 59  
N, nuclear; C, cytoplasmic, LD, low detection; HD, high detection; NPI, Nottingham Prognostic Index; LN, lymph node; ER, 
estrogen receptor; PR, progesterone receptor; AR, androgen receptor; all p values are calculated by X2 test. Bonferroni correction test 
was applied and reduced the (p) value of significance to 0.003. 
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The Relationship between p53 PTMs, Histone PTMs and Their Modulators  
High levels of nuclear p53K120ac showed a positive correlation with the histone 
variants mH2A (p<0.001) and several histone PTM marks (Table 4.5). 
Specifically, high levels of the histone methylation marks H3K4me3 and 
H3K9me3 (0.002 and 0.008 respectively) and the H3K9 methyltransferase 
SUV39H1 (p=0.01) was observed. This may be consistent with the colocalization 
of p53 and SUV39H1 in a complex capable of methylation of H3K9 (Chen et al., 
2010).  
 
 Moreover, the observed association with the DNA damage mark H3K56ac 
(p<0.001) may reflect the relationship between acetylation of p53 at K120 and its 
role in the DNA damage response (Li et al., 2009b). With regard to HATs, high 
levels of hMOF, which has been previously reported to acetylate p53 at K120 (Li 
et al., 2009c), correlated with high levels of nuclear p53K120ac (p= 0.006). In 
addition, high MORF levels also correlated with high levels of nuclear 
p53K120ac (p<0.001). Unpublished data from our group has shown that the MOZ 
related protein MORF can acetylate p53 at K120 (HM Collins, M Mesmer, data 
not shown). Conversely, low levels of nuclear p53K120ac correlated with high 
levels of the histone deacetylase HDAC2 (p=0.010), although the p value was not 
statistically significant after Bonferroni correction. With regard to DBC1, the 
SIRT1 negative regulator, high levels of DBC1 positively correlated with nuclear 
p53K120ac (p<0.001), which may be consistent with SIRT1-mediated p53 
deacetylation (Zhao et al., 2008). 
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  Cytoplasmic detection of p53K120ac was found to correlate positively 
with high levels of mH2A (p<0.001). In contrast to the nuclear fraction, 
cytoplasmic p53K120ac negatively correlated with the histone methylation mark 
H3K9me3 (p<0.001), which may indicate differential functions of the nuclear and 
cytoplasmic fractions of p53K120ac, although how this might occur is unknown. 
 
 A number of significant correlations were observed for p53K373ac levels 
among histone variants, histone PTMs and histone modulators (Table 4.5). High 
levels of p53K373ac correlated with high levels of mH2A (p<0.001); histone 
acetylation and methylation marks (p<0.001), which may be consistent with 
p53K373ac role in genome transcription (Knights et al., 2006b). Knights et al., 
(2006b) reported that acetylation of p53 at K373 enhances p53 phosphorylation at 
NH2-terminal residues and improves p53 interaction with gene promoters. In 
addition, high levels of p53K373ac correlated with high levels of H3K56ac 
(p<0.001); which was previously described to localize at DNA repair foci after 
DNA damage (Masumoto et al., 2005, Vempati et al., 2010, Yuan et al., 2009) 
and is consistent with p53 and H3K56ac colocalization at DNA damage sites 
(Vempati et al., 2010). With regard to HATs, high levels of p53K373ac correlated 
with high levels of MORF (p<0.001); The histone acetyltransferase MOZ or 
MORF genes have been described to be associated with the nuclear receptor 
coactivators TIF2, p300 or CBP. In our lab MOZ-TIF2 was previously described 
to inhibit p53 gene transcription through impairment of CBP function (Kindle et 
al., 2005). In addition, high levels of hMOF correlated with high p53K373ac 
levels (p<0.001); which is consistent with the role of hMOF p53 acetylation and 
ATM activation in response to DNA damage response (Rea et al., 2007). 
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Concerning HDACs, high levels of p53K373ac correlated with high levels of both 
SIRT1, the p53 deacetylator (Hasegawa and Yoshikawa, 2008) and DBC1 
(p<0.001 and p=0.007 respectively). These results may be consistent with the 
previously reported deregulation of the p53-SIRT1-DBC1 regulatory loop (Tseng 
et al., 2009) in breast cancer. With regard to SUV39H1, high levels correlated 
with p53K373ac high levels (p=0.002). Interestingly, SUV39H1 and p53 form a 
complex capable of H3K9 methylation (Chen et al., 2010).  
 
 Finally, significant differences in p53K386ac levels also correlated with 
histone variants, histone PTMs and histone modulator levels (Table 4.5). Like 
p53K373ac, high p53K386ac levels also correlated with mH2A with a highly 
significant value (p<0.001) and remarkably there was significant correlation 
between p53K386ac and all histone acetylation and methylation marks. This may 
reflect the activity of HATs that target both histone and p53 acetylation. Like 
p3K373ac, high levels of p53K386ac positively correlated with high levels of 
H3K56ac the DNA damage marker (Masumoto et al., 2005, Vempati et al., 2010, 
Yuan et al., 2009) in highly significant value (p<0.001). High levels of 
p53K386ac also correlated with high levels of the histone acetyltransferases 
MORF and hMOF (p<0.001 in both), the p53 acetylators (Dai and Gu, 2010, 
Meek and Anderson, 2009). High p53K386ac levels also positively correlated 
with both SIRT1 and HDAC1 (p<0.001 and p=0.022 respectively) which may be 
consistent with their suppression of p53-dependent apoptosis in post neuronal 
cells (Hasegawa and Yoshikawa, 2008) and promoting Mdm2-dependent p53 
degradation (Ito et al., 2002). With regard to SUV39H1, high levels positively 
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correlated with high levels of p53K386ac (p<0.001) consistent with their 
colocalization in a complex responsible for H3K9 methylation (Chen et al., 2010).  
 
 Interestingly, high levels of p53K386ac correlated with high levels of 
nuclear p53K120ac and p53K373ac (p=0.005, p<0.001 respectively). However, 
cytoplasmic p53K120 levels negatively correlated with nuclear p53K373 with a 
highly significant p value (p<0.001), which may indicate a varied p53 function 
dependent on either the site or localization of its PTMs. Taken together, our data 
shows that monitoring p53 acetylation status may be a useful prognostic indicator 
in breast cancer and may also reveal how changes in p53 acetylation occur during 
tumour progression indicating this may be important for the advance of the 
disease. 
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Table 4:5: p53 PTMs in Relation to Histone PTMs and their Modulators. 
Parameter 
p53K120ac (N) p53K120ac (C) p53K373ac p53K386ac 
Total LD HD p Total LD HD p Total LD HD p Total LD HD p 
mH2A 478   <0.001 478   0.249 526   <0.001 579   <0.001 
Low  179 97   135 141   191 120   202 132  
High  90 112   106 96   76 139   93 152  
 
                
H2A.Z 478   0.010 478   <0.001 533   0.051 587   0.498 
Low  156 99   154 101   160 132   164 158  
High  112 111   85 138   114 127   134 131  
 
 
 
   
 
   
 
      
H2A.Zac 453   0.334 453   0.005 515   0.004 467   0.124 
Low  121 98   122 97   149 101   103 116  
High  135 99   101 133   126 139   131 117  
 
 
 
   
 
   
 
      
H3K9ac 360   0.016 360   0.509 406   <0.001 447   <0.001 
Low  126 73   101 98   133 86   141 86  
High  83 78   81 80   70 117   97 123  
  
 
   
 
   
 
      
H3K18ac 370   0.326 370   0.104 415   <0.001 450   <0.001 
Low  117 78   92 103   144 73   144 87  
High  100 75   95 80   62 136   93 126  
 
 
 
   
 
   
 
      
H4K12ac 356   0.096 356   0.184 391   <0.001 428   <0.001 
Low  128 81   101 108   142 51   151 87  
High  79 68   79 68   80 118   77 113  
                 
H4K16ac (Millipore) 469   0.185 469   0.006 523   <0.001 576   <0.001 
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Low  136 116   110 142   182 92   177 120  
High  127 90   121 96   92 157   116 163  
                 
H3K4me2 356   0.002 356   0.539 397   <0.001 439   <0.001 
Low  125 66   95 96   133 79   147 83  
High  82 83   82 83   67 118   86 1230  
                 
H4K20me3 342   0.032 342   0.553 376   <0.001 415   0.001 
Low  38 16   28 26   45 19   50 21  
High  161 127   149 139   131 181   167 177  
                 
H3K9me3 400   0.008 400   <0.001 440   <0.001 554   <0.001 
Low  120 109   97 132   153 82   185 102  
High  111 60   105 66   72 133   97 170  
                 
H4R3me2 407   0.018 407   0.350 449   <0.001 485   0.002 
Low  148 97   124 121   160 113   169 117  
High  80 82   78 84   66 110   91 108  
 
                
H3k56ac 432   <0.001 432   0.251 480   <0.001 500   <0.001 
Low  144 81   117 108   158 92   163 104  
High  98 109   100 107   80 150   91 142  
 
                
MORF 385   <0.001 385   0.169 409   <0.001 511   <0.001 
Low  131 65   106 90   107 99   181 83  
High  88 101   92 97   89 114   92 155  
 
                
hMOF 476   0.006 476   0.181 534   <0.001 588   <0.001 
Low  167 107   143 131   184 132   196 131  
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High  99 103   96 106   87 131   102 159  
 
                
SUV39H1 358   0.010 358   0.306 381   0.002 442   <0.001 
Low  123 77   96 104   118 87   148 80  
High  77 81   81 77   75 101   87 127  
 
                
HDAC2  414   0.215 414   0.010 453   0.207 566   0.149 
Low  100 84   81 103   107 90   131 116  
High  135 95   129 101   128 128   154 165  
 
                
SIRT1 409   0.366 409   0.366 445   <0.001 552   <0.001 
Low  143 99   143 99   163 112   157 100  
High  95 72   95 72   68 102   136 159  
 
                
DBC1 418   <0.001 418   0.039 456   0.007 499   0.087 
Low  132 78   113 97   134 107   143 119  
High  96 112   93 115   94 121   114 123  
                 
p53k120ac (N)         488   0.309 438   0.005 
Low          144 133   144 107  
High          104 107   83 104  
                 
p53k120ac (C)         488   <0.001 438   0.220 
Low          104 139   110 111  
High          144 101   117 100  
                 
p53k373ac             478   <0.001 
Low              154 91  
High              92 141  
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N, nuclear; C, cytoplasmic; LD, low detection; HD, high detection; NPI, Nottingham Prognostic Index; all p values are calculated by X2 test. 
Bonferroni correction test was applied and reduced the (p) value of significance to 0.003. 
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4.2 p53 Acetylation Modulators 
In previous section we explored breast cancer TMA immunoreactivity for p53 
acetylation at (K120, K373 and K386). Those acetylation sites are catalysed by a 
number of modulators (Fig. 4.4); some of these modulators have been evaluated 
in the breast cancer TMA in the following section. TIP60, CBP and HDAC1 
staining patterns and intensities, their relationship with various tumour types, 
clinicopathological factors, and biological markers are determined. In addition, 
exploring their relationship to both (p53 and histone) PTMs and histone PTMs 
modulators.  
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Figure 4.4: p53 PTMs, HATs and HDACs and their effects on Cell Cycle 
Progression. 
  
 
p53 is acetylated at several lysine residues by histone acetyltransferases, such as 
hMOF, TIP60, CBP/p300, and possibly others; deacetylated by histone 
deacetylases such as SIRT1, which reduces p53 transcription activity and enhance 
p53 degradation. Acetylated p53 represses SIRT1 gene transcription. Acetylation 
of p53 at K120, and K373 facilitates p53 binding to pro-apoptotic genes. 
Acetylation at K320 facilitates p53 binding to cell cycle repression gens. 
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4.2.1 Detection of p53 Acetylation Modulators in Breast Tumour 
TMA 
We IHC stained the whole set of breast cancer TMAs (880 cases) as previously 
described in the Materials and Methods with antibodies against TIP60, CBP and 
HDAC1 (Antibody details are listed in Appendix 1) to assess their patterns and 
intensities in breast cancer tissue. The working dilution and method of antigen 
retrieval are also listed in Appendix 1. The TIP60 staining pattern was almost 
homogeneous in most of the cores examined. Immunoreactivity for TIP60 was 
confined to the nuclei of tumour cells. Positive reactivity to a lesser extent was 
also observed in stromal, myoepithelial and inflammatory cells. A range of 
staining intensities from totally negative to highly stained breast cancer cores was 
observed (Fig. 4.5A and B).  As for CBP staining, the pattern of 
immunoreactivity was near to homogeneous in most of the tumour cores and the 
intensity ranged from low to high levels. CBP immunoreactivity was mainly seen 
in the nuclei but also occasionally in the cytoplasm of tumour cells. Stromal cells 
were usually devoid of staining (Fig. 4.6A and B). An assessment of HDAC1 
staining revealed a homogeneous pattern of immunoreactivity confined to the 
nuclei of tumour cells and sometimes in the cytoplasm. Stromal cells, 
myopepithelial cells and lymphocytes were usually devoid of staining as shown in 
Figure 4.7A and B.  
 
 H-scores for TIP60, CBP and HDAC1 were dichotomized according to the 
median and the H-score distributions are illustrated in Figure 4.5E, 4.6E and 4.7E. 
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Figure 4.5: Detection of TIP60 in Breast Cancer TMAs as determined by IHC staining. 
 
Breast tumour tissue cores presenting with low (A) and high (C) levels for TIP60; further magnifications are presented below (B and D). 
Original magnification is X40. Distribution of H-score of breast cancer TMA stained for p53K386ac (E). 
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Figure 4.6: Detection of CBP in Breast Cancer TMAs as determined by IHC staining. 
 
 
Breast tumour tissue cores presenting with low (A) and high (C) levels for CBP; further magnifications are presented below (B and D). Stromal 
FHOOVDUHµORZ¶IRU&%3DUURZLQ'Original magnification is X40. Distribution of H-score of breast cancer TMA stained for p53K386ac (E). 
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Figure 4.7: Detection of HDAC1 in Breast Cancer TMAs as determined by IHC staining. 
 
Breast tumour tissue cores presenting with low (A) and high (C) levels for HDAC1; further magnifications are presented below (B and D). 
Original magnification is X40. Distribution of H-score of breast cancer TMA stained for p53K386ac (E). 
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p53 Acetylation Modulators in Relation to Breast Cancer Histopathological 
Types  
p53 acetylation modulators showed considerable variation among tumour 
histopathological types (Table 4.6). Invasive duct/NOS type tumours did not 
show considerable variation except those stained for CBP where 219 out of 366 
(60%) of the tumours were low for CBP.  Remarkably, NST & lobular tumour 
WHQGHGWREHµKLJK¶IRUERWK7,3DQG&%3:KHUHRXWRIDQG
out of 24 (58%) of NST& lobular tumours were high for TIP60 and CBP. 
However, high TIP60 levels were seen in 33 out of 56 (59%) of lobular tumours. 
As for medullary tumours, considerable percentages were observed among the 
µORZ¶JURXSVIRU7,3&%3DQG+'$&,QWHUHVWLQJO\PRVWPXFLQRXVWXPRXUV
stained for CBP (8 cases) were µlow¶ for CBP. 
 
p53 Acetylation Modulators in Relation to Breast Cancer Phenotypic Groups  
Regarding the breast cancer tumour phenotypes proposed by Nielson and 
colleagues (Nielsen et al., 2004), statistical differences in CBP and HDAC1 levels 
(p=0.022, not significant; p=0.003 respectively) were noted. Low levels of CBP 
were noted in 57% of HER2-positive, and in 86% of basal subtypes. In addition, 
low levels of HDAC1 were also found in 66% of HER2-positive, and 63% of 
basal subtypes. However, TIP60 expression did not show significant association 
with Neilson breast groups. These results propose an association between both 
CBP and HDAC1 levels and poor prognostic tumour groups.  
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 With regard to tumour classes proposed by Abd El-Rehim and colleagues 
(Abd El-Rehim et al., 2005, Soria et al., 2010) TIP60 levels tended to vary among 
luminal type tumours. High levels of TIP60 were noted in luminal A and N 
classes; where 63% of luminal A and 66% of luminal N tumours were high in 
TIP60 levels. Conversely, although not very different, 56% of luminal B tumours 
were low in TIP60 levels. CBP levels were also low in 63% of luminal B class. In 
addition, low levels of CBP were also noted in 71% of the HER2 and both basal 
classes. Similarly, low levels of HDAC1 were also noted in luminal B, HER2 and 
basal classes (Table 4.8). These suggest an association between low levels of both 
CBP and HDAC1 and poor prognostic tumour classes. 
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Table 4:6: The Detection level of p53 Acetylation Modulators in Different 
Tumour Histopathological Types. 
Histopathological type 
TIP60  CBP  HDAC1 
LD HD  LD HD  LD HD 
Invasive Ductal/NOS Type 159 150  219 147  154 150 
Invasive papillary 3 0  1 3  2 1 
NST& Lobular 5 14  10 14  8 7 
NST& Special 8 9  9 10  9 8 
Classical lobular 23 33  39 33  32 28 
Tubular 9 6  13 6  8 7 
Tubular mixed 54 60  78 77  50 64 
Medullary 13 4  14 8  10 4 
Mucinous 3 2  7 1  3 1 
Cribriform 2 2  2 3  1 1 
Miscellaneous 1 1  0 3  3 1 
Total 561  697  552 
LD, low detection; HD, high detection; NOS, no other specified. 
  
Chapter Four: Evaluation of p53 PTMs and Their Modulators in Breast Cancer TMA 
 
221  
 
Table 4:7: The Detection level of p53 Acetylation Modulators and Phenotype Groups of Breast Cancer as defined by Nielsen and 
Colleagues (Nielsen et al., 2004). 
Nielsen classes of 
breast cancer (Nielsen 
et al., 2004)  
TIP60 CBP HDAC1 
Total LD HD p Total LD HD p Total LD HD p 
Neilson Groups 425   0.069 531   0.022 448   0.003 
HER2  35 21   39 29   31 16  
Luminal  138 173   197 198   153 177  
Basal-like  30 28   46 22   45 26  
 
LD, low detection; HD, high detection; all p values are calculated by X2 test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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Table 4:8: The Relationship of p53 Acetylation Modulators to Phenotype 
groups of Breast Cancer as defined by Abd El-Rehim and Colleagues (Abd 
El-Rehim et al., 2005). 
Abd El-Rehim classes 
of breast cancer 
TIP60 CBP HDAC1 
Total LD HD Total LD HD Total LD HD 
Cluster Class 286   343   590   
Luminal A  12 20  14 19  15 16 
Luminal B  14 11  20 12  13 7 
Luminal N  24 47  51 38  32 32 
HER2  14 14  20 8  16 11 
Basal-p53 altered  6 11  13 5  8 9 
Basal-p53 normal  10 13  20 7  13 9 
Not classified  47 43  64 52  44 46 
LD, low detection; HD, high detection. 
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p53 Acetylation Modulators in Relationship to Breast Cancer Clinico-
pathological Factors  
A number of correlations were found between p53 acetylation modulators and 
clinicopathological variables as shown in Table 4.9. High levels of CBP 
significantly correlated with advanced patient age (p=0.001). Conversely to CBP, 
although not statistically significant, high levels of TIP60 were noted in younger 
patients, smaller tumour size and low grade tumours (grade I and II), where 106 
out of 184 (58%) of grade II tumours were more likely to show high TIP60 
expression. Conversely, 146 out of 261 (56%) of grade III tumours showed low 
levels of TIP60.  
 
p53 Acetylation Modulators Correlate with Breast Cancer Biological 
Markers  
Correlations between TIP60, CBP and HDAC1 expression levels and different 
biological markers were also noted (Table 4.9). Remarkably, high levels of p53 
PTM modulators correlated with high levels of steroid hormone receptors levels, 
especially CBP and HDAC1 which correlated with high estrogen receptor levels 
in highly significant p value (p=0.001). Similarly, high levels of TIP60 correlated 
with high levels of androgen receptors (p=0.001) for which it is reported to be 
coacivator (Brady et al., 1999). Conversely, low levels of TIP60 correlated with 
CK5/6, the basal tumour type marker (p=0.005). Analysis of HDAC1 
immunoreactivity revealed that low levels of HDAC1 also correlated with high 
levels of CK5/6 (p=0.029). Conversely, high levels of HDAC1 were significantly 
correlated with high levels of CK7/8 the luminal type-specific marker (p=0.002). 
These results denote a close association between TIP60, CBP, HDAC1 and 
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hormonal receptors; and a tendency for low expression of those marks in basal-
type tumours.   
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Table 4:9: The Relationship between detection levels of the p53 Acetylation 
Modulators and Clinico-pathological Parameters and Biological Factors. 
Parameter 
TIP60 CBP HDAC1 
Total LD HD p Total LD HD p Total LD HD p 
Age 561   0.050 698   0.001 552   0.051 
<50  90 110   155 86   106 84  
>50  190 171   238 219   174 188  
 
            
Grade 561   0.017 698   0.119 552   0.157 
I  56 60   82 68   53 63  
II  78 106   119 111   84 92  
III  146 115   192 126   143 117  
             
Stage 558   0.112 695   0.953 549   0.899 
1  30 28   259 203   185 175  
2  138 173   93 71   69 68  
3  35 21   40 29   25 27  
             
NPI  561   0.069 695   0.554 549   0.260 
Good  89 97   133 108   85 100  
Moderate  142 156   200 158   151 134  
Poor  46 28   59 37   43 36  
             
Size  561   0.011 698   0.159 552   0.021 
< 5cm  160 188   254 185   165 184  
> 5cm  120 93   139 120   115 88  
             
LN Metastasis 558   0.096 695   0.431 549   0.390 
Negative  190 177   259 203   185 175  
Positive  87 104   133 100   94 95  
             
ER receptor 522   0.056 648   0.001 513   0.001 
Low  91 75   134 74   105 68  
High  167 189   226 214   154 186  
 
            
PR receptor 520   0.007 642   0.005 503   0.189 
Negative  137 108   183 115   123 108  
Positive  123 152   175 169   133 139  
             
AR receptor  486   0.001 601   0.034 478   0.179 
Negative  121 94   154 98   104 86  
Positive  113 158   186 163   144 144  
             
P53 (Altered) 521   0.122 648   0.266 509   0.370 
Negative  177 195   257 209   182 180  
positive  80 69   106 76   77 70  
 
            
c-MYC 246   0.059 327   0.228 259   0.210 
Low  108 68   130 105   97 88  
High  51 19   46 46   34 40  
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CK7/8  547   0.016 672   0.150 531   0.002 
Negative  110 84   144 101   115 77  
Positive  165 188   23 195   157 182  
             
CK18  465   0.305 579   0.138 462   0.258 
Negative  69 68   103 69   75 64  
positive  155 173   222 185   162 161  
             
CK19 542   0.517 669   0.008 525   0.092 
Negative  54 53   87 45   57 41  
positive  218 217   289 248   214 213  
             
CK5/6 550   0.005 678   0.504 534   0.029 
Negative  196 221   290 228   194 205  
Positive  80 53   89 71   205 56  
             
CK14  530   0.024 658   0.307 515   0.123 
Negative  200 218   288 227   203 200  
positive  66 46   84 59   64 48  
             
nBRCA1   414   0.382 493   0.012 394   0.102 
Low  87 102   137 78   95 73  
High  108 117   148 130   112 114  
             
FOXA1   453   0.369 558   0.459 448   0.526 
Low  125 121   164 136   126 117  
High  101 106   139 119   106 99  
             
FHIT 352   0.336 427   0.532 428   0.453 
Low  96 106   132 107   45 41  
High  67 83   104 84   174 168  
             
EGFR 377   0.030 465   0.475 369   0.183 
Low  139 168   212 170   153 146  
High  41 29   47 36   31 39  
N, nuclear; C, cytoplasmic, LD, low detection; HD, high detection; NPI, 
Nottingham Prognostic Index; LN, lymph node; ER, estrogen receptor; PR, 
progesterone receptor; AR, androgen receptor; all p values are calculated by X2 
test. Bonferroni correction test was applied and reduced the (p) value of 
significance to 0.003. 
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The Detection Levels of p53 Acetylation Modulators Correlate with Histone 
PTMs and p53 Acetylation Marks 
High levels of TIP60 in breast tumours correlated with high levels of H2A.Zac 
(p<0.001) and all histone acetylation marks except H4K16ac. Specifically, high 
levels of TIP60 correlated with high levels of the active gene marks H3K9ac 
(Lindeman et al., 2010), the transcription activation mark H3K4me3 (Ruthenburg 
et al., 2007),  H3K18ac and H4K12ac and as shown in Table 4.10. Interestingly, 
high levels of the DNA damage mark H3K56ac (Masumoto et al., 2005, Vempati 
et al., 2010, Tjeertes et al., 2009) also correlated with high TIP60 levels. Perhaps 
consistent with the TIP60 role in the DNA damage response in cancer cells 
(Mattera et al., 2009). With regard to HATs, TIP60 levels correlated positively 
with hMOF (p<0.001) which is consistent with their role in acetylating p53 at 
K120 (Tang et al., 2006b, Li et al., 2009c). Concerning p53 acetylation marks, 
TIP60 levels correlated positively with p53 acetylation at K373 and K386 
(p=0.018 and p=0.008 respectively). However, unexpectedly, TIP60 was not 
correlated with CBP which is responsible for those acetylation marks. 
Furthermore, we found TIP60 not statistically correlated with p53K120ac levels. 
 
 With regard to CBP, high levels significantly correlated with high levels 
of both mH2A and H2A.Z (where p<0.001 for both) and most histone acetylation 
marks considered in this study with the exception of H4K16ac. In particular, CBP 
levels positively correlated with the active gene mark H3K9ac (Lindeman et al., 
2010). With regard to histone methylation, high CBP levels positively correlated 
with the favourable prognostic mark H4K20me3 (Van Den Broeck et al., 2008) 
with a highly significant p value (p<0.001) but not with any other methylation 
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marks. With regard to the relationship to p53 acetylation marks, high levels of 
CBP positively correlated with high levels of nuclear p53K120ac and p53K373ac 
(p<0.001 and p=0.003 respectively); which may be consistent with CBP 
localization with p53 in a complex structure during  acetylation-related 
transcription activation (Eichenbaum et al., 2009). However, no significant 
correlation has been noted between CBP and p53K386 acetylation, suggesting a 
negligible role for CBP in inducing K386 acetylation if compared with hMOF. 
 
 Significant differences in HDAC1 levels were observed in relationship to 
histone PTMs, p53 PTMs and their modulators (Table 4.10). Specifically, high 
HDAC1 levels correlated high levels of H4K16ac (p<0.001); the repressed gene 
mark H3K9me3 and its modulator SUV39H1 (p=0.004 and p=0.042 
respectively). Which may be consistent with the central role of HDAC1 in 
regulating gene activity (Renthal et al., 2008, Gurtner et al., 2008) and its 
involvement in heterochromatin formation (Zhou and Grummt, 2005, 
Bandyopadhyay et al., 2007). Concerning HATs, interestingly, high levels of 
HDAC1 also correlated with MORF (p=0.001); which may be consistent with 
HDAC1 and MORF being reported in a complex required for normal cell cycle 
progression through S phase.  With regard to other HDACs included in the study, 
HDAC1 positively correlated with SIRT1 (p=0.002); which may be consistent 
with interaction of SIRT1 with mSIN3A/HDAC1 complex that mediates 
transcription repression (Binda et al., 2008). These results may suggest a role for 
HDAC1 in transcription regulation in breast cancer. For further confirmation, 
evaluation of the relationships between HDAC1 and p53 acetylation marks K120, 
K373 and K386 were analysed, this revealed a correlation with high p53 
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acetylation levels at K120 and K386 (p=0.015 and p=0.022 respectively). 
Although not statistically significant, it may be consistent with a cascade of 
events related to cell cycle regulation in response to DNA damage that includes 
S DFHW\ODWLRQ +'$& UHFUXLWPHQW &GF DQG F\FOLQ % SURPRWHUV¶ UHSUHVVLRQ 
which are key regulators of the G2/M transition (Imbriano et al., 2005). Together, 
these propose a critical role for HDAC1 in regulating cell cycle progression and 
cell fate.   
 
 Collectively, our results revealed apparent associations between TIP60, 
CBP and HDAC1 with their biological targets, i.e. histone and p53 PTMs. 
However, we did not always detect associations between these enzymes and their 
experimentally defined targets. For example, our data suggest significant positive 
correlations between TIP60 and p53K373 and K386 acetylation but not with its 
proposed target p53K120ac. Similarly, high levels of CBP were associated with 
p53K120ac but not its target p53K386 acetylation. This may be due to the 
limitation of the IHC staining sensitivity or the H-scoring system. More likely it 
reflects the complexity of biological systems, as compared to in vitro 
experiments. It is not clear whether subtle changes in the global levels of the 
PTMs will be detected by this approach, or whether the expressed levels of the 
modulator enzymes are functional. Moreover there may be enzymatic redundancy 
between HAT enzymes with regard to their histone and p53 Lysine targets. There 
may also be indirect effects from other regulators that are not really clear yet. 
Despite these limitations, TMA staining data as appears to be a useful approach to 
the discovery of cancer biomarkers.     
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Table 4:10: p53 PTM Acetylation Modulators Detection Levels in 
Relationship to Histone PTMs and their Modulators. 
Histone and 
Histone 
Modulators 
TIP60 CBP HDAC1 
Total LD HD p Total LD HD p Total LD HD p 
mH2A 554   0.485 720   <0.001 515   0.039 
Low  158 160   251 157   156 129  
High  116 120   149 163   107 123  
 
            
H2A.Z 550   0.010 708   <0.001 523   0.447 
Low  163 137   249 143   152 140  
High  110 140   143 173   118 113  
 
 
 
   
 
      
H2A.Zac 425   <0.001 516   0.318 404   0.326 
Low  124 76   145 110   106 88  
High  96 129   142 119   109 101  
 
 
 
   
 
      
H3K9ac 397   0.016 487   <0.001 391   0.282 
Low  119 103   159 98   103 101  
High  74 101   104 126   88 99  
  
 
   
 
   
 
  
H3K18ac 402   0.006 496   0.016 386   0.152 
Low  109 93   149 101   102 95  
High  82 118   122 124   87 102  
 
 
 
   
 
   
 
  
H4K12ac 388   0.008 470   0.033 371   0.060 
Low  118 105   158 110   107 96  
High  66 99   101 101   74 94  
             
H4K16ac 
(Millipore) 
545   0.162 701   0.027 513   <0.001 
Low  150 137   186 172   150 106  
High  123 135   204 139   109 148  
             
H3K4me2 387   0.020 477   0.143 375   0.012 
Low  113 99   148 110   105 89  
High  74 101   114 105   76 105  
             
H4K20me3 374   0.439 450   <0.001 364   0.056 
Low  31 33   56 21   32 22  
High  144 166   191 182   144 166  
             
H3K9me3 442   0.083 523   0.143 475   0.004 
Low  116 114   146 133   145 107  
High  92 120   140 104   100 123  
             
H4R3me2 441   0.038 541   0.237 428   0.001 
Low  144 123   171 146   142 108  
High  78 96   13 111   74 104  
 
            
H3K56ac 514   0.002 570   0.088 433   0.125 
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Low  148 123   168 129   126 100  
High  101 142   138 135   103 104  
 
            
MORF 405   0.059 480   0.012 419   0.001 
Low  87 124   145 98   137 91  
High  96 98   116 121   86 105  
 
            
hMOF 553   <0.001 708   0.006 524   0.420 
Low  176 130   239 163   155 149  
High  99 148   152 154   115 105  
 
            
CBP 545   0.467     499   0.236 
Low  155 153       144 129  
High  121 116       111 115  
 
            
SUV39H1 361   0.386 409   0.261 364   0.042 
Low  91 104   113 105   110 83  
High  74 92   106 85   81 90  
 
            
HDAC1  411   0.486 499   0.236     
Low  107 111   144 111      
High  96 97   129 115      
             
HDAC2  451   0.137 544   0.509 480   0.120 
Low  89 109   133 102   107 95  
High  128 125   174 135   131 147  
 
            
SIRT1 445   0.309 543   0.055 475   0.002 
Low  119 146   202 132   129 90  
High  86 94   111 98   115 141  
 
            
DBC1 526   0.110 591   0.042 286   0.277 
Low  141 128   175 127   75 67  
High  120 137   146 143   70 74  
             
p53k120ac (N) 396   0.116 463   <0.001 366   0.015 
Low  110 116   167 97   119 82  
High  92 78   85 114   78 87  
             
p53k120ac (C) 396   0.383 463   0.009 366   0.303 
Low  98 98   141 94   102 82  
High  104 96   111 117   95 87  
             
p53k373ac 417   0.018 512   0.003 411   0.178 
Low  116 93   160 102   114 95  
High  93 115   121 129   100 102  
             
p53k386ac 470   0.008 562   0.531 492   0.022 
Low  128 110   164 125   148 114  
High  98 134   155 118   108 122  
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N, nuclear; C, cytoplasmic; LD, low detection; HD, high detection; all p values 
are calculated by X2 test. Bonferroni correction test was applied and reduced the 
(p) value of significance to 0.003. 
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4.2.2 Tumour Outcome in relation to p53 Acetylation Marks and 
their Modulators 
As p53 acetylation was found to be indispensable for the p53 proapoptotic 
function (Tang et al., 2008), we explored the impact of the levels of p53 
acetylation marks and their acetylation modulators with regards to tumour 
outcome and patient survival.  
 
As shown in the Kaplan Meier survival curves in Figure 4.8A and B, tumours 
showing high levels of p53K120ac (Nuclear and cytoplasmic) were slightly better 
than those showing low levels in relationship to BCSS and DFS. However, the p 
values were not statistically significant.  
 
 With regard to p53K373ac, high levels were found associated with better 
breast cancer specific survival (BCSS) (p=0.081). Where 36 out of 270 (13%) 
patients in p53K373ac high-level group died from breast cancer; while 54 out of 
287 (19%) in p53K373ac low-level group died from breast cancer. High levels of 
p53K373ac also correlated with longer disease free survival (DFS) (p=0.046). 35 
patients out of 270 (13%) in the high p53K373ac group presented with recurring 
of breast cancer; while 54 out of 287 (19%) in low p53K373ac presented with 
recurring breast cancer (Fig. 4.8C). 
 
 High levels of p53K386ac (Fig. 4.8D) correlated with better BCSS 
(p=0.045); where, 30 out of 299 (10%) patients in the high p53K386ac group died 
from breast cancer, while 48 out of 309 (15.5%) in the low p53K386ac group died 
from breast cancer. Regarding DFS, high levels of p53K386ac were also 
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associated with a favourable outcome (p=0.052); where 30 out of 299 (10%) 
patients in the high p53K386ac group had a recurrence of breast cancer; while, 47 
out of 308 (15%) in low p53K373ac had a recurrence of breast cancer. 
 
 As TIP60 and CBP have been previously reported to acetylate p53 (Tang 
et al., 2006a, Li et al., 2009c, Meek and Anderson, 2009) the impact of both these 
markers and HDAC1 levels were also explored in relation to patient survival. 
 
 Analysis revealed trend for high levels of both TIP60 and HDAC1 with 
both BCSS and DFS (Fig. 4.9A and B). However the p values did not reach the 
values of significance for TIP60 (p=0.19 and p=0.217 respectively) or HDAC1 
(p=0.091 and p=0.071 respectively). Unexpectedly, we found that CBP detection 
levels have no impact on patient survival as shown in Figure 4.9C Multivariate 
analysis using the Cox proportional regression model (Cox, 1972) showed that the 
prognostic effect of  p53 acetylation marks and their modulators on survival was 
dependent on other key prognostic factors in breast cancer including histological 
grade, tumour size, tumour stage and lymph node stage. 
 
 As a number of significant statistical relationships have been noted 
between p53 acetylation marks and their modulators, we gathered data from those 
marks together to perform a cluster analysis. Further evaluation of association 
between the revealed cluster classes in relationship to tumour grades and patient 
survival was also explored. 
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Figure 4.8: Tumour outcome in Breast Cancer TMA stained for p53 Acetylation Marks and their Acetylation Modulators 
 
Kaplan-Meier curves for the levels of p53 acetylation marks (A, B, C, D) in breast cancer TMA with respect to breast cancer specific survival 
(BCSS) and disease free survival (DFS) The green and blue colours represent in order the high and low detection groups for each marker, the Y 
axis represents survival probability, X axis represents time relapse in months.   
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Figure 4.9: Tumour outcome in Breast Cancer TMA stained for p53 Acetylation Modulators 
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Kaplan-Meier curves for the levels of p53 acetylation modulators (A, B, C) in 
breast cancer TMA with respect to breast cancer specific survival (BCSS) and 
disease free survival (DFS) The green and blue colours represent in order the high 
and low detection groups for each marker, the Y axis represents survival 
probability, X axis represents time relapse in months.  
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Table 4:11: Cox proportional Hazard Model Showing Hazard Ratios for 
BCSS and DFS conferred by p53K373ac and p53K386ac and 
clinicopathological variables 
A 
BCSS 
Variable Hazard Ratio 95% CI p 
     
Tumour size (cm) 0.640 0.386 to 1.101 0.110 
    
Tumour stage 1.450 1.633 to 3.073 <0.001 
    
Grade 2.233 1.533 to 3.758 <0.001 
    
p53K373ac 0.511 0.836 to 2.435 0.192 
    
p53K386ac 0.520 0.711 to 2.083 0.474 
 
B 
DFS 
Variable Hazard Ratio 95% CI p 
     
Tumour size (cm) 0.640 0.373 to 1.092 0.101 
    
Tumour stage 1.450 1.654 to 3.174 <0.001 
    
Grade 2.233 1.537 to 3.800  <0.001 
    
p53K373ac  0.514 0.881 to 2.566 0.134 
    
p53K386ac 0.518 0.698 to 2.030 0.522 
 
A, p53K373ac and p53K386ac are dependent of other prognostic factors in breast 
cancer with respect to breast cancer specific survival (BCSS); (B), and disease 
free survival (DFS); CI, confidence interval ; p, X2 p value. 
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4.2.3 Cluster analysis of p53 PTMs and their regulators  
p53K373ac, CBP, SIRT1 and SUV39H1 cluster analysis 
Cluster analysis and validity indices tests were performed by Dr Daniel Soria, 
School of Computer Science, University of Nottingham. At first, the cluster 
analysis was applied to p53K373ac, CBP, SIRT1 and SUV39H1. CBP is 
responsible for p53 acetylation at K373 in association with p300 (Zhao et al., 
2006), SIRT1 has been described to deacetylate p53 (Hasegawa and Yoshikawa, 
2008) and SUV39H1 which has been described in a complex with p53 is capable 
of H3K9 methylation (Chen et al., 2010). The cluster analysis by K-means 
yielded 3 clusters (from 292 patients). The number of the clusters in the K-means 
algorithm was consistent in 3 (Calinski, Hartingan and Scott) out of the 6 K-
means validity indices tests (Fig. 4.6A and B). In addition, 4 clusters were 
obtained from the PAM algorithm; two of them were merged yielding 3 clusters 
(Fig. 4.7). Three common clusters (containing 267 patients) were obtained after 
using data from both K-means and PAM algorithm to assign patients to the same 
clusters; where 267 cases were clustered into three common cluster groups, only 
25 cases did not match (Fig. 4.10A). Analysis of the obtained common clusters 
revealed a remarkable association between cluster 2 (which is characterized by 
high levels of both p53K373ac and SUV39H1) and better BCSS (as illustrated in 
Fig. 4.10C) in a significant p value (p=0.045); Conversely, The cluster 1 and 3 
(which are characterized by low levels of SUV39h1) correlated with poorer 
patient survival and showed more tendencies toward being among higher grade 
tumours (Fig.4.10B). CBP and SIRT1 levels showed no significant impact on the 
clustering. However, the role of both SUV39H1 and p53K373ac in segregating 
clusters was obvious. The results indicate a potentially role for p53K373ac as a 
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marker (in conjunction with the H4K16ac, hMOF and SUV39H1) for better 
tumour outcome and patient survival.  
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Figure 4.10: K-means Clustering Algorithm and Validity Indices tests for Breast Cancer Tumour TMA with Regard to p53K373ac, 
CBP, SIRT1 and SUV39H1 Detection Levels. 
 
A, Boxplots for p53K373ac, CBP, SIRT1 and SUV39H1 grouped by K-means algorithm; B, Three out of six validity indices tests indicate 3 
clusters. 
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Figure 4.11: PAM Clustering Algorithm for Breast Cancer Tumour TMA 
with Regards to p53K373ac, CBP, SIRT1 and SUV39H1 Detection Levels. 
 
Boxplots for p53K373ac, CBP, SIRT1 and SUV39H1 grouped by PAM algorithm
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Figure 4.12: Clustering of (p53K373, CBP, SIRT1 and SUV39H1), Correlation with Tumour Grade and Tumour Outcome. 
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A, Boxplots for p53K373ac, CBP, SIRT1 and SUV39H1 grouped by common 
clusters, cluster 2 is characterized by high levels of both p53K373ac and 
SUV39H1 in comparison to the other two clusters; B, cluster 1 and 3 correlate 
with the ominous grade III; C, unadjusted Kaplan-Meier curves for p53K373ac, 
CBP, SIRT1 and SUV39H1 cluster groups are showing that cluster 2 correlates 
with favourable patient outcome. 
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p53K386ac, hMOF and SIRT1 cluster analysis 
hMOF and SIRT1 have been previously described in regulating acetylation of p53 
(Rea et al., 2007, Cheng et al., 2003). In addition, according to our results, both 
hMOF and p53K386ac correlated with favourable tumour outcome and patient 
survival. Therefore we decided to group the three biomarkers together in a cluster 
analysis. Initially, the cluster analysis was applied to 507 cases (valid cores for the 
three marks together) by both K-means and PAM algorithms; which yielded three 
clusters. However, the consensus was quite poor; the 3 groups obtained by K-
means were quite different from the 3 groups obtained by PAM. In addition, the 
QXPEHURI ³1&´ (not common/not matched cases) was quite high. So the cases 
were re-clustered into 4 groups (Fig. 4.13A, 4.14A), specially as 2 validity indices 
for PAM algorithm suggested 4 as the best number of clusters (Fig 4.14B). 
Reclustering showed an improved consensus where 365 cases were matching in 
the two algorithm; only 142 NC. 
 
  Among the obtained four common clusters (Fig. 4.15A), cluster 1 and 2 
which are characterized by high levels of p53K386ac and high or moderate levels 
of hMOF were (as illustrated in Fig. 4.15B) correlated with better patient survival 
at statistically significant value (p=0.026). Conversely, cluster 3 and 4 correlated 
with poor patient survival. These clusters are characterized by low levels of both 
p53K386ac and hMOF (Cluster 3) or very low levels of SIRT1 (cluster 4). These 
results may suggest a potentially role for p53K386ac as a biomarker (in 
conjunction with the H4K16ac, hMOF, SUV39H1) for better tumour outcome 
and patient survival.  
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 Figure 4.13: K-means Clustering Algorithm and Validity Indices tests for Breast Cancer Tumour TMA in Regards to p53K386ac, 
hMOF and SIRT1 Detection Levels. 
 
 
A, Boxplots for p53K386ac, hMOF and SIRT1 grouped by K-means algorithm; B, Three out of six validity indices tests indicate 3 clusters. 
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Figure 4.14: PAM Clustering Algorithm and Validity Indices tests for Breast Cancer Tumour TMA in Regards to p53K386ac, hMOF 
and SIRT1 Detection Levels. 
 
A, Boxplots for p53K386ac, hMOF and SIRT1 grouped by PAM algorithm; B, Two out of six validity indices tests indicate 4 clusters. 
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Figure 4.15: Clustering of (p53K386ac, hMOF and SIRT1) and Tumour Outcome 
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A, Boxplots for p53K386ac, hMOF and SIRT1 grouped by common clusters, 
cluster 1 and 2 are characterized by high levels of p53K386ac and high or 
moderate levels of hMOF. Conversely, cluster 3 and 4 are characterized by low 
levels of both p53K386ac and hMOF (Cluster 3) or very low levels of SIRT1 
(cluster 4); B, unadjusted Kaplan Meier curves for p53K3386ac, hMOF and 
SIRT1 cluster groups showing that cluster 1 and 2 correlate with favourable 
patient survival. 
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Summary of Findings:  p53 acetylation marka and their modulators in 
Breast tumours 
In this Chapter we examined global levels of p53 acetylation marks and protein s 
that regulate p53 acetylation in breast tumour tissue. The data indicated that low 
levels of p53 acetylation at K120, K373 and K386 tended to correlate with the 
poor tumour prognostic HER2 and basal tumour subtypes. Conversely, high 
levels of p53 acetylation at K373 and K386 correlated with favourable tumour 
grade, good NPI and positive hormonal receptors status including estrogen, 
progesterone and androgen receptors. In addition, high levels of p53 acetylation at 
K373 and K386 correlated with luminal tumour subtype specific markers such as 
CK7/8 and CK9 and inversely correlated with CK5/6, the basal subtype specific 
marker. Taken together, these results are consistent with the hypothesis that active 
i.e. acetylated p53 correlated with good tumour outcome related variables. 
  
 p53 acetylation markers also positively correlated with histone H2A 
variants and histone PTMs. High levels of p53K373ac and K386ac  were 
correlated with the good tumour outcome markers H3K18ac, H4K16ac and 
H4K20me3, which previously reported to be lost in human cancer (Fraga et al., 
2005) and high grade breast tumours (Elsheikh et al., 2009). Moreover, p53 
acetylation marks positively correlated with the DNA damage response mark 
H3K56ac (Masumoto et al., 2005, Vempati et al., 2010, Yuan et al., 2009). 
 
 We also determined the levels of the histone acetyltransferases TIP60 and 
CBP, which previously reported to acetylate p53 at K120, K373 and K386 (Tang 
et al., 2006b, Meek and Anderson, 2009); and the histone deacetylase HDAC1 
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which reported to deacetylate p53 at K373 (Meek and Anderson, 2009). Our data 
identified a correlation between low levels of TIP60, CBP and HDAC1 with 
HER2 and basal tumours, the poor prognostic breast cancer.  We also identified 
positive correlation between high levels of CBP and advanced patient age.  In 
addition, CBP and HDAC1 positively correlated with high levels of estrogen 
receptors, whereas TIP60 correlated with positive androgen receptor expression. 
 
 Consistent with the histone variant TMA data, high  levels of TIP60 
correlated with high levels of acetylated H2A.Z and the histone acetyltransferase 
hMOF, CBP correlated with high levels of histone H2A variants, the mH2A and 
H2A.Z, and high levels of H3K9ac and H4K20me3, the good outcome markers in 
human tumours.  
 
 Kaplan Meier survival curves in Figure 4.8 identified high levels of p53 
acetylation at K373 and K386 as markers for favourable patient survival. 
However, Cox regression test revealed that the prognostic effects of both 
p53K373ac and p53K386ac levels were dependent on key prognostic factors in 
breast cancer. With regard to TIP60 and HDAC1, high levels showed a trend 
towards favourable patient survival. Although they have been found not 
statistically significant (Fig. 4.9) we included those markers and HDAC1 in 
clustering analysis to identify their trend in breast cancer tumours. Our data 
identified that tumours characterized by high levels of p53K373ac, p53K386ac 
and SUV39H1 to correlate with favourable tumour grade longer patient survival.   
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 Collectively, according to our results in this chapter, acetylation of p53 
found to be correlated with better tumour outcome factors and longer patient 
survival, with a possible future application in medical practice, especially if 
explored in combination with SUV39H1. 
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5 THE EFFECT OF THE HAT 
INHIBITORs ON HISTONE AND p53 
PTMs AND MCF-7 CELL CYCLE 
PROLIFERATION
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In Chapters three and four we examined the levels of histone and p53 PTMs and 
their regulators in breast cancer TMAs by IHC staining. This revealed an 
association of several of these markers with patient survival, indicating that they 
may be useful individually or in combination as prognostic indicators. 
Interestingly, global loss of H4K16ac and H4K20me3 have been reported as 
hallmarks of human cancer, and loss of these PTMs have been detected in tumour 
suppressor genes (Fraga et al., 2005) and higher grade breast tumours (Elsheikh et 
al., 2009). Although it is not yet clear if histone/p53 PTMs are causal factors or a 
consequence of other changes driving tumourgenesis, they offer an attractive 
therapeutic target as they are amenable to reversal by small molecules. In the 
forthcoming chapter, I will present our results showing the influence of natural 
HAT inhibitor (HATi) treatment on these biomarkers in a cell model. We 
explored the effects of curcumin and garcinol HATi on histone and p53 PTMs 
levels and their effects on cell cycle progression and proliferation of MCF-7 cells.  
5.1.1 HAT inhibitors Alter Histone H3 and H4 Acetylation 
MCF-7 cells were treated with the HAT inhibitors, curcumin and garcinol for 24 
hrs as described in section 1.2.12. Curcumin is a natural HATi compound 
previously reported to inhibit p300 and CBP acetyltransferase activity 
(Balasubramanyam et al., 2004b) and to induce growth arrest of several cell lines 
with a potential chemotherapeutic potential (Chauhan, 2002, O'Sullivan-Coyne et 
al., 2009, Park et al., 2006, Sahu et al., 2009, Weir et al., 2007). Garcinol is 
another natural HATi compound reported to be highly cytotoxic to HeLa cells and 
has an inhibitory effect on both PCAF and p300 (Balasubramanyam et al., 2003). 
These compounds were used at a concentration of 10 and 20µM as preliminary 
range finding experiments indicated cell toxicity effects in excess of 30 M.  Cells 
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were then fixed and stained with antibodies specific for different histone PTMs 
and analysed by fluorescence microscopy using a Zeiss LSM510 confocal 
microscope as described in Materials and Methods (section 2.4.6).  In addition, 
changes in histone PTMs were monitored by preparation of cell free extracts and 
western blotting as described in Section 2.4.5. A list of antibodies and dilutions 
used are detailed in Appendix 1. As shown in Figure 5.1A, curcumin and garcinol 
treatment caused a decrease in bulk acetylation of histones H3 and H4 as 
determined by pan-acetyl H3 and pan-acetyl H4 antibodies. Specifically, 10 µM 
curcumin treatments caused greater reduction in histone H3 and H4 acetylation 
than 20 µM treatment; suggesting differential and dose-dependent effects of 
HATi on histone modifications in vivo (this experiment was verified by two 
researchers). Concerning garcinol, the decrease in acetylation was found 
proportional with the concentration of treatment (Fig. 5.1A).  
 
 Looking at specific histone acetylation marks, H3K18ac, an indicator of 
actively transcribed genes and DNA synthesis, (Horwitz et al., 2008) was 
markedly decreased by garcinol as measured by both immunoflourescence and 
western blotting (Fig. 5.1B and C). However, no significant change in H3K18ac 
was observed after curcumin treatment (Fig. 5.1B and C). Interestingly, global 
levels of H4K16ac, which barely detectable in MCF-7 cells, were increased after 
both curcumin and garcinol treatment (Fig. 5.1B and C). Conversely, no 
detectable change in H3K9ac detection levels was observed after HATi treatment 
(Fig. 5.1B and C). We also noted that garcinol treatment caused a marked 
increase in the H3K56ac, the CBP/p300 dependent histone PTM that has been 
reported to be associated with DNA damage response (Das et al., 2009). This 
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result suggests a possible garcinol-induced DNA damage response in MCF-7 cells 
(Fig. 5.1C). Actin was used as a loading control (Fig. 5.1C). For further 
confirmation, we quantified garcinol-induced H4K16ac by flow cytometry 
analysis as described in Materials and Methods (section 2.6.8). After garcinol 
treatment, MCF-7 cell were fixed, permeabilised and probed with anti-H4K16ac 
antibody, followed by evaluation of MCF-7 cells for H4K16ac. The number of 
cells showing high levels of H4K16ac increased upon garcinol treatment (Fig. 
5.1D). MRC-5 cells were also treated with 20µM curcumin or garcinol and 10µM 
isogarcinol or LTK14 for 24 hrs (Fig. 5.2). Isogarcinol and LTK14 are semi-
synthetic products of intermolecular cyclisation of garcinol reported to have 
potent p300 inhibitory effect (Mantelingu et al., 2007b). MRC-5 treated with 
HATi also showed increased H4K16ac and H3K56ac levels after garcinol, 
isogarcinol and LTK14 treatment. However, in contrast to MCF-7 cells, MRC-5 
cells showed a decrease in H4K16ac after curcumin and increased H3K18ac after 
garcinol treatment. Taken together, these results indicate that MCF-7 cells differ 
from the non-transformed MRC-5 cell line with regard to changes in global 
histone acetylation pattern after HATi treatment. In addition, in the MCF-7, 
garcinol can induce differential changes in the levels of histone PTMs; with 
potential impact on basic cellular function and behaviour. While the CBP-
dependent acetylation mark H3K18ac was reduced, another target for this HAT 
i.e. H3K56ac appeared to be increased. This might suggest pleiotropic effects of 
garcinol, outside of its HAT inhibitory activity. Alternatively it may indicate that 
while H3K18 acetylation is regulated by CBP/p300, other HATs that are 
unaffected by garcinol can acetylate H3K56.  
  
Chapter five: HATi induces histone and p53 PTMs 
257  
 
Figure 5.1: Differential Effects of HATi treatment on Histone H3 and H4 Acetylation. 
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A, Immunofluorescent staining for MCF-7 cells treated with vehicle (Ethanol), 
curcumin or garcinol in the concentration of 10 and 20 µM for 24 hrs. Cells were 
stained with pan acetyl H3 and H4 following treatment; B, MCF-7 cells were also 
evaluated for H3K18ac, H4K16ac and H3K9ac levels; C, Western Blotting for 
histone PTMs levels in MCF-7 cells treated with vehicle (Ethanol), curcumin and 
garcinol in the same concentration used in (A) and (B). Actin was used as a 
loading control; D, number of MCF-7 cells expressing high levels of H4K16ac 
after treatment with Vehicle (Ethanol) or Garcinol (20µM) for 24 hours. The total 
cell count was 4,000 cells.  
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Figure 5.2: Histone PTMs in MRC-5 Cells after HATi Treatment 
 
Detection of histone PTMs by immunoflourescence staining of MRC-5 cells, the 
cells were treated for 24 hrs with vehicle (Ethanol), 20 µM curcumin or garcinol 
and semi-synthetic derivatives of garcinol, the isogarcinol or LTK14 in a 
concentration of 10 µM. 
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5.1.2  HATi treatment Alters Histone H3 and H4 Methylation 
In addition to the effects on acetylation, we explored the effect of curcumin and 
garcinol treatment on histone methylation. H3K9me3, the repressed gene mark 
(Groner et al., 2010) was not altered after the treatment with curcumin or garcinol 
(Fig 5.3A and B). However, its regulator the methyltransferase SUV39H1 (Rea et 
al., 2000) which correlated with better breast cancer tumour outcome (as 
described in Chapter 3 and 4) was found to show increased expression after 
curcumin treatment (Fig 5.3B). This may be consistent with the anticarcinogenic 
properties of curcumin (Ravindran et al., 2009) ), and is of interest with regard to 
our observation that low expression levels of SUV39H1 are associated with 
higher grade tumours.  
 
 H4K20me3 levels are low or absent in cancer cell lines (Fraga et al., 2005) 
and to be a good outcome marker in breast and lung cancer (Elsheikh et al., 2009, 
Van Den Broeck et al., 2008). Remarkably, H4K20me3 was strongly induced by 
garcinol treatment in as shown by both immunoflourescence and western blotting 
(Fig. 5.3A and B). Consistent results for H3K9me3 and H4K20me3 in MRC-5 
cells are shown in Figure 5.2. Thus we conclude that garcinol has unexpected 
effects on the histone methylation status of H4K20, another important marker in 
cancer cells. 
 
Whereas monomethylation of H4K20 is catalysed by several 
methyltransferases such as SET8 (Fang et al., 2002) and PR-Set7 (Nishioka et al., 
2002b), di and tri-methylation appear to be catalysed by SUV420H1/H2 
respectively (Schotta et al., 2004, Schotta et al., 2008). As it seemed unlikely that 
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garcinol could act both as a direct inhibitor of selected acetyltransferase enzymes, 
and at the same time stimulate methyltransferase activity, we decided to assess the 
effects of garcinol on expression levels of chromatin modifying proteins. We 
therefore assessed the levels of the H4K20me3 methyltransferase SUV420H1 and 
SUV420H2 (Souza et al., 2009) in MCF-7 cells, before and after treatment. The 
antibody used is able to detect both SUV420H1 and H2 isoforms. As shown in 
Figure 5.3 SUV420 expression levels were markedly increased by garcinol, but 
not curcumin, as detected by western blots and flow cytometry analysis (Fig. 5.3C 
and D). After garcinol treatment, MCF-7 cell were fixed; permeabilised; probed 
with anti-H4K20me3 or SUV420H2 antibodies and followed by evaluation of 
MCF-7 cells for both biomarkers. The number of cells high for H4K20me3 and 
its regulator SUV420H2 were markedly increased by several fold upon garcinol 
treatment (Fig. 5.3D). 
 
These results indicate that garcinol treatment of MCF-7 cells invokes in a 
strong induction of H4K20me3 and a concomitant increase in the 
methyltransferases SUV420H1 and SUV420H2. To determine whether these 
enzymes are responsible for the observed increase in K20 trimethylation, an 
siRNA knockdown experiment was performed in combination with garcinol 
treatment. The experiment was carried out with my colleague Dr HM Collins, 
who has previous experience in siRNA techniques. MCF-7 cells were transfected 
with siSUV420H2 or control scrambled siVector For 24 hours. Following that, 
cells were treated with garcinol for a further 24 hrs. As shown in Figure 5.3E 
knockdown of SUV420H2 but not the control siRNA prevented the induction of 
H4K20 trimethylation by garcinol. This indicates that increased expression of 
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SUV420H2 in response to garcinol is likely to be responsible for the observed 
increase in H4K20 trimethylation induced by this agent. As H4K20 methylation 
has been previously observed in DNA damage response (Greeson et al., 2008, 
Hsiao and Mizzen, 2010, Sakaguchi and Steward, 2007, Sanders et al., 2004), our 
results suggest that SUV420 enzymes may be upregulated following DNA 
damage stress. 
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Figure 5.3: HAT inhibitors Treatment Alters Histone Methylation. 
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A and B, MCF-7 cells were treated with vehicle or 10, 20 µM curcumin or 
garcinol for 24 hrs. Cells were stained for methylation marks and assessed by 
immunoflourescence (A) and Western blotting (B), histone 3 (H3) levels were 
used as loading control; C, the number of MCF-7 cells expressing high levels of 
H4K20me3 and SUV240H1/2 after treatment with vehicle or 20µM garcinol  for 
24 hrs was assessed by FACS. The total cell count was 4,000 cells; D, siRNA of 
MCF-7 cells with scrambled siVector (siCTRL) or siSUV420H2, detection of 
H4K20me3 by western blotting following 24 hrs of garcinol treatment.   
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5.1.3 Effects of HATi on HATs and HDACs Expression  
To gain insight into the possible mechanistic role of garcinol in upregulation of 
H4K16 and H3K56 acetylation, we examined the expression levels of candidate 
factors responsible for acetylation and deacetylation of these residues. The 
commercial antibodies used to detect HATs, HDACs and methyltransferases are 
described in Appendix 1.  
 
 hMOF which acetylates H4 at K16 both in vivo and in vitro (Taipale et al., 
2005, Thomas et al., 2008) (Taipale et al., 2005, Thomas et al., 2008)was our first 
target. We did not observe any significant change in levels of hMOF present in 
MCF-7 cells after garcinol treatment as detected by western blots (Fig. 5.6B). 
Although the quality of hMOF immunodetection in breast cancer TMAs was 
acceptable (Fig 3.2D and E), we were also unable to assess changes in hMOF 
levels in cells due to poor quality of immunoflourescence staining for hMOF. 
However, TIP60, which was previously reported to acetylate H4K16 in vivo 
(Doyon et al., 2006) was found to be expressed at higher levels following garcinol 
treatment (Fig 5.6A and B); suggesting that the increase in H4K16 acetylation 
could be mediated by TIP60. There was insufficient time to test whether this 
increase could be prevented by siRNA knockdown of TIP60, although these 
experiments are currently in progress in the lab (Dr HM Collins). As TIP60 is 
known to be induced by DNA damage (Col et al., 2005), this is consistent with 
the notion that garcinol may cause DNA damage in MCF-7 cells. In contrast, 
garcinol did not alter the expression levels of SUV39H1 or SIRT1.  
 
Chapter five: HATi induces histone and p53 PTMs 
266   
 Treatment of MCF-7 cells with curcumin induced a strong increase in 
expression of the histone methyltransferase SUV39H1. However, this 
upregulation was not reflected in increased H3K9 trimethylation as might be 
expected (Fig 5.3A and B). Consistent data was observed for H3K9me3 in MRC-
5 cells following garcinol treatment (Fig 5.2). However as outlined in Chapter 3, 
SUV39H1 activity is negatively regulated by acetylation, and it is therefore 
possible that upregulation of HATs in response to garcinol induced DNA damage 
target K266 acetylation in SUV39H1. We were unable to confirm this as a 
specific antibody for SUV39H1 acetylation was not available. 
  
We also noted that garcinol and curcumin can induce changes in the 
cellular levels of HDACs. HDAC1 expression appeared to be suppressed by 
HATi treatments, whereas HDAC2 levels increased and SIRT1 was unaffected 
(Fi6 5.6A and B). However, these changes remain to be confirmed by western 
blots. We also noted what appeared to be enhanced expression of CBP in MCF-7 
and MRC-5 cells; however, as some of the staining observed was cytoplasmic we 
were unable to conclude whether this was a bona fide increase in CBP levels and 
subcellular localisation or an artefact. Thus results for CBP were largely 
inconclusive. 
 
 These results indicate that changes in histone PTMs induced by garcinol 
treatment are caused by changes in the expression levels of chromatin regulators, 
especially those that are implicated in the DNA damage response. Whether these 
changes are due to increased transcription, increased stability or changes in 
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activity remain to be established. These data emphasise the powerful effects 
natural products such as garcinol may have in the biology of cancer cells.  
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Figure 5.4: HAT inhibitors Induce Alterations in the Levels of Histone 
Acetylation Regulators. 
 
A, Immunoflourescence for the histone acetyltransferase TIP60; the histone 
deacetylases HDAC1, HDAC2 following treatment with vehicle (Ethanol), 
curcumin or garcinol in the concentration of 10 and 20 µM for 24 hrs; B, WB for 
hMOF, TIP60 and SIRT1 levels in MCF-7 cells following HATi treatment. 
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5.1.4 Garcinol induces DNA Damage in vivo 
As evidence was emerging for the upregulation of DNA damage markers after 
exposure to garcinol, we examined a number of DNA damage markers in MCF-7 
cells. MCF-7 cells were treated with 10, 20 µM curcumin or garcinol; 5, 10 µM 
isogarcinol or LTK14 (Mantelingu et al., 2007a) (Semi-synthetic derivatives of 
garcinol kindly provided by Prof. Tapas Kundu) and stained for ƣH2A.X 
(Yoshida et al., 2003), phospho BRCA and phospho ATM (Gatei et al., 2000) as 
described in Material and Methods (Section 2.4.5 and 2.4.6). As shown in Figure 
5.5A, treatment of MCF-7 cells with 10µM of curcumin, garcinol or the garcinol 
UHODWHG FRPSRXQG /7. LQGXFHG '1$ GDPDJH IRFL DV LQGLFDWHG E\ ȖH2A.X 
staining. As seen in the FigurHȖ+$;SRVLWLYHVLWHVDUHPDUNHGO\REVHUYHGLQ
the nuclei of MCF-7 cells. In comparison, to the control sample (left) that was 
WUHDWHGZLWKWKHYHKLFOH'062RQO\VLJQDOVIRUȖ+$;ZHUHKDUGO\GHWHFWHG
This result was confirmed by western blots showLQJ WKDW Ȗ+$; LV PDUNHGO\
upregulated following curcumin, garcinol and isogarcinol treatment. Similarly, 
other DNA damage markers, notably phospho BRCA and phospho ATM, were 
also elevated after isogarcinol treatment (Fig 5.5B). As shown later, isogarcinol is 
more potent and more cytotoxic than garcinol, and therefore increased ability to 
damage DNA in cells. The mechanism of DNA damage remains to be 
determined, whether it is due to direct genotoxic effects, or due to the induction of 
replication stress by indirect means. e.g. by blocking HAT activity required 
during DNA synthesis in S phase. 
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 Figure 5.5: HATi Induces High Levels of DNA Damage Response Markers. 
 
Detection of DNA damage marks in MCF-7 cells treated with vehicle (DMSO) or 
HATi for 24 hours, followed by A, immunoflourescence staining for ƣ+$; and 
B, Western Blot for ƣ+$;DQG phospho BRCA/ATM levels.  
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5.1.5 HATi Alters p53 Function 
Upon cellular stress such as radiation, mitotic stress, chemical insults and DNA 
damage p53 is activated with multiple possible consequences including apoptosis, 
cell cycle arrest and senescence (Jackson et al., 2010). According to our results 
presented in chapter 4, hyperacetylation of p53 at K373 and K386 correlated with 
favourable prognosis and patient survival in breast cancer. In order to explore the 
possibility that HATi compounds alter p53 acetylation status, MCF-7 cells were 
treated with either curcumin or garcinol as described previously; followed by 
detection of p53 and p53 PTMs using commercially available antibodies 
(antibodies used are detailed in appendix 1).  
Curcumin Alters p53 Expression and Acetylation 
Treatment of MCF-7 cells with 10 and 20 µM curcumin caused an increase in p53 
(Santa Cruz, DO1) detection levels in both immunoflourescence staining and 
western blotting (Fig 5.6A and B). This indicated that curcumin treatment induces 
some sort of cellular stress in MCF-7 cells. Acetylation at K120 was found 
markedly increased whereas acetylation of p53 at K373 and K386 was markedly 
diminished. These observations are consistent with the slightly elevated level of 
TIP60 after curcumin treatment which may increase K120 acetylation (Fig 5.6A 
and B). In contrast, expression analysis showed that the higher concentration of 
curcumin resulted in lower CBP levels, and thus correlates with the reduced levels 
of K373 and K386 acetylation (Fig 5.6A and B). Thus curcumin treatment of cells 
induces p53 expression and alters expression of HATs that regulate p53.  
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Figure 5.6: Curcumin Alters p53 Acetylation. 
 
MCF-7 cells were treated with vehicle (Ethanol) or curcumin (10 and 20 µM) for 24 hrs. A, Immunoflourescence staining; B, Western Blot, actin 
was used as loading control. 
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Garcinol Alters p53 Expression and Acetylation 
In order to discover whether garcinol treatment could also have any effect on the 
p53 PTM profile, MCF-7 cells were treated with 10 and 20 µM garcinol as 
previously described. Garcinol treatment was found to cause an increase in p53 
detection levels in both immunoflourescence staining and western blot 
experiments. The level of p53 induced was even higher than for curcumin. 
Concerning p53 post translational acetylation at K120, K373/382 and K386; 
treatment with garcinol was found to upregulate K120ac which is consistent with 
the observed increase in TIP60 (Fig.5.7A and B). Remarkably p53K120ac was 
detected in the cytoplasm (Fig 5.7A); which is consistent with its positive 
immunoreactivity in breast cancer TMA described in Chapter 4. This result 
suggests that garcinol treatment can also affect the subcellular localisation of p53, 
which has been reported to have cytoplasmic functions, relocalising to 
mitochondria during apoptosis (Galluzzi et al., 2008). However we did not 
confirm this by other methods, such as subcellular fractionation to separate 
nuclear and cytoplasmic compartments.  
 
  In contrast to curcumin, acetylation of p53 at K373 and K386 also 
appeared to be induced; curiously staining for CBP suggested a relocalisation of 
CBP to the cytoplasm (Fig 5.7A and B). Although other studies have detected 
cytoplasmic localisation of CBP under some conditions (Bellodi et al., 2006, Shi 
et al., 2009) these results would need to be confirmed by other antibodies 
targeting CBP.  
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 For further confirmation, p53 acetylation levels were quantified by flow 
cytometry as previously described in Materials and Methods (Section 2.4.7). 
MCF-7 cells were treated with either vehicle (Ethanol) or 20 µM garcinol for 24 
hrs. Levels of p53K120ac, p53K386ac and TIP60 were measured in each cell by 
Fluorescence Activated Cell sorting (FACS) machine. The results revealed an 
elevation in the number of cells showing high level of both p53K120ac and 
p53K386ac by more than 4 fold; which, was consistent with an increase by 50% 
in TIP60 (Fig. 5.8A). As both anti p53k120ac and anti BrdU antibodies were 
monoclonal mouse antibodies, I was unable to assess the changes in cell cycle 
profile in relationship to p53K120ac following garcinol treatment. 
 
 In order to validate the specificity of the used antibodies used for specific 
p53 PTMs, transfection by pcDNA mutant p53 at K372-3R, K381-2R, K386R 
and 6KR which contain mutated lysine residues 370, 372, 373, 381, 382, and 
386 to arginine residues (Rodriguez et al., 2000) into SaOs2 cells, a p53 null cell 
line. The vectors were kindly provided by Prof. Ronald Hay. Figure 5.8B shows 
the immunodetection of p53 and p53 acetylation forms by this set of anti p53 
antibodies. The results revealed that DO1 antibody was able to detect both wild 
type and all mutant forms of p53. The antibody against p53K373/ 382 was able to 
detect both wild type p53 and p53 mutant at K386R. Conversely, the antibody 
failed to detect mutant p53 at 6KR or K381-2R. In addition, the results also 
showed a remarkable reduced capacity to recognize p53 mutant at K372-3R. This 
suggests the specificity for the antibody against both lysine sites. In addition, the 
weak band at K372-3R was expected as the antibody should recognize K381 
lysine acetylation. Concerning the antibody against p53K386ac which was used in 
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breast cancer TMA staining; the antibody managed to identify both wild type p53 
and to lesser extent p53 mutant at K372-3R and K381-2R. Conversely, the 
antibody was unable to detect mutant p53 at K6R or K386R. This suggests that 
the antibody is highly specific against K386. On the other hand, the faint 
immunoreactivity band at K372-3 and K381-2R suggests lower sensitivity of 
p53K373/382ac and p53K386ac antibody if compared to p53 (DO1) antibody.
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Figure 5.7: Garcinol Alters p53 Acetylation. 
 
MCF-7 cells treated with 10 or 20µM garcinol (or vehicle) assessed for p53, TIP0 and CBP by Immunoflourescence staining (A) and Western 
Blot (B). Actin is used as loading control. 
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Figure 5.8: Cont. Garcinol Alters p53 Acetylation, Validation of p53 PTMs 
antibodies. 
 
(A) Analysis of the level of p53K120ac, K386ac and TIP60 in MCF-7 cells by 
flow cytometry analysis following 20µM garcinol treatment. The total number of 
cells is 4,000 cells. D, validation of p53 acetyl antibodies assessed using the 
transfection of p53 mutants into the p53 null cell line (SaOs2). 
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HATi Alters p53 Acetylation Marks in Non-cancerous MRC-5 Cells 
In order to discover any differences between cancerous and non-cancerous cells in 
the detection of p53 acetylation marks, acetylated forms of p53 at K120, 373/382 
and 386 were also explored in the human embryonic fibroblast cells, MRC-5 after 
HATi treatment. HATi treatment of MRC-5 cells caused an alteration in p53 
PTMs levels (Fig. 5.8). Consistent with the results obtained from MCF-7 cells, 
garcinol and its semi-synthetic derivatives isogarcinol and LTK14 caused 
enhanced detection levels of p53K386ac. However, HATi treatment did not 
appear to change p53K373ac levels. Remarkably, curcumin treatment caused 
increased p53K120ac detection level with marked shift of immunoreactivity into 
the cytoplasm. These results reinforce the finding using MCF-7 cells but show 
that similar effects are encountered in non-cancerous cells in culture. 
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Figure 5.9: HATi Treatment Alters p53 Acetylation at K386, K373 and K120 
in MRC-5 Cells. 
 
MRC-5 cells were treated with vehicle (DMSO), 20µM curcumin or garcinol; 10 
µM of isogarcinol or LTK14 for 24 hrs prior to Immunoflourescence staining for 
p53K386ac, p53K373/382ac, and p53K120ac (Magnification is x63).   
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5.1.6 HATi Treatment Alters p53 Function 
HATi Treatment Reduces p53 Transcriptional Activity 
In order to explore how HATi treatment affects p53 function, the p53 dependent 
reporter assays were performed. The experiment was designed (personal 
communication with Dr Hilary Collins) to analyse the effect of curcumin or 
garcinol treatment on p53 transcriptional activity. SaOS2 cells were co-
transfected with a luciferase reporter gene regulated by p53 binding sites derived 
from BAX, GADD45 and Mdm2 promoters as previously described (Collins et 
al., 2006). The cells were also transfected with p53 expression vector or empty 
vector as a negative control to normalize for transfection efficiency. None of the 
three reporters was active in the absence of p53 conferring the absence of 
endogenous p53 in this cell line (Fig. 5.10). Exogenous p53 induced the reporter 
activities approximately 100-fold for each of the three reporters.  However, 
curcumin treatment reduced reporter activities to 20%, 30% and 25% of the 
maximum activity for BAX, GADD45 and Mdm2 genes promoters. Similarly, 
garcinol also caused similar effects on the three reporters, showing a decrease to 
50%, 60% and 55% of control (Fig. 5.10A). These effects are most likely through 
targeting p53-ssociated HATs including CBP and p300 (Collins, Abdelghany et 
al, in preparation). 
 
 In order to understand the mechanism of cell cycle changes that takes 
place after HATi treatment, we evaluated the level of p21 protein, which is a 
major cell cycle regulator in the response to DNA damage (Cherrier et al., 2009) 
and a direct target of p53 (Eldeiry et al., 1993). HATi treatment for 24 hours 
induced a differential effect on p21 detection levels. Specifically, curcumin 
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caused an increase in the p21 level; however, garcinol caused the opposite effect 
(Fig. 5.10B). In addition, c-MYC level, a transcription factor acetylated by p300 
(Zhang et al., 2005, Faiola et al., 2005) was found markedly increased following 
garcinol treatment. This is consistent with the loss of H3K18 acetylation which 
catalysed by p300 that required for the activation of S phase in quiescent 
fibroblast cells (Horwitz et al., 2008, Ferrari et al., 2008). However, curcumin 
treatment did not affect c-MYC levels. Therefore, this result may suggest a 
differential effect of HATi treatment on MCF-7 cells cell cycle regulatory 
proteins. As altered p21, and c-MYC levels and reduced p53 transcription activity 
could possibly affect cell cycle progression, we evaluated the effect of HATi 
treatment on the cell cycle progression in cancerous and non-cancerous cell lines. 
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Figure 5.10: HATi Treatment Alters p53 Transcriptional Activity. 
 
A, The effect of curcumin and garcinol on p53 induction of the BAX, GADD45 
and Mdm2 promoters in SaOS2 cells (personal communication with Dr Hilary 
Collins); B, WB for p21 and c-MYC in MCF-7 cells treated with vehicle 
(DMSO), 10 and 20 µM curcumin or garcinol  for 24 hrs. 
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HATi Treatment Alters Cell Progression Through Cell Cycle  
In order to explore the effect of HATi treatment on cell cycle progression; we 
analysed cell cycle changes in both MCF-7 and MRC-5 cells following treatment 
for 24 hrs. The cell cycle analyses were performed by bivariate flow cytometry as 
described in Material and Methods (Section 2.4.7).   
 
 Remarkably, MCF-7 cells showed a dramatic reduction in S phase 
population upon treatment with garcinol, isogarcinol or LTK14 molecules. This 
effect indicates a failure of HATi treated cells to progress through the step of 
DNA synthesis, which require H3K18ac and a functioning p300/CBP (Horwitz et 
al., 2008).  In addition, both garcinol and LTK14 caused an increase in G1 and G2 
populations. Interestingly, 10 µM isogarcinol caused an increase in G2 at low 
treatment concentration and became markedly cytotoxic to the cells at higher 
concentration (20 µM) with a marked build up in subG1, the apoptotic population 
(Fig. 5.11). The EC50 (half-effective concentration) of isogarcinol in MCF-7 cells 
was in the range of 4-8 µM. This proposes a fundamental different cytotoxicity 
between isogarcinol and LTK14 as reported in MTT assays (Collins, Abdelghany 
et al, in preparation). Concerning the effects of curcumin treatment, similar to the 
others, it caused a reduction in S phase population; and a pronounced increase in 
G2/M population (Fig. 5.12) which is consistent with results reported after 
treatment of HEPG2 cells with curcumin (Sahu et al. 2009). 
  
 In order to evaluate the effects of HATi treatment on cell cycle 
progression in non-cancerous cells; MRC-5 cells were treated with 20 µM 
curcumin, 10µM of isogarcinol and LTK14 for 24 hours (20 µM was not used due 
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to its cytotoxic effects). Curcumin treatment for MRC-5 cells caused increased 
number of cells in the S and G2/M phases of the cell cycle, and a reduced number 
of cells in G1.  However, surprisingly, isogarcinol and LTK14 treatment caused 
minimal changes in cell cycle progression (Fig 5.13). This suggests a differential 
effect of curcumin treatment on MCF-7 and MRC-5 cells. In addition, MCF-7 
cells show marked sensitivity to isogarcinol (10 µM) treatment as compared to the 
non-cancerous MRC-5 cells.  
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Figure 5.11: Garcinol, Isogarcinol and LTK14 Treatment Impedes 
Proliferation of MCF-7 Cells by blocking S Phase.  
 
 
MCF-7 cells were treated with 10 and 20 µM garcinol, isogarcinol and LTK14 for 
24 hours, followed by flow cytometry cell cycle analysis. 
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Figure 5.12: Curcumin Treatment Impedes Proliferation of MCF-7 Cells by blocking S Phase. 
  
MCF-7 cells were treated with 10 and 20 µM curcumin for 24 hours, followed by flow cytometry cell cycle analysis. 
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Figure 5.13: Cell Cycle Changes in MRC-5 Cells upon HATi Treatment. 
 
MRC-5 cells were treated with 20 µM curcumin, 10 µM isogarcinol and 10 µM LTK14 followed by FACs cell cycle analysis.  
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5.1.7 HATi Treatment Sensitizes MCF-7 Cells to Etoposide and 
Reduces Colony Formation  
To further study the long term effects of HATi treatment on cell proliferation we 
explored the effects of garcinol or LTK14 treatment on the ability of MCF-7 cells 
to form cell colonies. MCF-7 cells, which were the optimum choice for the 
experiment, were used. MCF-7 cells are known to resist ionizing radiation (Wang 
et al., 2009a, Essmann et al., 2004), however, they are chemotherapy sensitive 
(Janicke et al., 2001). The cells were treated with 20 µM garcinol or LTK14 or in 
co-combination with (5 µM) etoposide (Fig. 5.12A), a well-characterized and 
specific topoisomerase II inhibitor used clinically in chemotherapy (Hajji et al., 
2008). Following 24 hrs of treatment, MCF-7 cells were incubated in fresh culture 
media for 12 days (Material and Methods section 2.4.8). The results revealed that 
garcinol alone or etoposide alone did not induce a marked reduction on colony 
count if compared with the effect when they were used in combination (Fig. 
5.12B). In addition, garcinol treatment mainly caused an effect on colony total 
area, which measures colony size (at least 50 cells to be visible) (Fig. 5.12C). 
Combination of garcinol and etoposide treatment resulted in marked reduction in 
colony total area (Fig. 5.12C). LTK14 treatment caused a marked reduction in 
both colony total area and count (Fig. 5.12B and C). In addition, combined 
LTK14 and etoposide treatment enhanced the effect of etoposide on MCF-7 cells 
colony area (Fig. 5.12C) and MCF-7 survival fraction (Fig. 5.12 D).  
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Figure 5.14: Effects of HATi on MCF-7 Cells Proliferation. 
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MCF-7 cells were treated with garcinol, or LTK14 alone or in combination with 
etoposide for 24 hrs. After washing, cells were incubated for an additional 12 
days to allow colony formation. The cultures was fixed with methanol and stained 
with Geimsa method, and the number of colonies were counted. A, MCF-7 cell 
colonies at day 12 after different treatments; B, count and total area of colonies, 
measurements were done by Image J software; C, survival fraction, which was 
calculated as the colony formation efficiency of the treated cells compared with 
control set to 100%. Data are pooled from three independent experiments. 
Column and error bars represent average and standard deviation. 
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5.1.8 Summary of Results: HATi Treatment can Reverse the Loss 
of Histone and p53 PTMs in Breast Cancer Cells. 
In Chapters 3 and 4 and in previous work we established that histone and p53 
PTM status, and the expression of their modulators in breast tumours, can be 
useful indicators of patient outcome. As these modifications are reversible, we 
explored whether small molecule inhibitors that target histone acetyltransferases 
might be able to alter histone p53 PTMs in MCF-7 cells, and to assess what 
implication this has on cancer cell proliferation. We therefore treated cells with 
curcumin, garcinol or synthetic garcinol derivatives. Our results confirmed that 
bulk acetylation of H3 and H4 is reduced following curcumin and garcinol 
treatment, although this effect was dose-dependent (Fig. 5.1A). At doses above 10 
M a marked induction of H4K16ac was observed (Fig.5.1B, C and Fig. 5.2). 
This result indicates that a cancer associated PTM i.e. hypoacetylation of H4K16, 
can be modulated by small molecule treatment. The increase in H4K16ac was 
accompanied by increased expression of the DNA damage regulator TIP60 (Fig. 
5.4), which was previously reported to acetylate H4K16 in vivo (Doyon et al., 
2006). However, hMOF, which has been claimed to be responsible for most of the 
cellular acetylation of H4K16, did not show any increased expression. siRNA 
knockdown of TIP60 in cell treated with garcinol will be performed by other 
members of the group to confirm whether TIP60 is responsible for increased 
H4K16 acetylation in response to garcinol. 
 
 Consistent with these data, marked increases in H3K56 acetylation and 
Ȗ+$; and other DNA damage markers including p53, phospho BRCA1 and 
phospho ATM were observed following garcinol treatment (Fig 5.5 and 5.7). This 
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provides a strong indication that these effects are associated with a cell stress such 
as DNA damage invoked by the treatment with garcinol compounds. In contrast 
garcinol compounds induced a marked reduction of H3K18ac (Fig. 5.1B).This 
PTM is deposited by CBP/p300 and is required for S phase progression in 
fibroblasts (Horwitz et al., 2008, Ferrari et al., 2008). This shows that garcinol 
action in vivo is plieotropic. Although it may inhibit CBP/p300 activity and thus 
block H3K18 acetylation, it also affects expression of other HATs and histone 
modulators, leading to other effects on histone PTMs. Conversely, garcinol 
treatment did not block H3K18 acetylation in the non-transformed MRC-5 cells 
(Fig. 5.2). These results are consistent with the observed effects on cell cycle 
arrest and reduction of the numbers of cells in S phase. Interestingly, H3K56 has 
been reported to be acetylated by CBP/p300 (Das et al., 2009). Thus, our result 
suggests that other HATs may target this residue after DNA damage, or distinct 
mechanisms are involved in H3K18 or H3K56 acetylation. 
 
In addition to effects on histone acetylation, HATi compounds also 
induced expression of p53 protein and altered p53 acetylation profiles (Fig. 5.7 
and Fig. 5.8). Remarkably, while curcumin inhibited acetylation of the C-terminal 
activation domain of p53, it strongly enhanced TIP60-dependent acetylation of 
K120 within the DNA binding domain. Garcinol markedly increased the three 
p53 acetylation marks. This was accompanied by a switch in the subcellular 
localisation of p53K120ac from the nucleus to the cytoplasm. This highlights the 
profound effects that drug-like molecules such as garcinol can have on the growth 
of tumour cells in culture by reprogramming key PTMs in histones and p53. 
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 In addition to effects on acetylation garcinol induced a very strong 
increase in cellular levels of H4K20me3 in MCF7 cells and MRC5 (Fig. 5.2 and 
Fig. 5.3); however, this was not observed for another methylation, i.e. H3K9me3 
(Fig. 5.2 and 5.3). As for H4K16ac, H4K20me3 is considered a hallmark of 
cancer, thus this provides another example of the reversal of loss of a histone 
PTM associated with cancer. Our data showed that garcinol induced an increase 
in SUV20H2 suggesting that this might be responsible for the observed increase 
in H4K20 trimethylation. This was confirmed by siRNA experiments showing 
that the increase in H4K20me3 induced by garcinol is blocked by knockdown of 
SUV420H2 (Fig. 5.3). 
 
Curcumin had distinct effects on the cell cycle causing an arrest in G2/M 
(Fig. 5.12). This was also reflected by differential effects on histone and p53 
PTMs which were less robust and we did not observe an induction of DNA 
damage markers to the same extent as garcinol compounds. We did note that 
curcumin induced expression of SUV39H1, which we have shown to be a good 
prognostic indicator in breast tumours.  
 
  Moreover, curcumin and garcinol were found to have opposing effects on 
expression of p21, the p53 dependent protein (Eldeiry et al., 1993) and the 
transcription factor C-MYC (Fig. 5.10). These effects on p21/C-MYC expression 
may be related to the differential effects of curcumin and garcinol on p53 
 acetylation at K373 which can alter p53 activity (Knights et al., 2006b). 
Moreover, the altered cell cycle profile following HATi treatment in MCF-7 (Fig. 
5.11 and Fig.5.12) and in MRC-5 cells (Fig. 5.13) may be a consequence of 
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HATi-induced histone and p53 PTMs. Finally we found that curcumin and 
LTK14 treatment sensitize the MCF-7, the breast cancer tumour cell line to 
etoposide treatment (Fig.5.14), which may propose a potential chemotherapeutic 
application of such small molecules in medical practice. Future studies in the lab 
will include mouse xenograft models of breast tumours, to explore the breast 
tumour response to HATi treatment.   
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Conventional histopathological diagnostic reports for breast cancer cases 
constitute histopathological typing, tumour grade, size, stage and nodal metastasis 
and lymphovascular invasion status. Additionally, immunoreactivity for ER, PR 
and HER2 is also included. In spite of the involvement of those variables with 
patient prognosis and tumour outcome (Elston and Ellis, 1991, Costa et al., 2002, 
Pritchard et al., 2006), these conventional variables remain unable to predict 
tumour behaviour, especially in response to treatment (Alizadeh et al., 2001). 
Histopathological diagnosis is basically a descriptive and rather subjective 
methodology, although digital imaging analysis may be available in the future .It 
is increasingly recognised that new approaches that characterize the complex 
genetic alterations that are involved in different tumour s need to be developed 
(Stange et al., 2006).  
 
 Cytogenetic and molecular genetic analysis of breast cancer samples 
demonstrates that various genetic alterations including amplification of oncogenes 
and mutation or loss of tumour suppressor genes are involved in tumour 
development and seem to be pathognomonic for the development or progression 
of a specific histological subtype (Beckmann et al., 1997). High throughout 
genomic studies have managed to classify breast cancer into biologically and 
clinically distinct groups based on gene expression profiles (Perou et al., 2000, 
Sorlie et al., 2001, Sorlie et al., 2003, Sotiriou et al., 2003). Those classifications 
DUH EDVLFDOO\ EDVHG RQ µJHQHWLF PRGHO¶ DV D FDXVH RI FDQFHU (Feinberg, 2004) 
without taking in to consideration the epigenetic model of cancer (Li et al., 
2005b). Genome wide epigenetic profiling and transcriptional profiling may soon 
provide a better understanding of the biology of breast tumours and identify 
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cohorts of biomarkers that predict outcome. However, the cost is currently 
prohibitive for a practical application. Thus PCR or antibody detection of panels 
of biomarkers is the best current approach.  
 
 In an earlier study based on the same breast cancer tissue cohort, Abdel 
El-Reheim et al (2005) characterized breast cancer tumours according the 
immunodetection of groups of proteins related to epithelial cell differentiation, 
hormonal receptors, growth factors receptors and gene products that known to be 
altered in some forms of breast cancer. The study revealed an association between 
those variables and tumour outcome and patient survival. Clustering of breast 
cancer cases into biological classes that characterized by distinctive expression of 
a group of variable (see previously in Introduction) revealed a significant 
association between those cluster classes with clinical and pathological variables. 
However that study did not profile the epigenetic aspect of breast tumours.  
 
 Our recent study in the same breast cohort profiled the global modification 
of histone PTMs and revealed an association with tumour types, conventional 
histopathological and biological variables. In addition cluster analysis of Histone 
PTMs revealed a distinctive hyper-modified class (which characterized by high 
levels of histone PTMs) as a class correlated with longer patient survival and 
better tumour outcome. However further study will be required to explore in 
depth the relationship between high levels of those marks and cellular function, or 
understand how those histone PTMs are regulated in breast cancer tumours. 
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 In Chapter 3 I tried to explore the profile of histone H4K16ac and its 
regulatory axis in breast cancer. I determined the levels of several members of the 
H4K16ac regulatory axis among breast cancer tumour various types, subtypes; 
correlated their levels to conventional prognostic factors and assessed the impact 
of their level in breast cancer tissue on tumour outcome and patient survival. 
According to my knowledge, although H4K16ac and hMOF levels were 
previously studied in breast tumours (Elsheikh et al., 2009, Pfister et al., 2008), 
this study was the first to explore H4K16ac regulatory axis in breast cancer or 
other tumours. High levels of H4K16ac, hMOF, and SUV39H1 were correlated 
with better tumour outcome and patient survival. Previous study on smaller 
number of cases (298) reported down regulation of hMOF and low acetylation 
levels of H4K16 in breast tumours in compare to normal tissue (Pfister et al., 
2008). Our study-according to my knowledge- is the first to study the protein 
level of SUV39H1 in breast cancer or any other tumour tissue. However, analysis 
of SUV39H1 mRNA levels in fresh frozen tissue from 219 colorectal cancers 
patients revealed elevated SUV39H1 levels in 25% of 219 colorectal cancers. In 
addition, global analysis of H4K16ac regulatory axis levels revealed their 
potential classification into distinctive clusters. High (H4K16ac, hMOF, 
SUV39H1) cluster was correlated with favourable tumour grade and longer 
patient survival. Other classes were correlated with poor prognosis and poorly 
differentiated tumours. Those cluster classes were characterized by either low 
levels of H4K16ac or distorted relationship between the members of H4K16ac 
regulatory axis. Interestingly, the distorted SIRT1/DBC1 relationship was also 
reported previously in breast cancer tumours (Sung et al., 2010).  
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 Exploring histone H2A variant expression levels in breast tumours 
revealed a significant correlation with steroid hormone receptors levels. 
Consistently with H2A.Z involvement in ER signalling in breast cancer cells 
(Svotelis et al., 2009b).  High levels of H2A.Z in breast tumours were correlated 
with favourable tumour grade and patient survival; which in contrast to previous 
study reported high levels of H2A.Z as a poor prognostic marker in breast cancer 
(Hua et al., 2008).   
 
 In chapter four, I also explored in breast cancer tissue the level of a 
number of p53 acetylation sites and their regulators. The results revealed positive 
correlation between high levels of p53 acetylation and better tumour outcome, 
especially the p53K373ac and p53k386ac. Acetylation of p53 was found 
correlated with favourable tumour histopathological and biological variables. I 
noticed differences between nuclear and cytoplasmic p53K120ac levels among 
tumour cores assessed which may denote a differences in the function of 
acetylated p53 at K120 depending on its localization whether nuclear or 
cytoplasmic. 
 
 Global analysis of the different p53 PTMs and their modulators revealed 
that breast cancer can be classified into prognostically and biological distinct 
groups depending on their H-score pattern. The cluster analysis suggests 
acetylation of p53 as favourable mark in breast cancer. High levels of both 
SUV39H1 and p53K373ac were found significantly correlated with favourable 
tumour outcome and patient survival. In addition, p53 acetylation at K386 was 
also found correlated with favourable tumour outcome and patient survival in 
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breast tumours, especially if combined with high levels of hMOF. This is 
consistent with the critical role for hMOF in acetylating p53 in inducing apoptosis 
(Rea et al., 2007), suggesting an integrated apoptotic pathway in breast cancer 
groups characterized by high levels of both hMOF and p53 acetylation.  
  
 This study has shown that small molecule inhibitors can be used to alter 
histone and p53 modifications in breast cancer cells. In the case of garcinol 
compounds, these actions are pleiotropic and may be due to indirect effects (such 
as induction of DNA damage responses, as well as through direct HAT inhibitor 
function. My results identified reduced bulk acetylation of H3 and H4 following 
curcumin and garcinol treatment using pan-acetyl antibodies. However, when we 
used antibodies to detect specific histone PTMs, a marked induction of H4K16ac 
and H4K20me3 was observed, both of which are suppressed in breast cancer and 
other tumours (Elsheikh et al., 2009, Van Den Broeck et al., 2008).  
 
Curcumin induced expression of SUV39H1, a good outcome marker in breast 
cancer however we could not identify any change in H3K9me3, the SUV39H1 
target. Garcinol compounds markedly induced a range of DNA damage markers 
including H3K56ac levels (Das et al., 2009), Ȗ+$; and  phospho 
BRCA1/ATM levels (Fig. 5.1, 5.2 and 5.5). As shown in Figure 6.1 this was due 
in part to increased expression of chromatin regulators such as TIP60 and CBP 
levels which is likely to account for the observed increase in H4K16 and H3K56 
acetylation. In addition to having important effects on histone PTMs, garcinol was 
also found to increase a profound change in the acetylation status of p53. Garcinol 
induced p53 acetylation at K373/382 and K386 which mediated by CBP/p300; 
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p53K120ac which catalysed by TIP60 in response to DNA damage. Moreover, 
the subcellular localisation of p53 was altered from the nucleus to the cytoplasm. 
While the mechanism responsible for this translocation is unclear, we note that 
acetylation regulates nuclear/ cytoplasmic trafficking through importin/exportin 
pathways (Bannister et al., 2000, Ryan et al., 2010). 
 
 We identified curcumin/garcinol- induced cell cycle changes in MCF-7 
cells, in the form of failure of S phase progression, which consistent with the 
marked reduction of H3K18ac which catalysed by CBP/p300 (Horwitz et al., 
2008); and a marked built up of SubG1 population following isogarcinol 
treatment. Curcumin treatment was previously reported to cause antiproliferative 
effect through G2/M arrest in many cell lines including colon and 
Rhabdomyosarcoma cell lines (Goel et al., 2001, Hanif et al., 1997, Beevers, 
2006). Small molecules HDACi like SAHA caused growth arrest, differentiation, 
and/or apoptosis of many tumour types in vitro and in vivo (Butler et al., 2002). 
SAHA also caused an inhibition of proliferation in MCF-7 cells; accumulation of 
cells in a in G (1) then G (2)-M phase of the cell cycle in a dose-dependent 
manner (Munster et al., 2001). 
 
 HATi treatment induced an induction of p53 and p53 PTMs, which are 
likely to impact on p53 transcriptional activity, as observed through the distinct 
effects on p21 and c-MYC expression. This may also be linked to the observed 
effects of HATi treatment on cell cycle progression. We found that curcumin and 
LTK14 treatment altered long term MCF-7 cellular proliferation and sensitized 
the cells to etoposide treatment which reflected on the ability of MCF-7 cell to 
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form visible cell colonies. Trichostatin A and Valproic acid which are HDACi  
have also been shown to sensitize drug resistant MCF-7 tumour cells to etoposide, 
the  topoisomerase II inhibitor, with concomitant increase in H4K16ac (Hajji et 
al., 2009). My results show that HATi treatment (curcumin and garcinol) is able 
to induce H4K16ac in more than one cell line, and sensitizes the MCF-7 cells to 
etoposide. Collectively, our results propose a potential chemotherapeutic 
application of such small molecules in medical practice. 
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6.1: The Possible Pathways Through Which Garcinol Treatment Alters Cell 
Proliferation. 
 
 This cartoon demonstrates the effects of garcinol treatment on histone and p53 
acetylation. Garcinol induces a DNA damage response manifested by TIP60 and 
SUV420H2 over expression that enhances H4K16 acetylation (H4K16ac) and 
H4K20 trimethylation (H4K20me3). DNA synthesis is blocked as demonstrated 
by reduced H3K18ac. H3K56 acetylation is enhanced suggesting targeting by 
CBP/p300 or other HATs upon garcinol treatment. Garcinol induces p53 
expression although p53 transcription activity is reduced. DNA damage induces 
p53 acetylation at K120, K373/382 which may trigger its function in cell cycle 
regulation/apoptosis 
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Future Work 
In future work I could extend the panel of study to include PTMs other than 
acetylation and methylation of histone and p53 PTMs as phosphorylation, 
ubiquitination, sumoylation, and ADP-ribosylation (Khorasanizadeh, 2004, Dai 
and Gu, 2010). Those modifications are also important in mitosis and 
chromosomal condensation, cell cycle progression, DNA damage response, 
tumour proliferation and others (Bannister and Kouzarides, 2011). Another set of 
enzymes µ&OLSSDVHV¶ that can remove histone N-terminal tails (Best and Carey, 
2010, Bannister and Kouzarides, 2011) have been identified in yeast. Evaluation 
of those enzymes could be a part of my future study in relationship to breast 
cancer tumour outcome. 
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Appendix 1: List for Antibodies Used in the study and Working Concentration used in Each Technique.  
Antibody Name Descriptio
n 
Catalogue No. Lot No. Application/ dilution Provider 
IF WB FACS IHC 
Con. Antigen 
Retrieval 
Anti-Actin (C-2) Ms Mono Sc-8432   1/5000    Santa Cruz 
Anti-H2A Rb      1/500 Citrate Dr. Dimitrove 
Anti-H2A.Z(688) Rb   1/50 1/500  1/25 Citrate Dr. Dimitrove 
Anti-H2A.Z(2595) Rb      1/50 Citrate Dr. Dimitrove 
Anti-H2A.Z (acetyl 
K4+K7+K11) 
Sh Poly ab18262 618318  1/500  1/5 Citrate Abcam 
          
Anti-Histone H3 (N-20) Gt Poly sc-8653   1/2000    Santa Cruz 
Anti-acetyl-Histone H3 Rb Poly 06-599 21514 1/100 1/2000    Upstate, Millipore 
Anti-H3K18ac Rb Poly ab1991  1/200 1/500    Abcam 
Anti-acetyl-Histone H4 Rb Poly   1/00      
Anti-H4K16ac Rb 06762 31884 1/100 1/200 1/100 1/20 EDTA Upstate, Millipore 
Anti-H3K9me3 Rb ab8898  1/300 1/250 1/100 1/300 Citrate Abcam 
Anti-H4K20me3 Rb Poly ab9053  1/200 1/500 1/100   Abcam 
Anti-PCAF (C-16) Gt Poly sc-6300   1/500    Santa Cruz 
Anti-CBP (A-22) Rb Poly sc-369 E2406 1/50 1/500  1/50 Citrate Santa Cruz 
Anti-p300 (N-15) Rb Poly sc-584   1/250    Santa Cruz 
MOZ (N-19) Rb Poly sc-5713  1/10     Santa Cruz 
Anti-MORF Rb Poly ab58823  1/10   1/75 Citrate Abcam 
Anti-hMOF Ms Mono ab54276  1/100   1/8 Proteinase k Abcam 
Anti-Tip60 Ms Mono ab54277 405324 1/200    1/5,00
0 
Citrate Abcam 
Anti-HDAC1(H-51) Rb Poly sc-7872  1/15   1/15 EDTA Santa Cruz 
Anti-HDAC2 (H-54) Rb Poly sc-7899  1/50   1/50 Citrate Santa Cruz 
Anti-SIRT1 Rb Mono ab32441  1/00 1/100  1/25 Citrate Abcam 
Anti-SUV39H1 Rb Poly ab33056  1/10 1/125  1/25 Proteinase k Abcam 
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Anti-SUV420h1/2 Rb Poly Ab18186 864861  1/100 1/100    
Anti-DBC1 Ms Mono Ab57608 528169 1/25   1/25 Citrate Abcam 
Anti-p53          
Anti-p53(DO-1) Ms Mono sc-126   1/500    Santa Cruz 
Anti-Ac-p53 (K386) Rb Poly ab52172  1/200 1/00 1/200 1/200 Citrate Abcam 
Anti-Acp53 (K120) Ms Mono Ab78316  1.100 1/500 1/500 1/50 Citrate Abcam 
Anti-Acp53 (K373) Rb Mono Ab62376  1/100 1/500 1/400 1/100
0 
Citrate Abcam 
Anti-Acp53  
(K373& K382) 
Rb poly 06-758 22561  1/500    Abcam 
Anti-p21 (C-19) Rb Poly sc-397   1/250    Santa Cruz 
Anti-C-Myc (9E10) Ms sc-40   1/250    Santa Cruz 
Anti-IRF-1 Rb Poly ab26109     1/100  Abcam 
Anti-H3K56ac Rb Poly    1/500  1/200 Citrate A Collaborator 
          
FITC Anti-BrdU Ms Mono 556028 17253   1/50   BD Pharmingen 
DNA Damage Antibody Kit          
Anti-Phospho-ATM (Ser1981) Ms 4526   1/500    Cell Signaling 
Anti-Phospho-ATR (Ser 428) Rb 2853   1/500    Cell Signaling 
Anti-Phospho-BRCA1 (1524) Rb 9009   1/500    Cell Signaling 
Anti- Phospho-H2A.X 
(Ser139) 
Rb 2577   1/250    Cell Signaling 
Anti-Hb1(D-15) Gt Poly Sc-10217     1/500  Santa Cruz 
Anti-Abobec3 Rb Poly ARP46114_P0
50 
    1/75  AVIVA SYSTEMS 
BIOLOGY 
Where RB, Rabbit; Ms, Mouse; Sh, Sheep; Gt, Goat; Poly, Polyclonal; Mono, Monoclonal; IHC, immunohistochemistry; IF, 
immunoflourescence; WB, Western Blotting. 
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Appendix 2: HATi Alters H2A.Z and its Acetylated Form Level in MCF-7 Cells. 
 
 
 
 
A, Immunoflourescence staining of MCF-7 cells for H2A.Z following 24hrs of HATi treatment; garcinol treatment induces increases H2A.Z 
levels; B, H2A.Z antibody is specific for H2A.Z, no immunoreactivity to core histone was seen; C, Western blotting for MCF-7 cells treated with 
curcumin or garcinol for 24 hours, garcinol induces H2A.Z levels, curcumin increases acetylation of H2A.Z. TIP60 is markedly increased 
following garcinol treatment. No considerable changes in SIRT1 level were detected. H3 was used as a loading control. 
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Appendix 3: Curcumin Treatment for 8 and 48 Hours Alters Cell Cycle progression in MCF-7 Cells 
 
 
Cell cycle analysis of MCF-7 cells treated with curcumin for 8 (Left panel) or (Right panel) 48 hrs. No significant changes have been noted after 
8 hrs of treatment; however, marked reduction in S phase cells were observed after 48 hrs. 
 
 
 
CONTROL/8Hrs          10µM Curcumin/8Hrs      20µM Curcumin/8Hrs
11%10%6%G2M
27%28%31%S 
62%59%62%G1
1%3%1%SubG1
CONTROL/48Hrs     10µM Curcumin/48Hrs       20µM Curcumin/48Hrs
21%8%6%G2M
12%23%30%S 
62%66%61%G1
6%3%3%SubG1
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Appendix 4: Garcinol Treatment for 8 and 48 Hours Alters Cell Cycle progression in MCF-7 Cells  
 
Cell cycle analysis of MCF-7 cells treated with garcinol for 8 (Left panel) or 48 (Right panel) hrs. No significant changes have been noted after 8 
hrs of treatment; however, 48 hrs of treatment caused a marked loss in S phase cells and an increased (Sub G1) cells.  
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